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Myocardial infarction is a leading cause of morbidity and mortality worldwide. The 
purpose of this thesis was to develop strategies for the assessment of patients with 
suspected myocardial infarction using a high-sensitivity cardiac troponin I assay, and 
to evaluate the relationship between the aetiology of myocardial infarction and long 
term clinical outcomes to identify opportunities to modify outcomes.  
In the United Kingdom, approximately 1 million patients present to hospital with chest 
pain each year and are assessed for suspected myocardial infarction, yet fewer than 
20% of patients receive this diagnosis. Prior clinical standards mandated the admission 
of patients for serial cardiac troponin testing to identify myocardial necrosis and 
determine if myocardial infarction had occurred. However, new high-sensitivity 
assays offer a magnitude improvement in diagnostic precision, and as such provide a 
novel approach to diagnose or exclude myocardial infarction at an earlier stage.  
In our first study, I evaluate the performance of a high-sensitivity cardiac troponin I 
assay as a risk stratification tool in patients with suspected acute coronary syndrome. 
A systematic review and individual patient-level data meta-analysis was performed, 
including prospective studies measuring high-sensitivity cardiac troponin I in patients 
with suspected acute coronary syndrome, where the diagnosis was adjudicated 
according to the universal definition of myocardial infarction. The primary outcome 
was myocardial infarction or cardiac death during the index hospitalization or at 30 
days. Meta-estimates for primary and secondary outcomes were derived using a 
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binomial-normal random effects model. Performance was evaluated in subgroups and 
across a range of troponin concentrations (2-16 ng/L) using individual patient data.  
A total of 22,457 patients were included in the meta-analysis (age 62 [15.5] years; 
n=9,329 (41.5%) women), of whom 2,786 (12.4%) experienced myocardial infarction 
or cardiac death at 30 days. Cardiac troponin I concentrations were <5 ng/L at 
presentation in 11,012 (49%) patients, with a negative predictive value of 99.5% (95% 
confidence interval [CI] 99.3-99.6) for myocardial infarction or cardiac death at 30 
days. Lower thresholds did not improve safety, but did significantly reduce the 
proportion identified as low risk. 
This threshold of 5 ng/L formed the basis for the development of a diagnostic pathway 
for patients with suspected acute coronary syndrome. In a cohort study of 1,218 
patients with suspected acute coronary syndrome who underwent high-sensitivity 
cardiac troponin I measurement at presentation, 3 and 6 or 12 hours, I derived and 
validated a novel pathway (rule out myocardial infarction if <5 ng/L at presentation, 
or change <3 ng/L and <99th centile at 3 hours), and compared this with the established 
European Society of Cardiology 3-hour pathway (rule out myocardial infarction if 
<99th centile at presentation, or at 3 hours if symptoms <6 hours). The primary 
outcome was a comparison of the negative predictive value (NPV) of both pathways 
for myocardial infarction or cardiac death at 30 days. The primary outcome was 
evaluated in pre-specified subgroups stratified by age, gender, time of symptom onset 
and known ischaemic heart disease. 
In those <99th centile at presentation, the ESC pathway ruled out myocardial infarction 
in 28.1% (342/1,218) and 78.9% (961/1,218) at presentation and 3 hours respectively, 
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missing 18 index and two 30-day events (NPV 97.9%, 95% confidence intervals [CI] 
96.9-98.7%). The novel pathway ruled out 40.7% (496/1,218) and 74.2% (904/1,218) 
at presentation and 3 hours, missing two index and two 30-day events (NPV 99.5%, 
95% CI 99.0-99.9%; P<0.001 for comparison). The NPV of the novel pathway was 
greater than the ESC pathway overall (P<0.001), and in all subgroups including those 
presenting early or known to have ischaemic heart disease. 
There are a number of additional approaches for the rule out of myocardial infarction. 
Clinical risk scores apply conventional risk factors to estimate the probability of 
myocardial infarction. The most widely implemented scores, HEART, EDACS, 
GRACE and TIMI, have been extensively validated when used alongside 
contemporary troponin assays, however, their impact on pathways applying high-
sensitivity cardiac troponin testing is less clear.  
In 1,935 patients with suspected acute coronary syndrome, I evaluated the safety and 
efficacy of our novel pathway or the European Society of Cardiology 3-hour pathway 
alone, or in conjunction with low-risk TIMI (0 or 1), GRACE (≤108), EDACS (<16) 
or HEART (≤3) scores. Myocardial infarction or cardiac death at 30-days occurred in 
14.3% (276/1,935). The ESC pathway ruled out 70% with 27 missed events giving a 
negative predictive value (NPV) of 97.9% (95% confidence interval [CI], 97.1 to 
98.6%). Addition of a HEART score ≤3 reduced the proportion ruled out by the ESC 
pathway to 25%, but improved the NPV to 99.7% (95%CI 99.0 to 100%, P<0.001). 
The novel pathway ruled out 65% with three missed events for a NPV of 99.7% 
(95%CI 99.4 to 99.9%). No risk score improved the NPV, but all reduced the 
proportion ruled out (24-47%, P<0.001 for all).  
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Whilst myocardial infarction due to atherosclerotic plaque rupture and thrombosis 
(type 1) is well described, the natural disease course of myocardial infarction due to 
oxygen supply-demand imbalance without atherothrombosis (type 2) is poorly 
understood. I aimed to define long-term outcomes and explore risk stratification in 
patients with type 2 myocardial infarction and myocardial injury. Consecutive patients 
(n=2,122) with elevated cardiac troponin I concentrations (≥0.05 µg/L) were identified 
at a tertiary cardiac centre. All diagnoses were adjudicated as per the Universal 
Definition of Myocardial Infarction. The primary outcome was all-cause death. 
Secondary outcomes included major adverse cardiovascular events (MACE; non-fatal 
myocardial infarction or cardiovascular death) and non-cardiovascular death. To 
explore competing risks, cause-specific hazard ratios were obtained using Cox 
regression models. 
The adjudicated index diagnosis was type 1 or type 2 myocardial infarction or 
myocardial injury in 1,171 (55.2%), 429 (20.2%) and 522 (24.6%) patients, 
respectively. At five years, all-cause death rates were higher in those with type 2 
myocardial infarction (62.5%) or myocardial injury (72.4%) compared with type 1 
myocardial infarction (36.7%). The majority of excess deaths in those with type 2 
myocardial infarction or myocardial injury were due to non-cardiovascular causes (HR 
2.32, 95%CI 1.92-2.81, versus type 1 myocardial infarction). Despite this, the 
observed crude MACE rates were similar between groups (30.6% versus 32.6%), with 
differences apparent after adjustment for co-variates (HR 0.82, 95%CI 0.69-0.96). 
Coronary heart disease was an independent predictor of MACE in those with type 2 
myocardial infarction or myocardial injury (HR 1.71, 95%CI 1.31-2.24).  Patients with 
type 2 myocardial infarction were less likely to receive secondary prevention therapy, 
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suggesting a treatment gap may exist and there may be potential to modify clinical 
outcomes.  
A risk stratification threshold has been defined using high-sensitivity cardiac troponin 
I which identifies patients at very low risk of myocardial infarction or cardiac death. 
A diagnostic pathway incorporating this risk stratification threshold appears safer than 
established guidelines which apply the 99th centile alone. The use of clinical risk 
scores does not appear to improve the safety of this approach, however, does 
significantly reduce efficacy. Overall, these findings demonstrate the potential of high-
sensitivity cardiac troponin testing to improve the efficiency of the assessment of 
patients with suspected acute coronary syndrome without compromising patient safety. 
The observations in those with myocardial injury and infarction have identified a 
phenotype of patients with type 2 myocardial infarction and coronary artery disease 
who are at increased cardiovascular risk, and who may benefit from targeted secondary 
prevention. The studies presented will inform the design of future clinical trials, and 
may inform international guidelines for the assessment of patients with suspected acute 
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Myocardial infarction remains a leading cause of morbidity and mortality worldwide. 
Whilst presentations to hospital with chest pain suggestive of myocardial ischaemia are 
responsible for up to 1 million visits to the emergency department in the United 
Kingdom each year, fewer than 20% of patients receive a final diagnosis of myocardial 
infarction. The ability to identify patients without myocardial infarction at an earlier 
stage has the potential to reduce patient anxiety, to facilitate focused clinical assessment 
to identify alternative diagnoses and improve resource allocation by reducing 
unnecessary hospitalisation and testing.  
However, the diagnosis of myocardial infarction has been complicated through 
recognition that this condition may occur in patients without atherosclerotic plaque 
rupture and intraluminal thrombosis, but with an imbalance in myocardial oxygen 
supply and demand in the context of another acute illness, such as pneumonia or 
tachyarrhythmia. Our understanding of the natural disease course of this condition is 
limited, with no consensus approach to risk stratification and no evidence based 
strategies for or treatment.  
Here, I discuss strategies for the assessment of patients with suspected myocardial 
infarction using cardiac troponin as a biomarker, evaluate the underlying mechanisms 
of myocardial necrosis and examine the reported long term outcomes of patients with 
myocardial injury and infarction. The purpose of this thesis is to provide further 
evidence and strategies for the assessment and classification of patients with myocardial 
injury and infarction.   
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1.2 Classification of myocardial infarction 
The definition of acute myocardial infarction has evolved to accommodate increasingly 
sensitive markers of myocardial necrosis and imaging methods that allow greater 
understanding of the pathogenic mechanisms of acute coronary syndrome. As such, the 
universal definition of myocardial infarction proposes that we classify patients with 
myocardial infarction based on aetiology (Figure 1.1) (Thygesen et al., 2012a). While 
this classification has been used in clinical trials to refine primary and secondary 
endpoints (Morrow et al., 2009, Bonaca et al., 2012, White et al., 2012), it has not been 
widely adopted in clinical practice, and the frequency and implications of subtypes of 
acute myocardial infarction are uncertain (Sandoval et al., 2014a). 
The third universal definition of myocardial infarction states the diagnosis of myocardial 
infarction requires evidence of myocardial necrosis in a clinical setting consistent with 
acute myocardial ischaemia. These criteria require detection of a rise and/or fall in 
cardiac biomarker levels (preferably cardiac troponin) with at least one value above the 
99th percentile upper reference limit, and at least one of the following: (1) symptoms of 
myocardial ischaemia, 2) new or presumed new significant ST-segment-T-wave 
changes or new left bundle branch block, 3) development of pathological Q-waves on 
the electrocardiogram, 4) imaging evidence of loss of viable myocardium or new 
regional wall motion abnormality or 5) identification of intra-coronary thrombus by 






Figure 1.1.  Classification proposed by the Third Universal Definition of Myocardial 
Infarction  (Thygesen et al., 2012a). 
 
The classification distinguishes between type 1 myocardial infarction due to thrombosis 
of an atherosclerotic plaque, and type 2 myocardial infarction due to myocardial oxygen 
supply-demand imbalance in the context of another acute illness. Myocardial infarction 
presenting as sudden death (type 3), or after percutaneous coronary intervention (type 
4) and coronary artery bypass grafting (type 5) are also defined. Acute myocardial injury 
is classified where troponin concentrations are elevated with evidence of dynamic 
change in the absence of overt myocardial ischemia, whereas in chronic myocardial 
injury troponin concentrations remain unchanged on serial testing. This is an important 
TYPE 1 MYOCARDIAL INFARCTION
TYPE 2 MYOCARDIAL INFARCTION
TYPE 3 MYOCARDIAL INFARCTION
TYPE 4 MYOCARDIAL INFARCTION
TYPE 5 MYOCARDIAL INFARCTION
Spontaneous myocardial infarction related to ischaemia due to a primary
coronary event such as plaque erosion and/or rupture, fissuring, or dissection
Myocardial infarction secondary to ischaemia due to either increased oxygen
demand or decreased supply
Sudden unexpected cardiac death often with symptoms suggestive of
myocardial ischaemia
Myocardial infarction associated with percutaneous coronary intervention (4a)
or stent thrombosis (4b)
Myocardial infarction associated with cardiac surgery
MYOCARDIAL INJURY
Multifactorial aetiology; acute or chronic based on change in cardiac troponin
concentrations with serial testing 
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distinction, as the underlying pathological mechanisms in acute and chronic myocardial 
injury are likely to differ.  
This classification is contentious and was based on expert consensus rather than 
evidence from prospective clinical trials. Whilst it has been adopted in research studies, 
implementation in clinical practice has been less consistent. The most contentious 
diagnosis is that of type 2 myocardial infarction; a concept based on clinical hypothesis 
and observation without prospective mechanistic evaluation. Patients classified with 
type 2 myocardial infarction are heterogeneous and have myocardial ischaemia 
secondary to a variety of acute medical or surgical conditions. Based on the current 
criteria, a diagnosis of type 2 myocardial infarction could be applied to patients without 
coronary artery disease. At present, there is no guidance or consensus on the optimal 
cardiac investigation, management or treatment strategy for patients with type 2 
myocardial infarction. Differentiating between patients with type 2 myocardial 
infarction and those patients with myocardial necrosis in the absence of ischaemia, in 
whom the recommended classification is myocardial injury, is challenging (Collinson, 
2015). Outcomes for both groups of patients are poor, and investigation and 
management are inconsistent in practice (Shah et al., 2015c). It is likely that this is at 
least in part due to variability in interpretation of the guidelines. 
The global task force are reviewing the Universal Definition of Myocardial Infarction 
and recognise the need to provide clearer diagnostic criteria and guidance to ensure 
consistent adoption in clinical practice (Alpert and Thygesen, 2016, Alpert et al., 2014, 
Sandoval et al., 2014a). Likewise, in the absence of an accepted definition it is difficult 
to perform standardised evaluations across different healthcare settings, or to conduct 
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randomised trials to determine the effectiveness of investigative strategies or 
preventative treatments for these patients. An improved understanding of the 
pathogenesis of these conditions is required to refine the universal definition further. If 
this leads to objective diagnostic criteria and a clear rationale for future investigation, 
this may improve the applicability and use of the universal definition in clinical practice.  
 
1.3 Mechanisms of myocardial injury 
Cardiac troponin is an integral component of the contractile apparatus of the 
cardiomyocyte, expressed exclusively within the myocardium. It is a complex of three 
subunits, C, I and T, which regulate calcium mediated excitation-contraction coupling. 
The majority of cardiac troponin is intracellular, with >90% of troponin isoforms located 
within the sarcomere, and the remainder unbound within the cytoplasmic pool (White, 
2011). In the setting of myocardial injury, cardiac troponin is released into the 
bloodstream in a time-dependent fashion, and may be detected using biochemical assays. 
The mechanisms of cardiac troponin release into the circulation are thought to include 
myocyte necrosis, apoptosis, formation and release of membranous blebs, increased 
membrane permeability and release of proteolytic troponin degradation products (White, 
2011).  
It is now recognised that cardiac troponin may be released outwith the context of 
myocardial ischemia and necrosis, with several purported mechanisms. Cardiomyocytes 
undergo mechanical stretch in response to pressure or volume overload, and this may 
trigger activation of intra-cellular proteases associated with intra-cellular degradation of 
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troponin (Wang et al., 2002). Furthermore, there is evidence that tachycardia may 
stimulate stress-responsive integrins within the cardiomyocyte, triggering release of 
intact cardiac troponin I from viable cardiomyocytes in the absence of necrosis (Hessel 
et al., 2008). Troponin release has also been demonstrated in vivo in patients who 
develop reversible ischaemia during nuclear perfusion imaging with stress testing. 
Using an ultra-sensitive cardiac troponin I assay with single molecule counting 
technology, change in cardiac troponin concentration following stress testing was 
associated with the extent of myocardial ischaemia (Sabatine et al., 2009).  
The universal definition makes a distinction between type 2 myocardial infarction and 
myocardial injury based on the presence or absence of symptoms and signs of 
myocardial ischaemia, however, there remains considerable overlap and to date there 
have been no prospective mechanistic studies to evaluate the range of underlying 
pathophysiology in these patients. Acute myocardial injury may occur in a variety of 
cardiac and non-cardiac illnesses (Table 1.1) as a consequence of myocardial oxygen 
supply-demand mismatch (hypotension, tachycardia or hypoxemia), due to direct injury 
in sepsis or viral myocarditis, or as part of the pathophysiological process in acute left 
ventricular failure. However, in some cases the presenting illness may be associated 
with a pro-inflammatory and pro-thrombotic state with myocardial injury due to 
embolisation of platelet aggregates and thrombus from an otherwise silent vulnerable 
plaque. Furthermore, myocardial injury can occur due to myocardial oxygen supply-
demand mismatch in the presence of prognostically important, but unrecognised stable 
coronary artery disease. It is not therefore appropriate to dismiss episodes of acute 
myocardial injury as mere bystander phenomenon of no clinical consequence. 
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Chronic myocardial injury may occur in structural heart disease (hypertensive heart 
disease, ischaemic or dilated cardiomyopathy) or secondary to other non-cardiac illness 
such as chronic renal failure. As an example, the detection of chronic myocardial injury 
may be clinically useful in valvular heart disease, with serum cardiac troponin I 
concentrations associated with cardiac mass, replacement fibrosis and prognosis in 
patients with aortic stenosis (Chin et al., 2014).  
The presence of chronic elevations in cardiac troponin associated with these conditions 
may contribute to diagnostic uncertainty in patients with suspected acute coronary 
syndrome. In recognition of this European guidelines for patients with non-ST-segment 
elevation myocardial infarction only recommend invasive management where a relative 
change in cardiac troponin concentration of at least 20% can be demonstrated, or where 
there is at least a five-fold elevation in cardiac troponin concentrations above the 99th 
centile on presentation (Roffi et al., 2016, Thygesen et al., 2012b).
 
 
Table 1.1. Causes of myocardial necrosis stratified by aetiology.  
 
 
Adapted from the Third Universal Definition of Myocardial Infarction (Thygesen et al., 2012a).
Primary myocardial ischaemia Supply or demand imbalance causing myocardial ischaemia 








Coronary Artery Dissection  
Anaemia 
Aortic dissection  
Aortic valve disease 
Tachy- or Brady- Arrhythmias 
Coronary embolism or vasculitis 
Coronary endothelial 
dysfunction   
Coronary vasospasm 
Hypertension  






















Pulmonary embolism  
Pulmonary hypertension 
Acute Kidney Injury 




Subarachnoid Haemorrhage  
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1.4 Biochemical quantification of myocardial injury 
Cardiac troponin is the only recommended biomarker for the detection of myocardial 
necrosis, and it is integral to the diagnostic criteria for myocardial infarction (Thygesen 
et al., 2012a).  
Our ability to accurately measure cardiac troponin has improved through the 
development of more sensitive assays, with the latest generation high-sensitivity 
assays capable of detecting cardiac troponin concentrations in the majority of healthy 
individuals. This has allowed accurate identification of the normal reference range and 
the 99th centile upper reference limit (Apple et al., 2012, Shah et al., 2015b, Apple 
and Collinson, 2012). 
The universal definition has recommended the 99th centile as the diagnostic threshold 
for acute myocardial infarction since 2007, with a rise or fall in cardiac troponin 
concentrations necessary to confirm the diagnosis (Thygesen et al., 2012a). 
Improvements in assay precision have identified differences in cardiac troponin 
concentrations between men and women, with the 99th centile twofold lower in 
women than men across a range of assays (Apple et al., 2012). The use of high-
sensitivity cardiac troponin and sex-specific 99th centile upper reference limits 
increases the diagnosis of myocardial injury and infarction, particularly in women, and 
identifies a high-risk group of patients with poor outcomes (Shah et al., 2015b). 
There is now widespread adoption of cardiac troponin assays in clinical practice across 
Europe, with >95% of laboratories using cardiac troponin as the preferred marker for 
the diagnosis of myocardial infarction (Collinson et al., 2016). In this survey in 2015, 
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over 50% of European laboratories used the 99th centile upper reference limit as the 
diagnostic threshold; however, given the widespread availability of high-sensitivity 
cardiac troponin assays and their prominence in national guidelines, the actual 
proportion in current practice is likely to be higher. 
 
1.5 High-sensitivity troponin and risk stratification  
Recent studies have demonstrated that cardiac troponin concentrations below the 99th 
centile can help in the risk stratification of patients with suspected acute coronary 
syndrome (Thygesen et al., 2012a, Shah et al., 2015b, Mills et al., 2011, Body et al., 
2011, Rubini Gimenez et al., 2013, Neumann et al., 2016). As such, the latest European 
Society of Cardiology guidelines include additional pathways incorporating lower 
thresholds of cardiac troponin for risk stratification and earlier testing (Roffi et al., 
2016). We recently demonstrated in consecutive patients with suspected acute 
coronary syndrome that a high-sensitivity cardiac troponin I concentration <5 ng/L at 
presentation had a negative predictive value of 99.6% (95% CI 99.3 to 99.8) for 
myocardial infarction during the index presentation, or myocardial infarction or 
cardiac death in 30 days (Shah et al., 2015a). Furthermore, patients with troponin 
concentrations <5 ng/L at presentation had very low rates of adverse cardiac events at 
1 year, compared with those with ≥5 ng/L but <99th centile (Shah et al., 2015a). 
However, alternative thresholds have been proposed, and there is a lack of clinical 
consensus as to the optimal approach.   
 
 39 
The use of cardiac troponin testing in clinical practice is evolving rapidly, with cardiac 
troponin concentrations increasingly used as a continuous measure of cardiovascular 
risk, rather than a binary test to identify those patients with and without myocardial 
infarction. In 2016, the National Institute for Health and Care Excellence (NICE) 
updated their guidance on the evaluation of patients with suspected acute coronary 
syndrome. For the first time, they recommended clinicians consider ruling-out 
myocardial infarction if a patient has very low concentrations of cardiac troponin at 
presentation when measured using a high-sensitivity assay (NICE, 2016). This 
guidance could lead to a significant reduction in the proportion of patients who require 
serial testing, and may tempt clinicians to consider upgrading their infrastructure to 
facilitate implementation. In the United Kingdom, two high-sensitivity assays are 
recommended by NICE for use in clinical practice, the Roche Elecsys high-sensitivity 
cardiac troponin T assay (hs-cTnT) and the Abbott ARCHITECTSTAT high-sensitivity 
cardiac troponin I assay (hs-cTnI). There are important differences in the normal 
reference range, diagnostic thresholds, levels of imprecision and in the lowest absolute 
concentrations which can be reliably detected, also known as the limit of detection 





Table 1.2. High-sensitivity cardiac troponin assays in use in clinical practice in the 
United Kingdom  
 











troponin T (1)  




cardiac troponin I (2)  
16 ng/L (females) 
34 ng/L (males) 
26 ng/L (single 
threshold) 
4.7 ng/L 1.2 ng/L 
*Lowest concentration where coefficient of variation is <10% (measure of dispersion 
of replicate sample results around the mean [SD/mean]).  
(1) (Giannitsis et al., 2010) (2) (Shah et al., 2015b) 
 
 
NICE recommend clinicians apply the LoD as a threshold below which myocardial 
infarction can be safely ruled out at presentation. Such a strategy is only recommended 
for patients deemed to be at low risk of myocardial infarction ‘as indicated by a 
validated tool’. During their appraisal, NICE considered evidence from studies 
including both the Thrombolysis in Myocardial Infarction (TIMI) score and the Global 
Registry of Acute Coronary Events (GRACE) score. Both scores were derived and 
validated in patients with confirmed myocardial infarction to confer prognosis, but 
over time these scores have been implemented for risk stratification in patients with 
suspected, not confirmed myocardial infarction. Importantly, cardiac troponin 
concentrations are embedded in both risk scores. NICE ultimately recommend the 
TIMI score, which has been previously validated in patients with suspected acute 
coronary syndrome alongside a contemporary troponin assay and serial testing (Than 
et al., 2012), but not with a high-sensitivity assay and the LoD at presentation alone.  
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This guidance was recently validated in a pooled study of over 5,000 patients, in five 
observational cohorts across two continents, with varying prevalence of major adverse 
cardiovascular events (4.8% to 15.6%), (Carlton et al., 2017). This study demonstrated 
when a high-sensitivity cardiac troponin T of <5 ng/L (LoD) was applied alongside a 
TIMI score of 0 and a non-ischaemic electrocardiogram, the sensitivity and NPV were 
extremely high, at 99.5% (95% CI 98.1 to 99.9%) and 99.6% (95% CI 98.7 to 100%), 
respectively. The meta-estimate for sensitivity was 98.7% (95% CI 96.5 to 99.6%), 
with low heterogeneity observed between cohorts (I2 15.3). For the high-sensitivity 
cardiac troponin I assay, using the limit of detection (<2 ng/L) and a TIMI score of 0 
alongside a non-ischaemic electrocardiogram, the sensitivity was 98.9% (95% CI 97.4 
to 99.6%) and NPV was 99.5% (95% CI 98.8 to 99.8%). The meta-estimate for 
sensitivity was similar (98.5%, 95% CI 95.4 to 99.5%) but the heterogeneity was high 
(I2 73.7). The reason for the observed heterogeneity is unclear, but may reflect 
differences in the assay used for diagnostic adjudication and testing between cohorts. 
These strategies would identify between 17.9% (95% CI 16.6 to 19.3%) and 21.0% 
(95% CI 19.9 to 22.2%) of patients as low risk, respectively. However, the use of 
thresholds above the LoD in combination with the TIMI score (such as <7 ng/L on the 
hs-cTnT assay, or <5 ng/L on the hs-cTnI assay) was shown to increase in the 





1.6 Clinical risk scores  
Whilst NICE recommend use of the TIMI score in addition to high-sensitivity cardiac 
troponin testing, the true need for clinical risk scores in this setting is uncertain. A 
recent meta-analysis of 9,269 patients found a normal electrocardiogram and a hs-
cTnT result below the LoD provided excellent NPV (99.3%, 95% CI 97.3 to 99.8%) 
and sensitivity (98.7%, 95%CI 96.6 to 99.5%) for the diagnosis of myocardial 
infarction, without the need for additional risk scores (Pickering et al., 2017). There 
were no deaths at 30 days in patients classified as low risk with the index test. This 
reflects our understanding that patients classically considered high risk (due to 
increasing age or cardiovascular risk factors such as diabetes, renal disease or prior 
ischaemic heart disease) have chronic elevation in high-sensitivity cardiac troponin 
concentrations (within the normal reference range) and are less likely to have low 
concentrations to support early discharge. Indeed, the European Society of Cardiology 
advocate use of the LoD at presentation in conjunction with the electrocardiogram, but 
do not recommend the addition of clinical risk scores (Roffi et al., 2016).  
However, there is undoubtedly an appetite for clinical risk scores in some settings, 
perhaps due to the additional perceived diagnostic confidence they provide. Unlike the 
GRACE (Global Registry of Acute Coronary Events) score and the TIMI score which 
were derived as markers of prognosis in those with confirmed myocardial infarction, 
the HEART score was developed and validated in a suspected acute coronary 
syndrome population. This score is based on clinical variables selected a priori 
(History, ECG, Age, Risk factors, cardiac Troponin) with arbitrary weighting chosen 
on a pragmatic basis. A recent meta-analysis of 11,217 patients demonstrated this 
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score had a sensitivity of just 96.7% (95% CI 94.0 to 98.2%), below the threshold of 
99% which most emergency department physicians deem acceptable (Van Den Berg 
and Body, 2017, Than et al., 2013). Whether use of this score offers additional benefit 
over risk stratification with troponin alone is unclear. Comparative studies including 
risk stratification thresholds alone, or in combination with risk scores are required to 
determine if improvements in safety can be obtained. 
The evidence supporting implementation of strategies including low high-sensitivity 
cardiac troponin concentrations is strong, but some uncertainty remains. All studies on 
which the NICE recommendations are based were observational in nature (i.e. no 
patients were discharged from hospital on the basis of a single troponin result), and the 
same applies to the vast majority of studies in this area. Patients who present early 
after onset of symptoms are challenging to recruit and therefore under-represented in 
all observational cohort studies. It is therefore recommended that serial testing is 
performed in all who present early after onset of symptoms. Similarly, any patient with 
myocardial ischaemia on the electrocardiogram should not be considered for early 
rule-out and should undergo serial troponin testing. Of utmost importance is an 
awareness of the assay in use, the normal reference range, and the appropriate 
diagnostic and risk stratification thresholds which are not equivalent. Where low 
concentrations are reported, it is important to ensure appropriate standards for clinical 
reporting can be met and maintained under routine working conditions. As noted by 
NICE, implementation of a proposed early rule-out strategy should include clinical 
audit, with attention paid to the time taken to rule-out the diagnosis and on the clinical 
outcomes of patients with suspected acute coronary syndrome. 
 
 44 
Clinicians should be confident that newer approaches using low concentrations of 
cardiac troponin are a magnitude safer than prior strategies using the 99th centile alone. 
High-sensitivity cardiac troponin testing has the potential to improve both the 
efficiency and safety of healthcare delivery for patients with suspected acute coronary 
syndrome, however, further investigation to define the optimal approach and to 
achieve consensus is required.  
 
1.7 Incidence of myocardial injury and type 2 
myocardial infarction  
The introduction of high-sensitivity cardiac troponin assays and lower diagnostic 
thresholds into clinical practice may result in a disproportionate increase in the number 
of patients with type 2 myocardial infarction or myocardial injury compared to type 1 
myocardial infarction (Shah et al., 2015b, Thygesen et al., 2012b), and could lead to 
diagnostic uncertainty with the potential for over treatment  in patients who do not 
have acute coronary syndrome (Shah et al., 2013, Melanson et al., 2008, Makam and 
Nguyen, 2015). 
To date, the majority of studies of patients with type 2 myocardial infarction and 
myocardial injury have not implemented high-sensitivity cardiac troponin assays and 
therefore may under recognise the true prevalence of these conditions. The largest 
reported registry (Baron et al., 2015) assessed all patients with acute myocardial 
infarction admitted to hospital in Sweden during 2011 (n=20,138). All diagnoses were 
classified by the attending clinician, with 88.5% of patients classified as type 1 
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myocardial infarction and 7.1% as type 2 myocardial infarction. Of note, the 
prevalence of type 2 myocardial infarction varied markedly between different centres 
(0% to 13%), illustrating the challenge of consistently applying the current diagnostic 
classification. In studies which classified all patients with elevated cardiac troponin 
concentrations, the reported prevalence of type 2 myocardial infarction varies between 
7% to 37% in unselected hospitalised patients, and from 5% to 74% in patients 
attending the Emergency Department (Table 1.3), (Saaby et al., 2013, El-Haddad et 
al., 2012, Smith et al., 2013, Sandoval et al., 2014b). Differences in the reported 
prevalence may in part be explained by the inconsistent approach to distinguishing 
type 2 myocardial infarction from acute and chronic myocardial injury across studies. 
It is perhaps unsurprising that the diagnosis of type 2 myocardial infarction has been 










 Diagnostic Classification  
(%) Proportion of all patients with elevation in baseline cardiac troponin 
  Population Troponin assay 
and upper 




concentrations   





Type 1 MI 
(%) 
Type 2 MI 
(%) 
Type 3/4/5 MI 
(%) 
Unclassified 

























807 (100%) Not reported 512 (63.4%) 295 (36.6%) Nil Nil 











1,961 (43.6%) 1,408 (71.8%) 397 (20.2%) 144 (7.3%) 12 (0.1%) Nil 











2,165 (100%) 522 (24.1%) 1,171 (71.3%) 429 (26.1%) 43 (2%) Nil 
 
 47 
Table 1.3. continued. Classification of myocardial injury and infarction in published cohort studies. 
 
 
   Diagnostic Classification  
(%) Proportion of all patients with elevation in baseline cardiac troponin 
  Population Troponin assay 
and upper 




concentrations   





Type 1 MI 
(%) 
Type 2 MI 
(%) 
Type 3/4/5 MI 
(%) 
Unclassified 







cTnI, cTnT, CK, 
CK-MB 









2,882 (100%) Not reported 2824 (98%) 58 (2%) Nil Nil 







Not reported 2,818 (100%) Not reported 2,691 (95.5%) 127 (4.5%) Nil Nil 










1,403 (7.1%) 141 (0.7%) 731 (3.7%) 
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 Diagnostic Classification  
(%) Proportion of all patients with elevation in baseline cardiac troponin 
  Population Troponin assay 
and upper 




concentrations   





Type 1 MI 
(%) 
Type 2 MI 
(%) 
Type 3/4/5 MI 
(%) 
Unclassified 








(Roche Elecsys)  
 
1,093 (100%) Not reported 967 (88.5%) 17 (1.6%) 109 (9.9%) Nil 
 
 
















OCD Vitros  
256 (23%) Not reported 66 (25.8%) 190 (74.2%) Nil Nil 









Siemens Stratus  








 Diagnostic Classification  
(%) Proportion of all patients with elevation in baseline cardiac troponin 
  Population Troponin assay 
and upper 




concentrations   





Type 1 MI 
(%) 
Type 2 MI 
(%) 
Type 3/4/5 MI 
(%) 
Unclassified 









134 (12.2%) Not reported 127 (95%) 7 (5%) Nil Nil 














96 (25.2%) Not reported 86 (90%) 10 (10%) Nil Nil 













298 (25.4%) 40 (3.6%) 242 (81.2%) 56 (18.8%) Nil Nil 
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A previous study at our centre evaluated all patients with elevated plasma cardiac 
troponin concentrations irrespective of presenting complaint (n=2,165), admitted 
during the validation and implementation of a contemporary sensitive cardiac troponin 
I assay (Shah et al., 2015c). The frequency of type 1 myocardial infarction, type 2 
myocardial infarction, and myocardial injury was 54%, 20% and 24% respectively. 
Type 2 myocardial infarction and myocardial injury were as common as type 1 
myocardial infarction in clinical practice, and indeed more common than type 1 
myocardial infarction in patients ≥75 years of age (Figure 1.2). Lowering the 
diagnostic threshold with a more sensitive cardiac troponin assay reduced recurrent 
myocardial infarction or death in patients redefined as having type 1 myocardial 
infarction, but more than doubled the number of patients with type 2 myocardial 
infarction or myocardial injury. Despite undergoing additional cardiac investigations, 
this did not result in changes in treatment, and there was no observed improvement in 

























Figure 1.2.  Incidence of myocardial infarction and myocardial injury stratified by age in unselected consecutive hospital inpatients with 






























































Type 1 Myocardial Infarction
Myocardial Injury 
Type 2 Myocardial Infarction
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Whether adoption of high-sensitivity troponin assays and the 99th centile for diagnosis 
of myocardial infarction translates into improvements in clinical outcomes for patients 
with suspected acute coronary syndrome is being evaluated in a stepped wedge cluster 
randomised trial across Scotland (High-STEACS, NCT:01852123). If increased 
sensitivity does not impinge on specificity for the diagnosis of type 1 myocardial 
infarction, then these assays will improve patient outcomes through better targeting of 
therapies for coronary artery disease. However, if increased sensitivity leads to poor 
specificity, then patients may be misdiagnosed and given inappropriate cardiac 
medications with potentially detrimental outcomes. This trial will establish whether 
the introduction of high-sensitivity assays into routine clinical practice is detrimental 
or beneficial to patient management and outcomes; a fundamental and critical 





1.8 Outcomes of myocardial injury and type 2 
myocardial infarction 
Patients with type 2 myocardial infarction or myocardial injury have poor clinical 
outcomes, worse than those patients with type 1 myocardial infarction (Figure 1.3), 
with 1 in 3 patients dead at one year (Shah et al., 2015c). In a prospective study of 
patients with  acute coronary syndrome (n=2,818), Stein et al. (2014) found an 
increased risk of death in those with an adjudicated diagnosis of type 2 versus type 1 
myocardial infarction at 30 days (13.6% vs. 4.9%, P<0.0001) and at one year (23.9% 
vs. 8.6%, P<0.0001). Another single centre study by El-Haddad et al. (2012) reported 
mortality rates 6.9 times greater in type 2 versus type 1 myocardial infarction at one 
year.  
Sarkisian et al. (2016) reviewed 3,762 patients who underwent cardiac troponin testing 
on clinical indication. Patients with acute myocardial injury were at significantly 
greater risk of all-cause mortality than those with myocardial infarction at a median 
follow up of 3.2 years (59% versus 39%, P<0.0001 by log-rank test). In a sub-group 
analysis, they demonstrate no difference in risk of all-cause mortality between patients 
with type 2 myocardial infarction or myocardial injury (adjusted hazard ratio [HR] 
1.28, 95%CI 0.97-1.65). Whether it is possible to improve outcomes in these patients 




The distinction between type 2 myocardial infarction and myocardial injury may 
however be clinically important, as it has been demonstrated that patients classified as 
having a type 2 myocardial infarction are twice as likely as those with myocardial 
injury to be readmitted with a type 1 myocardial infarction at one year (Shah et al., 
2015c). This potentially important observation suggests a proportion of patients with 
type 2 myocardial infarction may benefit from further investigation and treatment for 
coronary artery disease. Selection of patients for further investigation requires a 
greater understanding of the clinical features that identify those patients at increased 
risk of future acute coronary events, and a better understanding of the mechanisms of 
myocardial injury in this setting.  
Figure 1.3.  All-cause mortality in cohort studies of patients with type 1 or type 2 
myocardial infarction, or myocardial injury.  
Size of bubble indicates number of patients (small <1000, medium <3000, large >3000). 
Colour indicates diagnosis (type 1 myocardial infarction = red, type 2 myocardial infarction 


































































Whilst it is well recognised that patients with type 2 myocardial infarction have an 
increased rate of all-cause mortality, a clear limitation of the majority of studies to date 
is establishing cause-specific mortality and future cardiovascular risk (Sandoval and 
Thygesen, 2017). Such analyses are warranted to guide estimates of the proportion of 





The implementation of more sensitive troponin assays in clinical practice has increased 
our awareness of the spectrum of both acute and chronic myocardial injury. High-
sensitivity cardiac troponin assays offer a novel avenue to improve the efficacy and 
safety of risk stratification in patients with suspected acute coronary syndrome, but 
consensus as to the optimal approach is required. Whilst the universal definition 
classifies myocardial infarction by aetiology, inconsistency in the interpretation and 
application of these guidelines may impact on patient care and outcomes. Identifying 
patients with acute or chronic myocardial injury, and accurately defining clinical 
outcomes is a necessary first step. A better understanding of mechanism may guide 
the need for further investigations and identify those patients with type 2 myocardial 




1.10 Aims and hypotheses 
The principle aims of this thesis are to develop a systematic approach to the assessment 
of patients with suspected acute coronary syndrome using high-sensitivity cardiac 
troponin testing, and to improve the characterisation of patients with type 2 myocardial 
infarction and myocardial injury. 
In Chapter 3, I will determine the optimal threshold of high-sensitivity cardiac troponin 
I to rule out myocardial infarction at presentation in a systematic review and individual 
patient-level data meta-analysis.  
In Chapter 4, I will develop a clinical pathway incorporating a risk stratification 
threshold based on high-sensitivity cardiac troponin concentrations at presentation and 
serial testing at 3 hours. This will be compared to the established European Society of 
Cardiology 3-hour rule-out pathway.  
In Chapter 5, I will evaluate whether the addition of clinical risk scores such as the 
GRACE score, TIMI score or HEART score improves the performance of the clinical 
pathway derived in Chapter 4.  
In Chapter 6, I will determine long term outcomes of myocardial injury and infarction 
by subtype in a cohort of consecutive hospitalised patients. Specifically, I will 
determine the risk of future cardiovascular events and cause-specific mortality, and 
determine whether the diagnosis of type 2 myocardial infarction is an independent 




The following hypotheses will be addressed: 
1. That a high-sensitivity cardiac troponin I threshold of 5 ng/L will provide the 
optimal balance between safety and efficacy in the risk stratification of patients with 
suspected acute coronary syndrome. (Chapter 3). 
2. That the integration of a risk stratification threshold at presentation and serial testing 
at three hours in a clinical pathway will offer improved safety compared to the 
established European Society of Cardiology 3-hour rule-out pathway (Chapter 4). 
3. That the addition of clinical risk scores (GRACE, TIMI and HEART) will not 
provide additional safety over the clinical pathway incorporating high-sensitivity 
cardiac troponin risk stratification thresholds (derived in Chapter 4), but will improve 
the safety of the European Society of Cardiology 3-hour rule-out pathway (Chapter 5).  
4. That patients with type 2 myocardial infarction and myocardial injury are at 
increased risk of all-cause mortality at five years, but are at similar risk of future 















The specific study design and methodology for each of the cohorts are described in 
detail in the relevant chapters. The following methodology sections will provide an 
overview of the patient populations studied and the general principles applied.  
 
2.2 Study Populations 
This thesis includes patients recruited in a number of different prospective 
observational cohort studies. Four cohorts were recruited from hospitals in Edinburgh, 
Scotland, and are described in detail below. An additional 16 cohorts from eight 
countries worldwide were evaluated as part of an individual patient-level data meta-
analysis; the characteristics of these cohorts are detailed in Appendix 3.  
 
High-STEACS Pilot, Edinburgh, Scotland (Chapter 3) 
The High-Sensitivity Troponin in the Evaluation of patients with suspected Acute 
Coronary Syndrome (High-STEACS) pilot study prospectively identified consecutive 
patients presenting to the Royal Infirmary of Edinburgh, United Kingdom, from 1st 
August to 31st October 2012, in whom the attending doctor suspected an acute 
coronary syndrome. Serum troponin concentrations were measured on admission and 
repeated six or 12 hours after the onset of symptoms using both a contemporary 
sensitive troponin I assay and a high-sensitivity cardiac troponin I assay. Clinical 
decisions were based on the contemporary assay only, with clinicians blinded to the 
results of the high-sensitivity assay. To ensure all eligible patients were included and 
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to avoid selection bias, consent was not sought from individual patients. Patients not 
resident in the south east of Scotland were excluded from the study.  
 
High-STEACS Validation, Edinburgh, Scotland (Chapter 3) 
The High-STEACS validation study prospectively identified consecutive patients with 
suspected acute coronary syndrome presenting to the emergency departments of two 
secondary care hospitals (St John’s Hospital, Livingston, and Western General 
Hospital, Edinburgh) and a tertiary care hospital (Royal Infirmary of Edinburgh, 
Edinburgh) in the southeast of Scotland between the 1st June 2013 and 31st January 
2014. Patients were enrolled in the standard care arm of a stepped-wedge cluster 
randomised clinical trial evaluating the implementation of a high-sensitivity cardiac 
troponin I assay (High-STEACS, ClinicalTrials.gov number: NCT:01852123). All 
patients who had cardiac troponin requested by the attending clinician and an 
electrocardiogram done were included. In order for any request for cardiac troponin to 
be processed, the requesting healthcare practitioner had to indicate if acute coronary 
syndrome was suspected, and document the primary presenting symptom and time of 
symptom onset. Clinical decisions were based on the contemporary assay only, with 
clinicians blinded to the results of the high-sensitivity assay. To ensure all eligible 
patients were included and to avoid selection bias, consent was not sought from 
individual patients. Patients were excluded if they had been admitted previously during 







High-STEACS Substudy, Edinburgh, Scotland (Chapters 3, 4 and 5) 
Patients with suspected acute coronary syndrome were recruited from the emergency 
department of the Royal Infirmary of Edinburgh, a tertiary care hospital in Scotland, 
between the 1st June 2013 and the 31st March 2017 into a substudy of the High-
STEACS trial. All patients in whom the attending clinician requested cardiac troponin 
for suspected acute coronary syndrome were eligible for inclusion, using the same 
electronic request process as for the High-STEACS trial. We did not enrol patients 
with ST-segment elevation, those who were unable to provide consent or those from 
outside our region to ensure complete follow-up. Blood samples were obtained at 
presentation and at 6 to 12 hours for high-sensitivity cardiac troponin testing as part of 
routine clinical care. Patients provided written informed consent for additional 
sampling at 3 hours with the results of testing at this time point not used to guide 
patient care.  
 
Myocardial injury cohort, Edinburgh, Scotland (Chapter 6) 
Consecutive hospital inpatients with elevated cardiac troponin I concentrations (≥0.05 
µg/L) were identified at a tertiary cardiac centre (Royal Infirmary of Edinburgh, 
Scotland, UK) during the validation (January 19th to July 31st 2008) and 
implementation (January 19th to July 31st 2009) phases of a contemporary sensitive 
cardiac troponin I assay. We included all patients in whom cardiac troponin was 
requested by the attending clinician, regardless of suspected etiology or hospital 
department. We excluded patients admitted for elective procedures, those with 
incomplete electronic hospital records, and patients who were not residents to ensure 
follow up was complete. To ensure all eligible patients were included and to avoid 
selection bias, consent was not sought from individual patients.   
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2.3 Ethical and regulatory considerations 
All studies were prospective and conducted in accordance with the Declaration of 
Helsinki. High-STEACS is a prospective stepped-wedge cluster randomised 
controlled trial evaluating the implementation of a high-sensitivity cardiac troponin 
assay in consecutive patients with suspected acute coronary syndrome across 
secondary and tertiary care hospitals in Scotland.  I sought and obtained ethical 
approval to not obtain individual patient consent in those recruited to the High-
STEACS pilot and validation studies. This approach was justified as whilst centres 
were randomised to the timing of implementation of the high-sensitivity assay, it was 
planned irrespective of the trial. Secondly, patients undergo no additional research 
study procedures, with the high-sensitivity assay measured in wastage plasma, and 
outcomes were recorded using routinely collected data. The High-STEACS study 
(including pilot, validation and substudy cohorts) was approved by the Scotland A 
Research Ethics Committee (12/SS/0115) and the Public Benefit and Privacy Panel 
for Health and Social Care for the National Health Service (NHS) Scotland (PAC 
92/14). The conduct of the trial was periodically reviewed by an independent data 
monitoring committee. All data was collected prospectively from the electronic patient 
record, deidentified and linked using a unique patient identifier within NHS Scotland. 
 
Ethical approval was not required for patients contributing to the myocardial injury 
cohort, although the study protocol was reviewed by the chairman and scientific 
advisor of the Lothian Research Ethics Committee who advised that it represented 
clinical audit and service evaluation. For this study, approval was sought from the 
NHS Caldicott Guardian for data collection and record linkage.    
 
 65 
2.4 Cardiac troponin assays 
2.4.1 High-sensitivity cardiac troponin I assay 
 
The Abbott ARCHITECTSTAT high-sensitive cardiac troponin I assay (Abbott 
Laboratories, Abbott Park, IL) is a two-step chemo-luminescent assay. Briefly, this 
assay uses a paramagnetic ‘capture’ antibody to bind cardiac troponin I present in a 
sample, which is then extracted from the reaction vessel during a wash phase using a 
magnetic field. A second cardiac troponin I detection antibody is then added. This 
‘detection’ antibody is conjugated to acridinium and activated by a trigger agent, 
generating fluorescence. This is then detected, with the strength of the signal obtained 
proportional to the concentration of cardiac troponin I present in the sample.  
This assay has a limit of detection (LOD; minimum absolute concentration reliably 
identified) of 1.2 ng/L and coefficient of variation (measure of dispersion of replicate 
sample results around the mean) of less than 10% at 6 ng/L. This assay performance 
has been independently validated across multiple centres under routine laboratory 
working conditions, with a reported inter-laboratory coefficient of variation of 12.6% 
at 3.5 ng/L across 33 instruments. The upper reference limit 99th centiles were 
determined in 4,590 samples from healthy individuals as 16 ng/L for women and 34 
ng/L in men (Shah et al., 2015b). 
2.4.2 Contemporary sensitive cardiac troponin I assay 
Plasma cardiac troponin concentrations were measured using a contemporary sensitive 
cardiac troponin I assay (ARCHITECTSTAT, Abbott Laboratories, Abbott Park, IL), in 
patients recruited into the myocardial injury cohort (Chapter 6). This assay has 
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previously been validated at our institution. According to the manufacturer, the limit 
of detection is 0.010 µg/L and the upper reference limit (99th centile) as determined in 
a normal reference population is 0.028 µg/L. However, a diagnostic threshold of ≥0.05 
µg/L was implemented in clinical practice as this was the minimum concentration 
where the coefficient of variation was <10% under local laboratory conditions. This 
diagnostic threshold was based on a standard assessment of precision using pooled 
serum at low concentration measured across multiple platforms and reagent lots, and 
was the lowest concentration that consistently provided a coefficient of variation <10%.  
 
 
2.5 Diagnostic adjudication 
In all cohorts, the final diagnoses were classified as per the third universal definition 
of myocardial infarction. Patients were classified as having a type 1 myocardial 
infarction when myocardial necrosis occurred in the context of a presentation with 
suspected acute coronary syndrome with symptoms of myocardial ischemia, or 
evidence of myocardial ischemia on the electrocardiogram. Patients with symptoms or 
signs of myocardial ischemia that were thought to be due to increased oxygen demand 
(e.g. tachyarrhythmia or hypertrophy) or decreased supply (e.g. hypotension, hypoxia 
or anaemia) and myocardial necrosis in the context of an alternative clinical diagnosis 
were classified as having a type 2 myocardial infarction. Myocardial injury was 
defined as evidence of myocardial necrosis in the absence of any symptoms or signs 
of myocardial ischemia. The diagnosis of type 1 or type 2 myocardial infarction 
required evidence of a rise and or fall in cardiac troponin concentration, with at least 
one value above the 99th centile. For the high-sensitivity cardiac troponin I assay 
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(Chapters 3, 4 and 5), sex-specific thresholds were applied (>16 ng/L for females, >34 
ng/L for males), and for the contemporary sensitive cardiac troponin I assay (Chapter 
6) a single threshold was applied (>0.05 µg/L). Each case was reviewed and classified 
independently by two cardiologists, and any discrepancies were resolved by consensus 
through in-depth review of source data. The specific cohort level criteria used by 
studies in Chapter 3 is available in Appendix 3. 
Where we evaluate high-sensitivity cardiac troponin I as a risk stratification tool 
(Chapter 4 and 5), as the adjudicating clinician was not blinded to cardiac troponin 
results, there is a risk of incorporation bias. However, the adjudication was completed 
by a panel of cardiologists prior to undertaking this analysis, and we pre-specified a 
target negative predictive value rather than a cardiac troponin threshold. Whilst an 
alternative troponin assay could have been used for adjudication, the agreement 
between assays is imperfect, and as this could have led to bias against the assay under 




2.6 Statistical analysis 
Specific statistical analysis has been described in depth in each chapter, with additional 
analysis code available in the supplementary appendix. All statistical analyses were 
performed using R (version 3.2.2).  
2.6.1 Evaluation of diagnostic performance  
The diagnostic performance of any test can be evaluated using a 2x2 table (Table 2.1), 
illustrating the agreement between the test and the disease state. From this 2x2 table, 
four key diagnostic metrics may be derived (Table 2.2). 




Table 2.2. Key diagnostic metrics 
 
 
 Condition positive Condition negative 
Test positive True Positive (TP) False Positive (FP) 
Test negative False Negative (FN) True Negative (TN) 
Sensitivity  
TP / (TP + FN)  
The proportion of patients who have the condition 
identified by the test  
Specificity  
TN / (TN + FP) 
The proportion of patients who do not have the 
condition identified by the test 
Negative predictive value  
TN / (TN + FN) 
The proportion of patients with a negative test 
who do not have the condition 
Positive predictive value  
TP / (TP + FP) 
The proportion of patients with a positive test 
who have the condition  
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In the evaluation of cardiac troponin concentrations at presentation for risk 
stratification in patients with suspected acute coronary syndrome, both sensitivity and 
negative predictive value have been reported as the primary metric in the literature. 
Here, a cardiac troponin concentration is not being applied for diagnosis, but for risk 
stratification in patients in whom the diagnosis is uncertain. NPV is an accepted 
method to evaluate tests of exclusion, analogous to d-dimer, and is determined in those 
without a diagnosis of myocardial infarction at presentation. Sensitivity is determined 
in patients with a diagnosis of myocardial infarction, including patients >99th centile 
who are not eligible for risk stratification. We therefore made an a priori decision to 
prioritise negative predictive value over sensitivity in studies evaluating a risk 
stratification threshold.  
As the negative predictive value was expected to be close to 100%, proportions were 
estimated using a Bayesian approach, sampling from a binomial likelihood with a non-
informative Jeffrey’s prior (beta distribution with both shape parameters equal to 0.5). 
This approach has demonstrated good coverage when proportions are close to zero or 
one (Brown et al., 2001). 
Unlike sensitivity and specificity, both negative and positive predictive values are 
influenced by changes in the prevalence of disease. For example, negative predictive 
value may be overestimated where the prevalence of disease is low. For this reason, a 
validation of risk stratification thresholds was undertaken across a range of cohorts in 





2.6.2 Derivation of clinical risk scores 
In Chapter 5, a number of clinical risk scores are evaluated. Using the High-STEACS 
substudy cohort, the HEART, GRACE, EDACS and TIMI scores were calculated on 
the basis of prospectively collected data by a trained research nurse at the time of 
recruitment. Where data were missing for continuous variables (time of symptom 
onset and creatinine concentration), the median value was imputed. Alternative 
modelling approaches for handling missing data may have provided a more accurate 
estimate of the risk score. Derivation of the HEART score was undertaken on a 
pragmatic basis, with the History aspect of the score based on typical (2) and atypical 
(1) chest pain. This differs from the original derivation of the HEART score, which 
was based on high suspicion (2) and slight suspicion (1). It is also noted that this score 
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High-sensitivity cardiac troponin I testing is widely used to evaluate patients with 
suspected acute coronary syndrome. A cardiac troponin concentration <5 ng/L 
identifies patients at presentation as low risk, but the optimal threshold is uncertain.  
Objective 
To evaluate the performance of a cardiac troponin I threshold of 5 ng/L at presentation 
as a risk stratification tool in patients with suspected acute coronary syndrome. 
Data Sources  
Systematic search of MEDLINE, EMBASE, Cochrane and Web of Science from 1st 
January 2006 to 18th March 2017. 
Study Selection:  
Prospective studies measuring high-sensitivity cardiac troponin I concentrations in 
patients with suspected acute coronary syndrome, where the diagnosis was adjudicated 
according to the universal definition of myocardial infarction.  
Data Extraction and Synthesis 
The systematic review identified 19 cohorts. Individual patient-level data was obtained 
from the corresponding authors of 17 cohorts, with aggregate data from two cohorts. 
Meta-estimates for primary and secondary outcomes were derived using a binomial-




Main Outcomes and Measures  
The primary outcome was myocardial infarction or cardiac death during the index 
hospitalization or at 30 days. Performance was evaluated in subgroups and across a 
range of troponin concentrations (2-16 ng/L) using individual patient data.  
Results 
Of 11,845 articles identified, 104 underwent full-text review, and 19 cohorts from 9 
countries were included. Among 22,457 patients included in the meta-analysis (age 62 
[15.5] years; n=9,329 (41.5%) women), the primary outcome occurred in 2,786 
(12.4%). Cardiac troponin I concentrations were <5 ng/L at presentation in 11,012 
(49%) patients, in whom there were 60 events, giving a NPV of 99.5% (95% 
confidence interval [CI] 99.3-99.6) for the primary outcome. There were no cardiac 
deaths at 30 days, and 7 (0.1%) at 1 year, with a NPV of 99.9% (95% CI 99.7 to 99.9%) 
for cardiac death. 
Conclusions and Relevance 
Among patients with suspected acute coronary syndrome, a high-sensitivity cardiac 
troponin I concentration <5 ng/L identified those at low risk of myocardial infarction 
or cardiac death within 30 days. Further research is needed to understand the clinical 





Chest pain is one of the most common reasons for presentation to hospital worldwide 
(Makam and Nguyen, 2015). Despite the majority of patients not having myocardial 
infarction (Goodacre et al., 2005), hospital admission for observation and serial 
cardiac troponin testing is required in many patients to identify those with and without 
myocardial infarction (Goodacre et al., 2013). Novel strategies to identify low risk 
patients at presentation have been proposed in order to reduce hospital admissions, 
serial testing and resource utilization as well as to improve care for patients (Skinner 
et al., 2010, Roffi et al., 2016). 
High-sensitivity assays are able to quantify cardiac troponin at low concentrations, and 
provide an opportunity to rule out myocardial infarction at an earlier stage. In a 
prospective study of consecutive patients with suspected acute coronary syndrome, a 
risk stratification threshold was defined using a high-sensitivity cardiac troponin I 
assay. In 4,870 patients, a threshold of <5 ng/L had a negative predictive value (NPV) 
of 99.6%, misclassifying less than one myocardial infarction for every 200 patients 
tested (Shah et al., 2015a). This threshold identified more than half of all patients with 
suspected acute coronary syndrome as low risk, reducing the proportion of patients 
who require admission for serial testing.  
Recent studies have questioned whether <5 ng/L is the optimal threshold to risk stratify 
patients and have proposed alternative thresholds that may miss fewer patients with 
myocardial infarction (Carlton et al., 2016, Neumann et al., 2017a, Sandoval et al., 
2017a, Goorden et al., 2016). To investigate these concerns, a systematic review of all 
studies of high-sensitivity cardiac troponin I testing in patients with suspected acute 
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coronary syndrome was undertaken, and individual patient level data was obtained. 
Across multiple cohorts with varying prevalence of myocardial infarction, the aim was 
to evaluate the performance of this threshold, to evaluate other risk stratification 




3.3.1 Search strategy and selection of articles 
A systematic search of MEDLINE, EMBASE, Cochrane and Web of Science was 
performed without language restriction from 1st January 2006 to 18th March 2017 using 
detailed search terms for: chest pain, acute coronary syndrome, acute myocardial 
infarction, troponin, high sensitive/sensitivity and emergency department (Figure 3.1, 
Appendix 1.1 for full search strategy). Studies were included if they met the following 
pre-specified eligibility criteria: 1) prospective studies of patients investigated in the 
Emergency Department for suspected acute coronary syndrome, 2) cardiac troponin 
measured using the Abbott ARCHITECTSTAT high-sensitive cardiac troponin I assay 
(Abbott Laboratories, Abbott Park, IL) at presentation, and 3) an adjudicated end-point 
of myocardial infarction on index hospitalization (Appendix 1.2 and 1.3). All findings 
are reported in accordance with the Preferred Reporting Items for Systematic review 
and Meta-Analysis of Individual Participant Data (PRISMA-IPD) (Stewart et al., 
2015). 
3.3.2 Data extraction 
Two investigators (AC, KL) performed the initial screening of titles and abstracts. Full 
text reports of potentially relevant articles were obtained and assessed by both 
investigators using our pre-specified protocol (PROSPERO register - 
CRD42017059128). A third investigator adjudicated all disagreements (AS). Where 
there were multiple articles from the same cohort, the article that included the largest 
number of participants was included. The corresponding authors of each eligible 
cohort were contacted with a request for anonymized data including cardiac troponin 
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concentrations, adjudicated diagnosis, outcomes and pre-specified covariates (age, sex, 
chest pain, time from symptom onset to presentation sample, myocardial ischemia on 
the electrocardiogram, cigarette smoking, diabetes mellitus, hypertension, 
hyperlipidemia, known angina, previous myocardial infarction, percutaneous coronary 
intervention, coronary artery bypass grafting, or stroke). All studies were prospective 
and conducted in accordance with the Declaration of Helsinki with approval from the 
regional ethics committee or institutional review board, and written consent obtained 
where required. This approval permitted each contributor to share individual-level data 
or aggregate data for inclusion in this meta-analysis. Bias was assessed by two 
investigators independently, with consensus from a third, using the Quality 
Assessment of Diagnostic Accuracy Studies version 2 (QUADAS-2) framework 
(Appendix 1.4).  
3.3.3 Analysis population and primary outcome 
The analysis population comprised patients with cardiac troponin concentrations ≤99th 
percentile at presentation, as those >99th percentile have evidence of myocardial injury 
and are not eligible for risk stratification at presentation. Patients with ST-segment 
elevation myocardial infarction and those who presented in cardiac arrest were 
excluded from this analysis. The pre-specified primary outcome was a composite of 
type 1 myocardial infarction or cardiac death at 30 days. The pre-specified secondary 
outcomes were recurrent myocardial infarction and cardiac death at 1 year. In addition, 
we evaluated the performance of cardiac troponin thresholds for the diagnosis of type 
1 or type 2 myocardial infarction on index presentation. The number of patients 



















Figure 3.1 Flow diagram of the study population and data analysis 
11845 Articles identified through database 
search a
11429 Article titles and abstracts screened 
for eligibility
11325 Excluded (did not meet 
eligibility criteria)
104 Full-text articles assessed 
for eligibility
68 Excluded (did not meet 
inclusion criteria) c
36 Articles included 
(19 unique cohorts)
2 Cohorts had aggregate data available 
(3856 total participants)
22457 Participants with individual 
patient-level or aggregate data d
18248 Included in analysis 
population (troponin 
concentration ≤99th centile at 
presentation) for primary 
outcome of myocardial 
infarction or cardiac death 
and subgroup analyses e
16537 Included in analysis of 
secondary outcome of index 
non-ST-segment myocardial 
infarction
416 Duplicate articles removed b
17 Cohorts had individual patient-level 
data available (18601 total participants)
18601 Participants with individual 
patient-level data
18601 Included in evaluation of 
additional cardiac troponin 
thresholds (2-16 ng/L) 
15601 had available 
electrocardiogram data
12953 Included in evaluation of 
cardiac death at 30 days
9271   Included in evaluation of 
cardiac death at 1 year
Flow diagram illustrating the systematic database review and screening 
of articles, level of exclusion, the number of articles included, and the 
individual patient-level data or aggregate data available for each 
analysis, based on the PRISMA-IPD guidelines.
a Articles identified through a systematic database search: MEDLINE = 
2078; EMBASE = 7116; Cochrane = 390;Web of Science = 2261.
b Any identical publications were removed, but articles from the same 
cohorts were retained at this stage.
c Articles excluded after full-text review because they evaluated a 
contemporary cardiac troponin I assay (n = 36), a different high-
sensitivity cardiac troponin I assay (n = 14), a high-sensitivity cardiac 
troponin T assay (n = 5), a different patient population (n = 4), or a 
different outcome measure (n = 9).
d Authors who did not provide individual patient-level data provided 
aggregate data for the primary outcome, subgroup analyses, and 
secondary outcome when available.
e Subgroup analyses were prespecified, with the following data available 
per group: age (n = 18 248), sex (n = 18 248), diagnosis of ischemic 
heart disease (n = 14 160), time from symptom onset to troponin sample 
time (n = 13 404), and electrocardiogram (n = 15 887).
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3.3.4 Statistical analysis 
Baseline characteristics are summarised as mean (standard deviation, SD) or median 
(inter-quartile range, IQR) as appropriate. The primary outcome measure was the NPV 
of a high-sensitivity cardiac troponin I concentration <5 ng/L at presentation. All 
cardiac troponin concentrations were rounded to integer values in line with clinical 
standards for reporting. Where individual patient level data were available, this was 
checked for consistency and completeness, and cohort level summary counts of 
patients with and without the primary outcome were derived for high-sensitivity 
cardiac troponin I concentration <5 ng/L at presentation. In the cohorts where raw data 
were not available, the corresponding authors were asked to provide these summaries. 
The NPV was calculated at a cohort level using a Bayesian approach, with a binomial 
likelihood and beta prior (a non-informative Jeffrey’s prior with both shape parameters 
equal to 0.5), as this produces confidence intervals with better coverage when 
proportions are close to 0 or 1 (Brown et al., 2001). Heterogeneity is reported using 
the I2 statistic (Higgins et al., 2003). Survival free from cardiac death at 30 days and 
one year was reported for patients with cardiac troponin I concentrations <5 ng/L, 5-
99th percentile and >99th percentile at presentation. 
3.3.5 Pre-specified subgroup analyses 
For the primary outcome, the NPV was evaluated in pre-specified subgroups stratified 
by age (≤65 or >65 years), sex, history of ischaemic heart disease, time of symptom 
onset (≤2 or >2 hours) and presence of myocardial ischaemia on the electrocardiogram. 
Most cohorts defined myocardial ischaemia as ≥2 mm ST-segment depression in two 
consecutive leads, or new T-wave inversion. To explore the clinical implications of 
differences in performance between subgroups, we undertook these subgroup analyses 
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in patients without myocardial ischaemia on the electrocardiogram. Studies have 
demonstrated imperfect calibration between high-sensitivity cardiac troponin I and T 
assays, with up to 17.5% of patients >99th percentile on the T assay shown to be <99th 
percentile on the I assay (Wildi et al., 2015). Therefore, a further analysis evaluated 
whether the assay used to adjudicate the index diagnosis affected the performance of 
the risk stratification threshold. In addition, we determined whether the assessed risk 
of bias and site of patient recruitment affected the NPV.  
3.3.6 Derivation of meta-estimates 
Meta-estimates of the NPV were derived in the analysis population for all primary and 
secondary outcomes by modelling cohort level proportions (true negative / [true 
negative + false negative]) in a binomial-normal random effects model, with an 
additional term where cohort-level characteristics (adjudication assay, assessment of 
bias or location of recruitment) were compared. We estimated odds ratios for the 
difference in NPV between pre-specified sub-groups, meta-analysing this across 
cohorts to obtain the mean odds ratio and a P-value for the null hypothesis of no 
association. For cohorts where individual patient level data were available, the cardiac 
troponin threshold which would identify the highest proportion of patients as low-risk 
for a NPV ≥99.5% was determined. For this analysis, we pre-specified a NPV of 99.5% 
as being clinically acceptable and equivalent to a miss rate of 5 per 1,000 low-risk 
patients (Than et al., 2013). To evaluate how the inclusion of a risk stratification 
threshold would affect the overall diagnosis in all patients with suspected acute 
coronary syndrome, meta-estimates of NPV, positive predictive value (PPV) and 
sensitivity were derived for risk stratification thresholds alone (2-16 ng/L), and in 
conjunction with a non-ischaemic electrocardiogram at presentation. At each threshold, 
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the proportion of the total population classified as low-risk and the miss rate per 1,000 
patients was reported. All analyses were performed in R (Version 3.2.2), with the 
meta-analyses performed using the Metafor package (Viechtbauer, 2010). The 




3.4.1 Systematic-review  
The initial search identified 11,845 articles, of which 104 articles underwent full text 
review. A total of 36 articles met inclusion criteria, reporting observations from 19 
individual cohorts across nine different countries (Figure 3.1). Five articles reported 
outcomes for a high-sensitivity cardiac troponin I concentration of <5 ng/L (Shah et 
al., 2015a, Carlton et al., 2016, Neumann et al., 2017a, Sandoval et al., 2017a, Shortt 
et al., 2017).  
3.4.2 Study population 
All corresponding authors from the 19 individual cohorts identified in the systematic 
review agreed to provide data for the meta-analysis. Individual patient-level data was 
obtained from 17 cohorts (Shah et al., 2015a, Chapman et al., 2017b, Carlton et al., 
2016, Neumann et al., 2017a, Goorden et al., 2016, Shortt et al., 2017, Shah et al., 
2015b, Pickering et al., 2016a, Keller et al., 2011, Than et al., 2012, Cullen et al., 
2017a, Korley et al., 2014, Parsonage et al., 2016, Than et al., 2014a, Kavsak et al., 
2013b, Body et al., 2014, Body et al., 2017), and aggregate data from two cohorts 
(Sandoval et al., 2017a, Wildi et al., 2016), for a total study population of 22,457 
patients with suspected acute coronary syndrome (age 62 (16) years, 58.5% male; 
Table 3.1).  
In 11 cohorts, data was available for the pre-specified primary outcome of type 1 
myocardial infarction or cardiac death at 30 days (Table 3.2). In the remainder, the 
outcome was index type 1 myocardial infarction (n=1) or non-ST-segment elevation 
myocardial infarction on index presentation (n=5) or at 30 days (n=2). The assessed 
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risk of bias was high in 11 cohorts due to patient selection or use of a contemporary 
reference standard (Appendix 1.3 and 1.4). Across all cohorts, the proportion with the 
primary outcome was 12.4% (range 2.4% to 24.0%). The analysis population 
comprised 18,248 of 22,457 patients where high-sensitivity cardiac troponin I 
concentrations were <99th percentile at presentation, and the prevalence of the primary 
outcome was 3.5% (range 0.6% to 6.1%). 
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(Pickering et al., 
2016a) 
Adjudication assay  High-sensitivity cardiac troponin I cohorts 
Number of patients 22457 4701 1630 1064 756b 558 
Age 62 (15.5)a 63.7 (16.3) 57.5 (15.3) 65.6 (15.9) 62 (14.2) 59.2 (11.9) 
Male (%) 13128 (58.5) 2651 (56.4) 911 (55.9) 579 (54.4) 462 (61.1) 340 (60.9) 
Presentation 
Chest pain (%) 16760 (80.2) 3917 (83.3) 835 (51.2) 880 (82.9) 651 (86.1) 558 (100) 
Time from symptom onset to 











Myocardial ischemia on ECG (%) 3663 (18.8) 795 (19.5) 126 (7.7) 326 (31.6) 84 (12.3) 25 (4.5) 
Cardiovascular risk factors 
Hypertension (%) 11018 (54.3) 1376 (33.3) 1074 (65.9) 570 (53.6) 327 (45.0) 290 (52) 
Hyperlipidaemia (%) 9270 (45.7) 1113 (27.0) 696 (42.7) 484 (45.65 291 (40.3) 284 (50.9) 
Smoker (%) 6093 (32.6) 842 (32.1) 592 (36.3) 255 (26.2) 149 (20.3) 84 (15.1) 
Diabetes mellitus (%) 3703 (18.3) 661 (16.0) 505 (31.0) 173 (16.2) 115 (15.6) 78 (14) 
Known angina (%) 4299 (28.7) 1379 (33.3) 264 (16.2) 451 (42.5) 220 (29.8) 139 (24.9) 
Previous MI (%) 4319 (21.3) 785 (19.0) 190 (11.7) 284 (26.7) 161 (21.9) 130 (23.3) 
Previous PCI (%) 2521 (15.6) 439 (10.6) 150 (9.2) 162 (15.2) 132 (18.1) - 
Previous CABG (%) 1536 (8.4) 242 (5.9) 73 (4.5) 83 (7.8) 37 (5.1) 26 (4.7) 
Previous stroke (%) 1603 (8.1) 333 (8.1) 153 (9.4) 136 (12.8) 40 (5.6) - 
High-sensitivity cardiac troponin at presentation 
≤ 99th percentile (%)  18248 (81.3) 3781 (80.4) 1326 (81.3) 828 (77.8) 617 (81.6) 494 (88.5) 
> 99th percentile (%) 4209 (18.7) 920 (19.6) 304 (18.7) 236 (22.1) 139 (18.4) 64 (11.5) 
Values are number (%) or mean (SD) or median (inter-quartile range). % as a proportion of data available. (-) Data not available.  
a Summary estimates for age and sample time exclude APACE and UTROPIA as only aggregate data available.  
b Only unique patients from High-STEACS sub-study cohort are included  




































(Kavsak et al., 
2013b) 
 Contemporary cardiac troponin I and T cohorts  
Number of patients 1598 804 1127 1137 808 1106 474 144 
Age 61.3 (13.6) 55.2 (15.2) 51.2 (12.6) 66.7 (16.5) 56.6 (13.3) 65.3 (13.0) 60.7 (12.6) 59.7 (13.7) 
Male (%) 1046 (65.5) 482 (60.0) 676 (60.0) 535 (47.1) 381 (47.2) 659 (59.6) 297 (62.7) 93 (64.6) 
Presentation 
Chest pain (%) 833 (52.1) 690 (85.8) 844 (74.9) 651 (57.3) 479 (59.3) 1106 (100) 474 (100) 134 (93.1) 
Time from symptom onset to 















Myocardial ischemia on ECG (%) 855 (54.1) 51 (6.3) 36 (3.2) - - 188 (17.0) 21 (4.4) - 
Cardiovascular risk factors 
Hypertension (%) 1190 (74.5) 403 (50.1) 447 (39.7) 804 (71.2) 509 (63) 679 (61.4) 214 (45.1) 92 (64.3) 
Hyperlipidaemia (%) 1178 (73.7) 386 (48) 427 (37.9) 676 (60.6) 340 (42.1) 636 (57.5) 243 (51.3) 79 (56.4) 
Smoker (%) 362 (22.8) 188 (23.4) 276 (24.5) 700 (61.6) 290 (35.9) 161 (14.6) 85 (17.9) 95 (66.4) 
Diabetes mellitus (%) 246 (15.7) 107 (13.3) 141 (12.5) 333 (29.7) 240 (29.7) 178 (16.1) 70 (14.8) 36 (25.9) 
Known angina (%) - 188 (23.4) 125 (11.1) 305 (27.5) 168 (20.8) 527 (47.6) 100 (21.1) 60 (41.7) 
Previous MI (%) 363 (23.2) 138 (17.2) 130 (11.5) 408 (36.6) 153 (18.9) 334 (30.2) 121 (25.5) 52 (36.4) 
Previous PCI (%) 335 (25.8) 87 (10.8) 85 (7.5) 251 (22.4) 112 (13.9) - - - 
Previous CABG (%) 165 (14.7) 55 (6.8) 44 (3.9) 251 (22.4) 61 (7.5) 122 (11.0) 37 (7.8) 46 (32.2) 
Previous stroke (%) 87 (5.5) 74 (9.2) 46 (4.1) 190 (17.0) 117 (14.5) 65 (5.9) 47 (9.9) 11 (7.7) 
High-sensitivity cardiac troponin at presentation 
≤ 99th percentile (%)  1193 (74.7) 720 (89.6) 1083 (96.1) 915 (80.5) 636 (78.7) 838 (75.8) 400 (84.4) 122 (84.7) 
> 99th percentile (%) 405 (25.3) 84 (10.4) 44 (3.9) 222 (19.5) 172 (21.3) 268 (24.2) 74 (15.6) 22 (15.3) 
 
Values are number (%) or mean (SD) or median (inter-quartile range). % as a proportion of data available. (-) Data not available.  




Table 3.1. continued. Baseline characteristics of study patients stratified by cohort 
 
 TI-AMO 
(Goorden et al., 
2016) 
APACE 
(Wildi et al., 2016) 
BACC 
(Neumann et al., 
2017a) 
TRUST 
(Carlton et al., 
2016) 
Stockport 
(Body et al., 2014) 
Manchester 
(Body et al., 2017) 
 High-sensitivity cardiac troponin T cohorts 
Number of patients 1552 2226 1496 867 229 180 
Age 67.2 (16.0) 62 (16.0) 62.6 (15.7) 57.9 (13.1) 65.4 (15.6) 57.2 (14.5) 
Male (%) 781 (50.3) 1512 (67.9) 955 (63.8) 515 (59.4) 137 (59.8) 116 (64.4) 
Presentation 
Chest pain (%) - 2226 (100) 1206 (80.7) 867 (100) 229 (100) 180 (100.0) 
Time from symptom onset to 
troponin sample (mins)  
- 300  
(120-720) 






Myocardial ischemia on ECG (%) 156 (10.5) 476 (21.4) 430 (29.4) 0 (0) 48 (21.0) 46 (25.6) 
Cardiovascular risk factors 
Hypertension (%) - 1383 (62.1) 1015 (68.2) 477 (55.0) 93 (40.6) 75 (41.9) 
Hyperlipidaemia (%) - 1111 (49.9) 592 (39.6) 583 (67.2) 91 (39.7) 60 (33.3) 
Smoker (%) - 1370 (61.5) 352 (23.6) 210 (24.2) 36 (15.7) 46 (26.9) 
Diabetes mellitus (%) - 405 (18.2) 201 (13.6) 145 (16.7) 42 (18.3) 27 (15.0) 
Known angina (%) - - - 223 (25.7) 97 (42.4) 53 (29.6) 
Previous MI (%) - 514 (23.1) 240 (16.1) 190 (21.9) 78 (34.1) 48 (27.0) 
Previous PCI (%) - 527 (23.7) - 168 (19.4) 34 (14.8) 39 (21.8) 
Previous CABG (%) - 211 (9.5) - 41 (4.7) 30 (13.1) 12 (6.8) 
Previous stroke (%) - 122 (5.5) 102 (6.8) 57 (6.6) 20 (8.7)d 3 (1.7)d 
High-sensitivity cardiac troponin at presentation 
≤ 99th percentile (%)  1156 (74.5) 1801 (80.9) 1202 (80.3) 810 (93.4) 179 (78.2) 147 (81.7) 
> 99th percentile (%) 396 (25.5) 425 (19.1) 294 (19.7) 57 (6.6) 50 (21.8) 33 (18.3) 
 
Values are number (%) or mean (SD) or median (inter-quartile range). % as a proportion of data available. (-) Data not available.  
c Only symptom to presentation time available. d Includes patients with transient ischaemic attack.  













hs-cTnI <5 ng/L  
at presentationa  
n (%) 
  All patientsa ≤99th percentileb    
HighSTEACS-V Type 1 MI or cardiac death (30d) 662 (14.1) 141 (3.7) Abbott hs-cTnI 99.6 (99.3-99.8) 2292 (48.8) 
UTROPIA Type 1 MI or cardiac death (30d) 70 (4.3) 22 (1.4) Abbott hs-cTnI 99.5 (99.0-99.9) 774 (47.5) 
HighSTEACS-P Type 1 MI or cardiac death (30d) 201 (18.9)  46 (5.6) Abbott hs-cTnI 99.7 (99.0-100) 469 (44.1) 
HighSTEACS-S Type 1 MI or cardiac death (30d) 115 (15.2) 25 (4.1) Abbott hs-cTnI 99.4 (98.5-99.9) 428 (56.6) 
EDACS Type 1 MI or cardiac death (30d) 66 (11.8) 17 (3.4) Abbott hs-cTnI 99.1 (97.9-99.8) 378 (67.7) 
STENOCARDIA Index NSTEMI 268 (16.8) 29 (2.4) Roche cTnT 99.9 (99.7-100) 563 (35.2) 
ADAPT-B Type 1 MI or cardiac death (30d) 48 (6.0) 8 (1.1) Beckmann Accu-cTnI 99.7 (99.1-100) 532 (66.2) 
IMPACT Type 1 MI or cardiac death (30d) 49 (4.3) 26 (2.4) Beckmann Accu-cTnI 99.5 (99.0-99.9) 923 (81.9) 
ROMI Index NSTEMI  133 (11.7) 40 (4.4) Abbott cTnI 99.1 (98.1-99.7) 503 (44.2) 
HOPKINS Index Type 1 MI 19 (2.4) 4 (0.6) Abbott cTnI 99.4 (98.3-100) 266 (32.9) 
ADAPT-C Type 1 MI or cardiac death (30d) 265 (24.0) 42 (5.0) Abbott cTnI 99.1 (98.0-99.7) 475 (42.9) 
ADAPT-RCT Type 1 MI or cardiac death (30d) 75 (15.8) 20 (5.0) Abbott cTnI 99.3 (98.0-100) 228 (48.1) 
RING Index NSTEMI 9 (6.2) 1 (0.8) Roche c-TnT 99.4 (97.8-100) 88 (61.1) 
TI-AMO Index NSTEMI 90 (5.8) 18 (1.6) Roche hs-cTnT 99.8 (99.2-100) 613 (39.5) 
APACE Index NSTEMI 399 (17.9) 117 (6.1) Roche hs-cTnT 99.2 (98.6-99.7) 1801 (49.8) 
BACC Type 1 MI or cardiac death (30d) 181 (12.0) 47 (3.9) Roche hs-cTnT 98.9 (97.8-99.6) 567 (37.9) 
TRUST Type 1 MI or cardiac death (30d) 66 (7.6) 28 (3.5) Roche hs-cTnT 98.3 (97.2-99.1) 664 (76.6) 
STOCKPORT NSTEMI (30 days) 43 (18.8) 9 (5.0) Roche hs-cTnT 99.0 (96.1-100) 48 (21.0) 
MANCHESTER NSTEMI (30 days) 27 (15.0) 5 (3.4) Roche hs-cTnT 98.4 (95.1-99.9) 93 (51.7) 
SUMMARY  2786 (12.4) 645 (3.5)  99.5 (99.3-99.6) 11012 (49.0) 
aProportion of total cohort size b Proportion of patients <99th centile. MI = Myocardial Infarction, NSTEMI = Non-ST segment Elevation Myocardial Infarction, 
hs-cTnI = high-sensitivity cardiac troponin I, cTnT = cardiac troponin T,  cTnI = cardiac troponin I, hs-cTnT= high-sensitivity cardiac troponin T, 30d = 30 days.  
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3.4.3 Meta-estimate of the risk stratification threshold  
High-sensitivity cardiac troponin I concentrations were <5 ng/L at presentation in 
11,012 (49%) patients, with a NPV of 99.5% (95% confidence intervals [CI] 99.3 to 
99.6%; Figure 3.2, Table 3.2) for the primary outcome, and a total of 60 missed index 
or 30-day events (59 index myocardial infarction, one myocardial infarction at 30 days, 
and no cardiac deaths at 30 days; Appendix 1.6). The NPV was similar across cohorts 
with varying prevalence of myocardial infarction. The estimate of heterogeneity (I2) 
was 31.9%. Cohort level two-by-two summary tables are provided for the analysis 
population in Table 3.3. Where data were available in the analysis population 
(n=16,537, 90.6%), we estimated the NPV for the secondary outcome of index non-
ST-segment elevation myocardial infarction (type 1 or type 2 myocardial infarction). 
Cardiac troponin I concentrations were <5 ng/L at presentation in 9,574 (48%) patients, 

























Figure 3.2. Negative predictive value of a cardiac troponin I concentration <5 ng/L at presentation by cohort for myocardial infarction or 
cardiac death at 30 days.  
 
Diamonds represent the central estimate of NPV with colour corresponding to the assay used to adjudicate myocardial infarction (red for cardiac troponin I, 
blue for cardiac troponin T), size corresponding to the number of patients per cohort (large diamond >3,000 patients, medium diamond ≥1,000 patients, small 
diamond <1,000 patients), and whiskers representing 95% confidence intervals. Dotted vertical line represents central estimate of NPV at 99.5%. TN = true 
negative. FN = false negative. Population (n) = number of patients per cohort <99th percentile at presentation. 
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Table 3.3. Diagnostic performance of a high-sensitivity cardiac troponin I concentration <5 ng/L for myocardial infarction or cardiac 
death at 30 days  
 
Cohort TP FP TN FN NPV 
% (95% CI) 
HighSTEACS-V  132 1357 2283 9 99.6 (99.3-99.8)  
UTROPIA  19 533 771 3 99.5 (99.0-99.9)  
HighSTEACS-P  45 314 468 1 99.7 (99.0-100)  
HighSTEACS-S  23 166 426 2 99.4 (98.5-99.9)  
EDACS  14 102 375 3 99.1 (97.9-99.8)  
STENOCARDIA  29 601 563 0 99.9 (99.7-100)  
ADAPT-B  7 181 531 1 99.7 (99.1-100)  
IMPACT  22 138 919 4 99.5 (99.0-99.9)  
ROMI  36 376 499 4 99.1 (98.1-99.7)  
HOPKINS  3 367 265 1 99.4 (98.3-100)  
ADAPT-C  38 325 471 4 99.1 (98.0-99.7)  
ADAPT-RCT  19 153 227 1 99.3 (98.0-100)  
RING  1 33 88 0 99.4 (97.8-100)  
TI-AMO  17 526 612 1 99.8 (99.2-100)  
APACE  109 584 1100 8 99.2 (98.6-99.7)  
BACC  41 594 561 6 98.9 (97.8-99.6)  
TRUST  17 129 653 11 98.3 (97.2-99.1)  
STOCKPORT  9 122 48 0 99.0 (96.1-100)  
MANCHESTER 4 50 92 1 98.4 (95.1-99.9)  
Abbreviations: TP = true positives; FP = false positives; TN = true negatives; FN = false negatives; NPV = negative predictive value; 95% CI = confidence 
intervals. Above table refers to population <99th centile at presentation (n=18,248). 
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3.4.4 Subgroup analysis  
Meta-estimates of NPV were obtained in a number of pre-specified subgroups (Figure 
3.3). The NPV was lower in those with myocardial ischaemia on the electrocardiogram 
(98.2%, 95% CI 96.4 to 99.1%, n = 2,178) compared to those without (99.7%, 95% CI 
99.4 to 99.8%, n = 13,709, P < 0.001), and in those who presented within two hours 
of symptom onset (99.0%, 95% CI 97.7 to 99.5%, n = 2,303, versus 99.6%, 95% CI 
99.4 to 99.8%, n = 11,101, P = 0.003). Differences in the NPV were also observed 
between patients >65 years (NPV 99.1%, 95% CI 98.5 to 99.5%, n = 6,818), compared 
to those ≤65 years (99.6%, 95% CI 99.4 to 99.8%, n = 11,430, P = 0.02) and in those 
with a history of ischaemic heart disease (NPV 98.8%, 95% CI 98.1 to 99.3%, n = 
3,990) compared to those without (NPV 99.6%, 95% CI 99.4 to 99.7%, n = 10,170, P 























Figure 3.3. Negative predictive value of a cardiac troponin I concentration <5 ng/L at presentation for myocardial infarction or cardiac 
death at 30 days in pre-specified subgroups 
 
Diamonds represent the central estimate of NPV with size corresponding to the number of patients per cohort (large diamond >3,000 patients, medium diamond 
≥1,000 patients, small diamond <1,000 patients), and whiskers representing 95% confidence intervals. The vertical dashed line and shaded areas represent the 
central estimate and 95% confidence intervals for the full analysis population. TN = true negative. FN = false negative. IHD = ischemic heart disease. All 19 
cohorts included unless otherwise specified. a) IHD status available in 16 of 19 cohorts, b) time of symptom onset available in 15 of 19 cohorts, c) 
electrocardiogram available in 15 of 19 cohorts. 
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When this analysis was restricted to patients without myocardial ischaemia on the 
electrocardiogram, estimates of NPV were >99% for all subgroups (Figure 3.4). 
Performance of the risk stratification threshold was similar regardless of the assay used 
for adjudication (high-sensitivity cardiac troponin I, NPV 99.6%, 95% CI 99.3 to 99.7, 
n = 7,046; contemporary cardiac troponin I or T, NPV 99.6%, 95% CI 99.3 to 99.7, n 
= 5,907; high-sensitivity cardiac troponin T, NPV 99.2%, 95% CI 98.6 to 99.6%, n = 
5,295, P = 0.27), the assessed risk of bias (high, NPV 99.5%, 95% CI 99.1 to 99.7%, 
n = 7,043; low, NPV 99.3%, 95% CI 99.3 to 99.6%, n = 11,205, P = 0.37) and the site 
of patient recruitment (Europe, NPV 99.5%, 95% CI 99.1 to 99.7, n = 11,714; North 
America, NPV 99.5%, 95% CI 99.0 to 99.8%, n = 2,999 and Asia-Pacific, NPV 99.5%, 






















Figure 3.4. Negative predictive value of a cardiac troponin I concentration <5 ng/L at presentation for myocardial infarction or cardiac 
death at 30 days in patients without myocardial ischaemia on the electrocardiogram by pre-specified subgroups  
 
Diamonds represent the central estimate of NPV with size corresponding to the number of patients per cohort (large diamond >3,000 patients, medium diamond 
≥1,000 patients, small diamond <1,000 patients), and whiskers representing 95% confidence intervals. Data obtained from the following cohorts where individual 
patient-level data (including ECG status) available: HighSTEACS-V, HighSTEACS-S, HighSTEACS-P, ADAPT-B, IMPACT, EDACS, ADAPT-RCT, ADAPT-C, 
BACC, TIAMO, TRUST, STOCKPORT, MANCHESTER and STENOCARDIA.
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Figure 3.5. Negative predictive value of a high-sensitivity cardiac troponin I 
concentration <5 ng/L at presentation for myocardial infarction or cardiac death at 30 
days, stratified by adjudicating assay, bias, and location. 
Diamonds represent the central estimate of NPV and whiskers represent 95% confidence intervals. 
Black colour indicates overall meta-estimate for negative predictive value.   
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3.4.5 Short and long term outcomes  
Follow up for cardiac death at 30 days and at 1 year was available in 12,953 (57.7%), 
and 9,271 (41.3%) patients, respectively (Table 3.4 and 3.5). In those patients with 
cardiac troponin concentrations <5 ng/L at presentation (n=6,956), there were no 
cardiac deaths at 30 days (NPV 100% [95% CI 99.9 to 100%], sensitivity 99.4% [95% 
CI 97.7-100%]), and 7 cardiac deaths (0.1%) at 1 year (NPV 99.9% [95% CI 99.7 to 
99.9%], sensitivity 96.1% [95% CI 92.9 to 98.3%]). In patients with cardiac troponin 
concentrations between 5 ng/L and the 99th percentile at presentation (n=3,817), there 
were 19 (0.5%) and 58 (2.1%) cardiac deaths at 30 days and 1 year respectively. By 
comparison, in those with troponin concentrations above the 99th percentile (n=2,180), 
there were 62 (2.8%) and 125 (8.2%) cardiac deaths at 30 days and 1 year, respectively. 
In patients with troponin concentrations <5 ng/L at presentation and an index or 30-
day myocardial infarction, there were no cardiac deaths at 30 days or 1 year. As the 
majority of studies did not adjudicate recurrent myocardial infarction events at 1 year, 




Table 3.4. Summary thirty day and one year cardiac death outcomes  
 
Group 30-day follow-up  
n 
30-day cardiac death 
n (%) 
1 year follow-up  
n 
1 year cardiac death 
n (%) 
High-sensitivity cardiac troponin at presentation 
<5 ng/L  6956 0 (0.0) 5054 7 (0.1) 
≥5 ng/L and ≤99th centile  3817 19 (0.5) 2698 58 (2.1) 
>99th centile 2180 62 (2.8) 1519 125 (8.2) 
Total number of patients  12953  9271  
 
30 day and or 1 year cardiac death outcomes obtained from the following cohorts:  
HighSTEACS-V, HighSTEACS-S, HighSTEACS-P, ADAPT-B, IMPACT, EDACS, ADAPT-RCT, ADAPT-C, BACC and TRUST  
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Table 3.5. Thirty day and one year cardiac death outcomes stratified by cardiac troponin concentration at presentation 
 
 
30 day and or 1 year cardiac death outcomes obtained from the following cohorts:  
HighSTEACS-V, HighSTEACS-S, HighSTEACS-P, ADAPT-B, IMPACT, EDACS, ADAPT-RCT, ADAPT-C, BACC and TRUST





death n (%) 
1 year follow-up  
n 
1 year cardiac death 
n (%) 
<2 ng/L  2024 0 (0.0) 1561 0 (0.0) 
<3 ng/L  4528 0 (0.0) 3334 1 (0.0) 
<4 ng/L 5912 0 (0.0) 4314 4 (0.1) 
<5 ng/L 6956 0 (0.0) 5054 7 (0.1) 
<6 ng/L 7623 0 (0.0) 5544 8 (0.1) 
<7 ng/L 8187 1 (0.0) 5951 9 (0.2) 
<8 ng/L 8558 1 (0.0) 6214 14 (0.2) 
<9 ng/L 8892 1 (0.0) 6444 14 (0.2) 
<10 ng/L 9144 1 (0.0) 6619 14 (0.2) 
<11 ng/L 9347 1 (0.0)  6748 14 (0.2) 
<12 ng/L 9506 2 (0.0) 6862 20 (0.3) 
<13 ng/L 9678 2 (0.0) 6981 23 (0.3) 
<14 ng/L 9807 3 (0.0) 7075 26 (0.4) 
<15 ng/L 9937 6 (0.1) 7164 28 (0.4) 
<16 ng/L 10053 6 (0.1) 7248 32 (0.4) 
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3.4.6 Risk stratification thresholds and diagnosis of myocardial 
infarction 
In all patients with suspected acute coronary syndrome where individual patient-level 
data were available (n=18,601, 82.8%), we evaluated how different risk stratification 
thresholds would affect the NPV and sensitivity for the primary outcome. When used 
in isolation, a troponin concentration of <5 ng/L gave a NPV of 99.5% (95% CI 99.3 
to 99.7%) and sensitivity of 98.0% (95% CI 96.4 to 98.9%), identifying 49.1% of 
patients as low risk with a miss rate of 5.4 (95% CI 4.0 to 7.0) per 1,000 patients. At a 
threshold of <2 ng/L, the NPV was 99.8% (95% CI 99.0 to 100%) and sensitivity was 
100% (95% CI 98.9 to 100%), but the proportion of patients identified as low risk was 
lower at 13.7%. Whilst the absolute number of missed cases was lower, the miss rate 









TP FP TN FN FN per 1000 
(Mean, 95% CI) 
NPV  
(Mean, 95% CI) 
Sensitivity  
(Mean, 95% CI) 
PPV 
(Mean, 95% CI) 
Proportion of all 
patients tested (%)a  
High-sensitivity cardiac troponin threshold only 
<2  2307 13744 2540 10 4.1 (2.0-6.9)  99.8 (99.0-100)  100 (98.9-100)  12.7 (9.8-16.3)  13.7 
<3 2297 10587 5697 20 3.6 (2.2-5.3)  99.7 (99.4-99.8)  99.3 (98.4-99.7)  16.2 (12.6-20.6)  30.7 
<4 2284 8700 7584 33 4.4 (3.0-6.0)  99.6 (99.4-99.8)  98.9 (97.5-99.5)  19.2 (14.9-24.4)  40.9 
<5 2268 7203 9081 49 5.4 (4.0-7.0)  99.5 (99.3-99.7)  98.0 (96.4-98.9)  22.5 (17.4-28.7)  49.1 
<6 2243 6199 10085 74 7.3 (5.8-9.1)  99.3 (99.0-99.5)  97.0 (94.9-98.3)  25.5 (19.5-32.5)  54.6 
<7 2213 5366 10918 104 9.5 (7.8-11.4)  99.1 (98.8-99.4)  95.7 (93.3-97.3)  28.4 (21.9-36.0)  59.3 
<8 2195 4803 11481 122 10.6 (8.8-12.5)  99.0 (98.7-99.3)  94.7 (92.0-96.5)  30.6 (23.6-38.6)  62.4 
<9 2175 4302 11982 142 11.8 (9.9-13.7)  98.9 (98.5-99.2)  93.8 (90.9-95.8)  33.1 (25.7-41.5)  65.2 
<10 2157 3943 12341 160 12.8 (10.9-14.9)  98.8 (98.4-99.2)  92.9 (89.6-95.2)  34.9 (27.1-43.7)  67.2 
<11 2129 3636 12648 188 14.7 (12.7-16.8)  98.6 (98.2-99.0)  91.3 (87.9-93.9)  36.8 (28.5-45.9)  69 
<12 2106 3395 12889 211 16.1 (14.1-18.4)  98.5 (98.1-98.9)  90.4 (86.8-93.0)  38.2 (29.6-47.5)  70.4 
<13 2089 3113 13171 228 17.1 (14.9-19.3)  98.4 (98.0-98.8)  89.5 (85.9-92.3)  40.5 (31.6-50.1)  72 
<14 2071 2932 13352 246 18.1 (16.0-20.4)  98.3 (97.9-98.7)  88.8 (85.3-91.5)  41.8 (32.7-51.5)  73.1 
<15 2050 2737 13547 267 19.4 (17.1-21.7)  98.2 (97.7-98.6)  87.7 (84.0-90.7)  43.4 (34.0-53.2)  74.3 
<16 2030 2575 13709 287 20.5 (18.3-23.0)  98.1 (97.6-98.5)  86.8 (82.8-90.0)  44.6 (35.1-54.6)  75.2 





Table 3.6. continued. Efficacy and safety of high-sensitivity cardiac troponin I thresholds for myocardial infarction or cardiac death at 30 
days 
 
Troponin (ng/L) TP FP TN FN FN per 1000 
(Mean, 95% CI) 
NPV  







Proportion of all 
patients tested 
(%)a  
High-sensitivity cardiac troponin threshold and non-ischaemic ECG* 
<2  2082 11538 2044 8 4.1 (1.8-7.3)  99.9 (98.5-100)  100 (96.6-100)  14.2 (11.3-17.6)  13.1 
<3 2077 8990 4592 13 2.9 (1.6-4.7)  99.8 (99.5-99.9)  99.7 (98.7-99.9)  18.0 (14.9-21.6)  29.4 
<4 2068 7547 6035 22 3.7 (2.3-5.4)  99.8 (99.4-99.9)  99.5 (98.1-99.9)  21.1 (17.5-25.2)  38.6 
<5 2059 6423 7159 31 4.4 (3.0-6.0)  99.7 (99.4-99.8)  99.0 (97.3-99.6)  24.5 (20.3-29.2)  45.9 
<6 2046 5744 7838 44 5.6 (4.1-7.4)  99.5 (99.2-99.7)  98.5 (96.3-99.4)  27.1 (22.4-32.5)  50.3 
<7 2026 5173 8409 64 7.6 (5.9-9.6)  99.3 (99.0-99.5)  97.4 (94.9-98.6)  29.7 (24.5-35.4)  54.1 
<8 2013 4798 8784 77 8.7 (6.9-10.8)  99.2 (98.9-99.4)  96.6 (93.8-98.2)  31.4 (25.9-37.5)  56.5 
<9 2004 4471 9111 86 9.4 (7.5-11.5)  99.1 (98.8-99.4)  96.0 (93.0-97.7)  33.1 (27.4-39.4)  58.7 
<10 1997 4244 9338 93 9.9 (8.0-12.0)  99.1 (98.7-99.4)  95.7 (92.5-97.5)  34.6 (28.6-41.2)  60.2 
<11 1980 4054 9528 110 11.5 (9.4-13.7)  98.9 (98.5-99.2)  94.7 (91.3-96.8)  35.9 (29.6-42.7)  61.5 
<12 1964 3904 9678 126 12.9 (10.8-15.2)  98.8 (98.4-99.1)  93.8 (90.3-96.1)  36.9 (30.2-44.1)  62.6 
<13 1949 3743 9839 141 14.2 (12.0-16.6)  98.6 (98.2-98.9)  92.9 (89.2-95.4)  38.0 (31.2-45.3)  63.7 
<14 1937 3645 9937 153 15.2 (12.9-17.7)  98.5 (98.1-98.9)  92.4 (88.5-95.0)  38.7 (31.6-46.2)  64.4 
<15 1925 3540 10042 165 16.2 (13.9-18.8)  98.4 (98.0-98.8)  91.5 (87.5-94.4)  39.4 (32.2-47.2)  65.1 
<16 1916 3449 10133 174 16.9 (14.5-19.5)  98.4 (97.9-98.7)  91.0 (86.7-94.0)  40.1 (32.6-48.0)  65.8 
Estimates derived from a binomial-normal random effects model. Analysis includes 18,601 patients from 17 cohorts where individual participant data was available  




In a subgroup analysis combining risk stratification thresholds and a non-ischaemic 
electrocardiogram (Figure 3.6), a cardiac troponin I concentration of <5 ng/L gave a 
NPV of 99.7% (95% CI 99.4 to 99.8%) and a sensitivity of 99.0% (95% CI 97.3 to 
99.6%), identifying 45.9% of patients as low risk with 4.4 (95% CI 3.0 to 6.0) false 
negatives per 1,000 patients and a PPV of 24.5% (95% CI 20.3 to 29.2%). The 
combination of a cardiac troponin I concentration <2 ng/L and a non-ischaemic 
electrocardiogram gave a similar NPV of 99.9% (95% CI 98.5 to 100%) and sensitivity 
of 100% (95% CI 96.6 to 100%), but identified just 13.1% of patients as low risk, with 
4.1 (95% CI 1.8 to 7.3) false negatives per 1,000 patients and a lower PPV of 14.2% 

































Figure 3.6. The optimal threshold of high-sensitivity cardiac troponin I at presentation 
to risk stratify patients with suspected acute coronary syndrome for myocardial 
infarction or cardiac death at 30 days 
 
A). Negative predictive value with 95% confidence intervals across a range of high-
sensitivity cardiac troponin I concentrations. Horizontal dotted grey line indicating 
pre-specified target of 99.5%, and vertical dotted grey line indicating a troponin 
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Figure 3.6. The optimal threshold of high-sensitivity cardiac troponin I at presentation 
to risk stratify patients with suspected acute coronary syndrome for myocardial 
infarction or cardiac death at 30 days. 
 
B). Cumulative proportion of all patients with suspected acute coronary syndrome 
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Figure 3.6. The optimal threshold of high-sensitivity cardiac troponin I at presentation 
to risk stratify patients with suspected acute coronary syndrome for myocardial 
infarction or cardiac death at 30 days 
 
C) Number of false negatives per 1,000 patients tested across a range of cardiac 
troponin thresholds. Panels display performance of cardiac troponin thresholds in all 
patients (red), and when applied to those patients with a non-ischemic 
electrocardiogram at presentation (blue). All estimates of NPV derived from binomial-
normal random effects model using individual cohort level data (available in 17 
cohorts) for each cardiac troponin threshold (n=18,601, Table 3.5). 
*Electrocardiogram data was not available in 2,929 patients (15.7%) 
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In 19 cohorts, across nine countries, encompassing over 22,000 patients, a cardiac 
troponin concentration <5 ng/L at presentation identified half of all patients with 
suspected acute coronary syndrome as low risk of myocardial infarction or cardiac 
death at 30 days, with 5 false negatives per 1,000 patients tested.  
There are a number of strengths to the analysis. This was a pre-specified systematic 
review and meta-analysis that included individual patient-level data from all cohorts 
identified. The findings were consistent across a range of healthcare settings and 
geographic regions with considerable differences in the prevalence of myocardial 
infarction. Individual level data was included from over 22,000 patients, allowing a 
meaningful analysis of important subgroups. All studies were prospective, and in all 
the final diagnosis was adjudicated according to the universal definition of myocardial 
infarction.  
Two recent meta-analyses have suggested an approach to risk stratification using the 
limit of detection of the high-sensitivity cardiac troponin T assay, which identifies up 
to 31% of patients with a NPV of 99.3% (Zhelev et al., 2015, Pickering et al., 2017). 
The limit of detection of the high-sensitivity cardiac troponin I assay identifies 19% to 
27% of patients as low risk, with a NPV of 99.5% or greater (Carlton et al., 2016, 
Neumann et al., 2017a, Sandoval et al., 2017a). The major limitation of this approach 
for both assays is analytical, with biases and analytical variation at the limit of 
detection associated with rates of misclassification that are twice that observed at 5 
ng/L (Lyon et al., 2017, Kavsak et al., 2013a).  
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In clinical practice, cardiac troponin concentrations are interpreted in conjunction with 
the electrocardiogram and clinical assessment. When a risk stratification threshold of 
<5 ng/L was evaluated in the subgroup of patients without myocardial ischaemia on 
the electrocardiogram, the NPV and sensitivity were excellent. To ensure safety 
estimates were conservative, performance was evaluated not just for an index 
diagnosis, but for a composite end-point that included events up to 30 days. Although 
there were 81 cardiac deaths at 30 days, none occurred in the 6,956 patients with 
cardiac troponin concentrations <5 ng/L. Furthermore, performance was similar for 
both spontaneous type 1 and secondary type 2 myocardial infarction. This is relevant 
as the diagnosis of type 2 myocardial infarction is more challenging and is associated 
with a worse prognosis (Shah et al., 2015c, Sandoval et al., 2014b). 
At a threshold of 5 ng/L, the analytical performance of the high-sensitivity cardiac 
troponin I assay is excellent (Shah et al., 2015a, Kavsak et al., 2017). The use of lower 
thresholds did not improve diagnostic accuracy. A miss rate of 5 per 1,000 patients 
was observed when applying <5 ng/L as the risk stratification threshold, with a miss 
rate of 4 per 1,000 patients observed at <2 ng/L. Although the true risk of missing an 
individual patient with myocardial infarction is the same at both thresholds, lower 
thresholds reduce the proportion of patients classified as low risk; only 1 in 10 patients 
had a troponin concentration <2 ng/L, compared with 5 in 10 patients <5 ng/L. Use of 
lower thresholds would result in more patients without myocardial infarction being 




Despite recent changes to guidelines,(Roffi et al., 2016) the majority of clinicians 
continue to rely on the 99th percentile to rule in and rule out myocardial infarction 
(Collinson et al., 2016). The use of low concentrations of cardiac troponin to risk 
stratify patients has been shown to improve safety compared to use of the 99th 
percentile in multiple studies (Parsonage et al., 2016, Pickering et al., 2016b). This 
approach to risk stratification using high-sensitivity cardiac troponin assays has major 
potential to improve both the efficiency of healthcare delivery and patient safety, and 






This study has several limitations. First, not all cohorts used identical protocols, with 
differences both in the inclusion criteria and diagnostic criteria used for adjudication 
(Appendix 1.3). However, no significant differences in NPV were observed when 
stratified by adjudicating assay, and the NPV was high across individual cohorts, 
suggesting these findings are generalizable. Second, the number of patients who 
presented early after onset of symptoms was low at just 10% of the study population. 
Despite observing an NPV of 99% in this subgroup, inconsistencies in the 
documentation of symptom onset across cohorts may affect the analysis, and until 
further research is available, serial testing is recommended in patients presenting 
within 2 hours of symptom onset (Roffi et al., 2016). The greatest number of false 
negatives were observed in the cohort with the shortest median symptom onset to 
sample time (179 minutes, IQR 119-349, Table 3.1), which may explain the lower 
NPV and sensitivity reported at this threshold in a previous study (Carlton et al., 2016). 
Third, whilst it is reassuring that patients with troponin concentrations <5 ng/L had a 
much lower rate of cardiac death at one year than those patients between 5 ng/L and 
the 99th percentile, this observation needs to be verified in prospective studies where 





Among patients with suspected acute coronary syndrome, a high-sensitivity cardiac 
troponin I concentration <5 ng/L at presentation identified those at low risk of 
myocardial infarction or cardiac death within 30 days. Further research is needed to 
understand the clinical utility and cost-effectiveness of this approach to risk 
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High-sensitivity cardiac troponin assays enable myocardial infarction to be ruled out 
earlier, but the optimal approach is uncertain. We compared the European Society of 
Cardiology (ESC) rule-out pathway, with a pathway that incorporates lower cardiac 
troponin concentrations to risk stratify patients. 
Methods  
Patients with suspected acute coronary syndrome (n=1,218) underwent high-
sensitivity cardiac troponin I measurement at presentation, 3 and 6 or 12 hours. We 
compared the ESC pathway (<99th centile at presentation, or at 3 hours if symptoms 
<6 hours) with a pathway developed in the High-Sensitivity Troponin in the Evaluation 
of patients with Acute Coronary Syndrome (High-STEACS) study population (<5 ng/L 
at presentation, or change <3 ng/L and <99th centile at 3 hours). The primary outcome 
was a comparison of the negative predictive value (NPV) of both pathways for index 
type 1 myocardial infarction, or type 1 myocardial infarction or cardiac death at 30 
days. We evaluated the primary outcome in pre-specified subgroups stratified by age, 
gender, time of symptom onset and known ischaemic heart disease. 
Results  
The primary outcome occurred in 15.7% (191/1,218) patients. In those <99th centile at 
presentation, the ESC pathway ruled out myocardial infarction in 28.1% (342/1,218) 
and 78.9% (961/1,218) at presentation and 3 hours respectively, missing 18 index and 
two 30-day events (NPV 97.9%, 95% confidence intervals [CI] 96.9-98.7%). The 
High-STEACS pathway ruled out 40.7% (496/1,218) and 74.2% (904/1,218) at 
 
 116 
presentation and 3 hours, missing two index and two 30-day events (NPV 99.5%, 95% 
CI 99.0-99.9%; P<0.001 for comparison). The NPV of the High-STEACS pathway 
was greater than the ESC pathway overall (P<0.001), and in all subgroups including 
those presenting early or known to have ischaemic heart disease.  
Conclusion 
Use of the High-STEACS pathway incorporating low high-sensitivity cardiac troponin 
concentrations rules out myocardial infarction in more patients at presentation and 
misses 5-fold fewer index myocardial infarctions than guideline approved pathways 





Chest pain is a frequent presenting symptom in patients attending the Emergency 
Department, with significant resource implications for healthcare providers (Makam 
and Nguyen, 2015). Whilst the majority of patients with chest pain do not have an 
acute myocardial infarction (Zhelev et al., 2015), prompt and accurate exclusion of 
this diagnosis remains challenging in clinical practice, and often results in unnecessary 
hospital admission (Goodacre et al., 2005, Skinner et al., 2010, Goodacre et al., 2013). 
Guidelines from the European Society of Cardiology (ESC) support the use of high-
sensitivity cardiac troponins and earlier testing to rule out myocardial infarction where 
concentrations are <99th centile upper reference limit (URL) at presentation in those 
patients with symptoms for more than 6 hours, and at 3 hours in the remainder (Roffi 
et al., 2016). A similar approach was recommended by the National Institute of 
Clinical Health and Excellence (NICE), although concerns were raised about the 
generalisability of the studies evaluating the effectiveness of this approach (NICE., 
2014b).  
Recent studies have demonstrated that very low cardiac troponin concentrations can 
help to further risk stratify patients (Thygesen et al., 2012a, Mills et al., 2011, Shah et 
al., 2015b, Body et al., 2011, Rubini Gimenez et al., 2013, Bandstein et al., 2014, Shah 
et al., 2015a, Carlton et al., 2016, Thelin et al., 2015, Body et al., 2016, Rubini 
Gimenez et al., 2015, Mueller et al., 2016, Reichlin et al., 2012, Reichlin et al., 2015, 
Pickering et al., 2016b). As such, the latest European guidelines include an additional 
one hour pathway incorporating lower thresholds of cardiac troponin for risk 
stratification (Roffi et al., 2016). We recently demonstrated in consecutive patients 
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with suspected acute coronary syndrome that a cardiac troponin concentration <5 ng/L 
at presentation had a negative predictive value of 99.6% (95%CI 99.3–99.8) for 
myocardial infarction during the index presentation, or myocardial infarction or 
cardiac death at 30 days. Furthermore, patients with cardiac troponin concentrations 
<5 ng/L had very low rates of adverse cardiac events at one year (Shah et al., 2015a).  
Whilst it is clear that high-sensitivity cardiac troponins enable myocardial infarction 
to be ruled out earlier, the optimal approach is uncertain. As such, we compared the 
safety and efficacy of the ESC pathway based on the 99th centile alone, with our 






4.3.1 Study population 
Patients with suspected acute coronary syndrome were recruited from the Emergency 
Department of the Royal Infirmary of Edinburgh, a tertiary care hospital in Scotland, 
between 1st June 2013 and 31st September 2015 into a sub-study of the High-Sensitivity 
Troponin in the Evaluation of patients with Acute Coronary Syndrome (High-
STEACS) trial. All patients in whom the attending clinician requested cardiac troponin 
for suspected acute coronary syndrome were eligible for inclusion. We did not enrol 
patients with ST-segment elevation myocardial infarction, those who were unable to 
provide consent, or those from outside our region to ensure complete follow up. Blood 
samples were obtained at presentation and at 6-12 hours for high-sensitivity cardiac 
troponin testing as part of routine clinical care. Patients provided written informed 
consent for additional sampling at 3 hours with the results of testing at this time-point 
not used to guide patient care. This pre-specified analysis was restricted to those 
patients where serial samples were available (Figure 4.1). This clinical trial was 
registered (NCT:01852123), approved by the national research ethics committee, and 
conducted in accordance with the Declaration of Helsinki.  
4.3.2 High-sensitivity cardiac troponin I assay 
The Abbott ARCHITECTSTAT high-sensitive cardiac troponin I assay (Abbott 
Laboratories, Abbott Park, IL) is a two-step chemo-luminescent assay with a limit of 
detection of 1.2 ng/L and coefficient of variation of less than 10% at 6 ng/L (Chin et 
al., 2014). This assay performance has been independently validated across multiple 
centres under routine laboratory working conditions, with a reported inter-laboratory 
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coefficient of variation of 12.6% at 3.5 ng/L across 33 instruments (Shah et al., 2015a). 
The upper reference limit 99th centiles were determined in 4,590 samples from healthy 
individuals as 16 ng/L for women and 34 ng/L in men (Shah et al., 2015b), and from 
10th December 2013 onwards these thresholds were used in clinical practice.  
4.3.3 Baseline characteristics 
Patient baseline characteristics, including chest pain characteristics, onset of 
symptoms, prior medical history, cardiovascular risk factors, medication, and clinical 
observations, in addition to investigations including serial 12-lead electrocardiography 
and cardiac imaging, were obtained from a dedicated case record form, patient 
questionnaire and the electronic patient record (TrakCare, InterSystems, Cambridge, 
MA).  Hyperlipidaemia or hypertension were defined as a history of the condition, or 
by the use of lipid-lowering or anti-hypertensive therapies, respectively. Ischaemic 
heart disease was defined as a history of angina, prior myocardial infarction or prior 
coronary revascularization. 
4.3.4 Diagnostic adjudication 
The final diagnosis was adjudicated for all patients by two independent physicians 
(AC/AA), with consensus from a third physician (JA/NM) where there was 
discrepancy following review of all clinical information, both non-invasive and 
invasive investigations and outcomes from presentation to 30 days. Patients were 
classified as having type 1 myocardial infarction, type 2 myocardial infarction or 
myocardial injury in accordance with the third universal definition of myocardial 
infarction as previously reported (Roffi et al., 2016, Shah et al., 2015a). Any cardiac 
troponin I concentration above the sex-specific 99th centile upper reference limit was 
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considered evidence of myocardial necrosis. Type 1 myocardial infarction was defined 
as myocardial necrosis in the context of a presentation with symptoms suggestive of 
acute coronary syndrome or evidence of myocardial ischemia. Patients with symptoms 
or signs of myocardial ischemia due to increased oxygen demand or decreased supply 
(e.g. tachyarrhythmia, hypotension or anaemia) secondary to an alternative pathology 
and myocardial necrosis were classified as type 2 myocardial infarction. Myocardial 
injury was defined as evidence of myocardial necrosis in the absence of any clinical 
features of myocardial ischaemia. Agreement for a diagnosis of type 1 myocardial 
infarction was very good (k= 0.82, 95%CI 0.75-0.89).  
4.3.5 Clinical outcomes 
The primary outcome was a composite of index type 1 myocardial infarction, or type 
1 myocardial infarction or cardiac death at 30 days. We used regional and national 
registries in addition to individual patient follow up at 30 days to ensure follow up was 
complete for the entire study population. All subsequent events were adjudicated using 
the same approach as for the index presentation. TrakCare software application 
(InterSystems Corporation, Cambridge, MA, USA) is a regional electronic patient 
record system, which provides data on all hospital admissions to both tertiary or 
secondary care hospitals in the southeast of Scotland. All in-hospital and community 
deaths are recorded in a comprehensive national database, the General Register of 
Scotland. Cardiac death was defined as any death due to myocardial infarction, 




4.3.6 Clinical pathways 
We compared the safety and efficacy of two pathways to rule out the composite 
outcome of index myocardial infarction, and myocardial infarction or cardiac death at 
30 days. The ESC pathway rules out myocardial infarction where cardiac troponin 
concentrations are <99th centile at presentation in patients with symptoms for more 
than 6 hours. In patients with symptoms for less 6 hours, a second troponin 
measurement is performed 3 hours from presentation, with myocardial infarction ruled 
out if cardiac troponin remains <99th centile or is >99th centile without a significant 
change in concentration (Roffi et al., 2016). Previously published guidance from the 
ESC Working Group on Acute Cardiac Care recommends use of a change in cardiac 
troponin concentration >50% of the 99th centile upper reference limit at 3 hours 
(Thygesen et al., 2012b). 
We compared the ESC pathway to the High-STEACS pathway, based on our previous 
observations, that utilises a risk stratification threshold of 5 ng/L at presentation (Shah 
et al., 2015a, Shah et al., 2016). This threshold has since been externally validated in 
separate populations, with a recent a multi-centre study across five independent 
cohorts finding a troponin concentration of <5 ng/L had a negative predictive value of 
99.2% (95%CI 98.8-99.5%) (Carlton et al., 2016). In our pathway, patients with 
cardiac troponin concentrations <5 ng/L at presentation are considered low risk and 
myocardial infarction is ruled out without further testing, unless they present early 
with symptom onset <2 hours from presentation where cardiac troponin is retested 3 
hours after presentation (Shah et al., 2015a). Patients with cardiac troponin 
concentrations ≥5 ng/L at presentation are retested at 3 hours. Myocardial infarction 
is ruled out at 3 hours if cardiac troponin concentrations are unchanged and remain 
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<99th centile on retesting. A change in cardiac troponin concentration was defined as 
an increase or decrease ≥3 ng/L at 3 hours, as this is the lowest measurable 
concentration within the normal reference range that exceeds analytical variation of 
the assay (Kavsak et al., 2016). This change in cardiac troponin concentration was 
internally and externally validated, using data from the APACE cohort (Appendix 2.1).  
4.3.7 Statistical analysis 
Baseline characteristics are summarised as mean (standard deviation, SD) or median 
(inter-quartile range, IQR) as appropriate. Patients with maximal cardiac troponin 
concentrations ≤99th centile were compared with those >99th centile using a chi-square 
test or Wilcoxon rank sum test. The primary outcome was the negative predictive value 
(NPV) of each pathway, using the composite endpoint of index type 1 myocardial 
infarction, or subsequent type 1 myocardial infarction or cardiac death at 30 days. As 
we estimated the NPV would approach 100%, we used a Bayesian approach with a 
Jeffrey’s prior (beta distribution with both shape parameters equal to 0.5) as this is 
more robust when confidence intervals approach 0 or 1 (Brown et al., 2001). We 
derived a weighted generalised score statistic to compare the NPV of the ESC and the 
High-STEACS pathway, as previously described (Leisenring et al., 2000). We 
evaluated the NPV in pre-specified subgroups stratified by time of symptom onset (<3, 
<6 or ≥6 hours), age (<65 or ≥65 years), sex, and history of ischaemic heart disease. 
We determined absolute (hs-TnI3hr – hs-TnI0hr) and relative ([(hs-TnI3hr – hs-TnI0hr) / 
hs-TnI0hr] x 100) change in cardiac troponin concentration from presentation to 3 hours, 
and determined sensitivity, specificity and positive predictive value (PPV) with 95% 
confidence intervals (CI) using a Bayesian approach as per the NPV. In a sensitivity 
analysis, we evaluated the NPV for a primary outcome encompassing type 1 or type 2 
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myocardial infarction, or myocardial injury, or myocardial infarction or cardiac death 
at 30 days. To ensure our findings were generalizable to those centres that do not apply 
sex-specific diagnostic thresholds, we evaluated the performance of both pathways 
using a single 99th centile upper reference limit for men and women of 26 ng/L. A 
further sensitivity analysis evaluated the NPV in patients without evidence of 
myocardial ischaemia (defined as ≥2mm ST-segment depression or new T-wave 
inversion) on the presenting electrocardiogram, who were considered intermediate or 
low risk with a GRACE score of <140 (Roffi et al., 2016). We evaluated pathway 
efficacy by determining the number of patients ruled out at 0 and 3 hours as a 
proportion of the total study population, with comparison by McNemar’s test for 
paired proportions. A two-sided P<0.05 was considered statistically significant. All 





We identified 1,218 patients with suspected acute coronary syndrome who met our 
inclusion and exclusion criteria (62.4±14.1 years, 61% male; Table 4.1, Figure 4.1). 
The adjudicated diagnosis was type 1 myocardial infarction in 15.5% (189/1,218), type 
2 myocardial infarction in 5.5% (67/1,218) and myocardial injury in 2.1% (26/1,218). 
There were six subsequent type 1 myocardial infarcts and six cardiac deaths at 30 days. 
At presentation, 216 patients had troponin concentrations >99th centile with 11.9% 
(145/1,218) type 1 and 3.8% (46/1,218) type 2 myocardial infarction, and 2.1% 




Table 4.1. Baseline demographics stratified by cardiac troponin concentration at 
presentation 
Values are number (%) or mean (SD) or median (inter-quartile range). Abbreviations: ACE = angiotensin converting enzyme; 
ARB = angiotensin receptor blocker;  MI = myocardial infarction; CCB = calcium channel blocker; PCI = percutaneous 


















Age  62.36 
(14.1) 





Male (%) 742 (60.9) 383 (55.3) 622 (62.1) 120 (55.6) 0.088 
Primary Symptom      
   Chest Pain 1044 (85.7) 614 (88.7) 873 (87.1) 171 (79.2) <0.001 
   Collapse 13 (1.1) 7 (1.0) 8 (0.8) 5 (2.3) 0.578 
   Dyspnoea 40 (3.3) 10 (1.4) 25 (2.5) 15 (6.9) 0.151 
   Palpitations 20 (1.6) 7 (1.0) 15 (1.5) 5 (2.3) 0.043 
Symptom onset       









      < 2 hours (%) 326 (26.8) 196 (28.4) 279 (27.9) 47 (21.8) 0.081 
      ≥ 2 and < 6 hours (%) 463 (38.0) 250 (36.1) 381 (38.0) 82 (38.0) 1.000 
      ≥ 6 hours (%) 429 (35.2) 246 (35.5) 342 (34.1) 87 (40.3) 0.102 
Cardiovascular Risk 
Factors  
     
   Smoker (%) 255 (20.9) 174 (25.1) 217 (21.7) 38 (17.6) 0.385 
   Diabetes mellitus (%) 184 (15.6) 75 (11) 140 (14.4) 44 (21.0) 0.024 
   Hypertension (%) 550 (47.2) 255 (38.4) 443 (46.3) 107 (51.4) 0.203 
   Hyperlipidaemia (%) 493 (43.3) 233 (33.5) 402 (42.9) 91 (44.8) 0.681 
   Family history (%) 569 (51.5) 350 (53.8) 479 (52.2) 90 (47.9) 0.312 
   Known angina (%) 409 (34.6) 180 (26.5) 334 (34.2) 75 (36.4) 0.597 
   Previous MI (%) 308 (26.1) 112 (16.5) 244 (25.2) 64 (30.6) 0.124 
   Previous PCI (%) 248 (21.3) 110 (16.4) 205 (21.4) 43 (20.9) 0.942 
   Previous CABG (%) 87 (7.5) 24 (3.9) 71 (7.5) 16 (7.8) 0.995 
   Heart failure (%) 42 (3.7) 4 (0.6) 25 (2.7) 17 (8.7) <0.001 
   Stroke (%) 81 (7.0) 26 (3.9) 63 (6.6) 18 (8.8) 0.337 
   PVD (%) 29 (2.6) 7 (1.1) 21 (2.2) 8 (4.0) 0.225 
Admission Medication      
   Aspirin (%) 442 (38.3) 210 (31.4) 361 (38.0) 81 (39.7) 0.707 
   Clopidogrel (%) 150 (13.5) 61 (9.5) 119 (13.1) 31 (15.6) 0.409 
   Warfarin (%) 84 (7.7) 25 (4.0) 66 (7.4) 18 (9.0) 0.52 
   Beta blocker (%) 353 (31.6) 159 (24.8) 286 (31.2) 67 (33.5) 0.587 
   ACEi or ARB (%) 379 (33.9) 170 (26.5) 306 (33.3) 73 (36.7) 0.405 
   CCB (%) 158 (14.4) 72 (11.4) 128 (14.2) 30 (15.2) 0.822 




Presentation hsTnI result 
≤99th centile
(n=1,002)




Type 1 MI (n=44)
Type 2 MI (n=21)
Myocardial Injury (n=1)
Adjudicated Diagnosis
Type 1 MI (n=145)
Type 2 MI (n=46)
Myocardial Injury (n=25)
30 day outcomes
Subsequent Type 1 MI (n=4)
Cardiac Death (n=5)
30 day outcomes















































4.4.1 ESC pathway  
The ESC pathway ruled out 28.1% (342/1,218) of patients at presentation and 78.9% 
(961/1,218) of all patients by 3 hours. However, this approach missed 18 index type 1 
myocardial infarctions (four on presentation, fourteen at three hours) and two 
subsequent myocardial infarctions within 30 days for an overall NPV of 97.9% [95% 
CI, 96.9-98.7%; Table 4.2, Figure 4.2 and 4.3]. The sensitivity of this pathway is 
89.3% [95% CI, 84.9-93.5%], and a summary of the missed events is provided in 
Appendix 2.2. 
4.4.2 High-STEACS pathway 
In comparison, the High-STEACS pathway ruled out 40.7% (496/1,218) of patients at 
presentation, and 74.2% (904/1,218) of all patients by 3 hours. There were two missed 
index type 1 myocardial infarction (none at presentation, two at three hours) and two 
recurrent events for an overall NPV of 99.5% [95% CI, 99.0-99.9]; Table 4.2, Figure 
4.2 and 4.3). All events missed by the High-STEACS pathway were also missed by 
the ESC pathway. The sensitivity of the High-STEACS pathway was 97.7% [95% CI, 
95.5-99.5%] and a summary of missed events is provided in Appendix 2.3. 
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  TP FP TN FN 
NPV 
(Mean, 95% CI) 
PPV 







High-STEACS  187 127 900 4 99.5 (99.0-99.9) 59.5 (54.1-64.9) 97.7 (95.5-99.5) 87.6 (85.6-89.6) 
ESC pathway 171 86 941 20 97.9 (96.9-98.7) 66.5 (60.6-72.1) 89.3 (84.9-93.5) 91.6 (89.9-93.3) 
Subgroup analysis 
<3 hours since 
onset 
(n=544) 
High-STEACS  81 60 402 1 99.6 (98.8-100) 57.4 (49.2-65.4) 98.2 (95.3-100) 86.9 (83.8-89.9) 
ESC pathway 73 43 419 9 97.8 (96.2-99.0) 62.8 (53.9-71.3) 88.6 (81.6-94.9) 90.6 (87.9-93.2) 
<6 hours since 
onset 
(n=789) 
High-STEACS  117 98 572 2 99.6 (98.9-99.9) 54.4 (47.7-61.0) 97.9 (95.4-99.9) 85.3 (82.6-88.0) 
ESC pathway 104 66 604 15 97.5 (96.1-98.6) 61.1 (53.7-68.3) 87.1 (81.0-92.8) 90.1 (87.8-92.3) 
>6 hours since 
onset 
(n=429) 
High-STEACS  70 29 328 2 99.2 (98.1-99.9) 70.5 (61.2-79.0) 96.6 (92.4-99.8) 91.8 (88.9-94.5) 
ESC pathway 67 20 337 5 98.4 (96.8-99.4) 76.7 (67.4-84.9) 92.5 (86.4-97.8) 94.3 (91.8-96.6) 
Men 
(n=742) 
High-STEACS  122 73 544 3 99.4 (98.5-99.8) 62.5 (55.6-69.1) 97.2 (94.4-99.6) 88.1 (85.5-90.6) 
ESC pathway 110 38 579 15 97.4 (96.0-98.5) 74.2 (66.9-80.8) 87.7 (81.9-93.2) 93.8 (91.8-95.6) 
Women 
(n=476) 
High-STEACS  65 54 356 1 99.6 (98.7-100) 54.6 (45.7-63.4) 97.8 (94.2-100) 86.7 (83.4-90.0) 
ESC pathway 61 48 362 5 98.5 (97.0-99.5) 55.9 (46.6-65.0) 91.8 (85.2-97.6) 88.2 (85.0-91.2) 
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Table 4.2 (continued) Diagnostic performance of ESC pathway and High-STEACS pathway for the primary outcome at three 
hours  
Abbreviations: TP = True Positive, FP = False Positive, TN = True Negative, FN = False Negative, NPV = Negative Predictive Value, PPV = positive predictive value 
 
  
  TP FP TN FN 
NPV 
(Mean, 95% CI) 
PPV 





Subgroup analysis (continued) 
Age <65 years 
(n=701) 
High-STEACS  78 39 583 1 99.7 (99.2-100) 66.5 (57.8-74.7) 98.1 (95.1-100) 93.7 (91.7-95.5) 
ESC pathway 72 29 593 7 98.8 (97.7-99.5) 71.1 (62.0-79.4) 90.6 (84.2-96.5) 95.3 (93.6-96.9) 
Age ≥65 years 
(n=517) 
High-STEACS  109 88 317 3 98.9 (97.5-99.7) 55.3 (48.4-62.2) 96.9 (93.7-99.5) 78.2 (74.2-82.2) 
ESC pathway 99 57 348 13 96.3 (94.1-98.0) 63.4 (55.7-70.7) 88.1 (82.0-93.7) 85.8 (82.4-89.2) 
Known ischaemic 
heart disease  
(n=518)  
High-STEACS  85 77 352 4 98.7 (97.4-99.6) 52.5 (44.8-60.1) 90.5 (90.5-98.9) 82.0 (78.3-85.6) 
ESC pathway 73 52 377 16 95.8 (93.6-97.6) 58.3 (49.6-66.8) 81.7 (73.6-89.3) 87.8 (84.7-90.8) 
No known ischaemic 
heart disease  
(n=680) 
High-STEACS  99 48 533 0 99.9 (99.6-100) 67.2 (59.5-74.5) 99.5 (98.1-100) 91.7 (89.4-93.9) 






























Figure 4.2  Summary of the ESC (A) and High-STEACS (B) rule out pathways. Percentages indicate number of patients ruled out at a 






























Figure 4.3 Negative predictive value for myocardial infarction or cardiac death at 30 days in the High-STEACS pathway (red) and the 
ESC pathway (blue). 
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4.4.3 Comparison of ESC and High-STEACS pathways 
The High-STEACS pathway identifies more patients potentially suitable for discharge 
at presentation following a single cardiac troponin measurement compared to the ESC 
pathway (40.7% [95% CI, 38.0-43.5%] versus 28.1% [95% CI, 25.6-30.7%] 
respectively, P<0.001; Figure 4.2). At three hours, the High-STEACS pathway ruled 
our fewer patients than the ESC pathway (74.2% [95% CI, 71.7-76.6%] versus 78.9% 
[95% CI, 76.5-81.1%], P<0.001). In the 57 patients ruled out at three hours by the ESC 
pathway but not the High-STEACS pathway, there were 13 missed index myocardial 
infarction (22.8%).  
The NPV of the High-STEACS pathway was greater than the ESC pathway overall 
(99.5% [95%CI 99.0-99.9] versus (97.9% [95%CI 96.9-98.9%]; P<0.001), and for all 
pre-specified subgroups (Table 4.2, Figure 4.3). In the subgroup of patients who 
presented within three hours of symptom onset there were more false negatives and 
the NPV was lower with the ESC pathway (9 false negatives, NPV 97.8% [95% CI, 
96.2-99.0%]) than with the High-STEACS pathway (1 false negative, NPV 99.6% 
[95% CI, 98.8-100.0%]). Similar differences were apparent in those patients 
presenting within six hours of symptom onset (ESC versus High-STEACS, NPV 
97.5% [95% CI, 96.1-98.6%] versus 99.6% [95% CI, 98.9-99.9%]). In men, the NPV 
of the ESC pathway was lower than the High-STEACS pathway (97.4% [95% CI, 
96.0-98.5%] versus 99.4% [95% CI, 98.5-99.8%]), although both pathways performed 
similarly in women. The lowest NPV for both the ESC and the High-STEACS 
pathway was in the subgroup of patients known to have ischaemic heart disease 
(95.8% [95% CI, 93.6-97.6%] and 98.7% [95% CI, 97.4-99.6%] respectively).  
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In patients with an index type 1 myocardial infarction missed by the ESC pathway, the 
median change in cardiac troponin concentration between presentation and 3 hours 
was 5.5 ng/L (inter-quartile range [IQR] 4.0-13.3 ng/L). The majority of these patients 
(16/18) were not ruled out at 3 hours by the High-STEACS pathway as the change in 
cardiac troponin concentration was ≥3 ng/L (Table 4.3) and further testing at 6 hours 
is recommended. 
 
Table 4.3. 2x2 table for internal validation of delta criteria at three hours 
 
  
 Type 1 MI No Type 1 MI 
 











Patients with cardiac troponin concentrations ≥5 ng/L and <99th centile on 
presentation are re-tested at three hours. Those with a change in cardiac 
troponin of <3 ng/L are ruled out if they remain <99th centile.  
 
 
In an external validation cohort of 2,533 patients with suspected acute coronary 
syndrome (Appendix 2.1), a change in cardiac troponin concentration <3 ng/L at 3 
hours ruled out 69.9% of those patients who required retesting (514/735), and missed 




Table 4.4. 2x2 table for external validation of delta criteria at three hours 
  
 Type 1 MI No Type 1 MI 
 











Patients with cardiac troponin concentrations ≥5 ng/L and <99th centile on 
presentation are re-tested at three hours. Those with a change in cardiac 
troponin of <3 ng/L are ruled out if they remain <99th centile. 
 
The specificity and PPV of the ESC pathway was greater than the High-STEACS 
pathway at three hours (specificity 91.6% [95% CI, 89.9-93.3] and PPV 66.5% [95% 
CI, 60.6-72.1] versus specificity 87.6% [95% CI, 85.6-89.6%] and PPV 59.5% [95% 
CI, 54.1-64.9%], Table 4.2). However, the overall specificity and PPV of the High-
STEACS pathway was comparable when patients requiring additional testing at 6 
hours were included (specificity 91.4% [95% CI, 89.7-93.1%] and PPV 67.9% [95% 





4.4.4 Sensitivity analyses 
In a sensitivity analysis, we evaluated both pathways using a single 99th centile upper 
reference limit for men and women of 26 ng/L. The performance of both pathways 
was similar, with a NPV of 97.7% [95% CI, 96.6-98.5%] for the ESC pathway (20 
missed index type 1 myocardial infarction and two missed events at 30 days), and 
99.4% [95% CI, 98.8-99.8%] for the High-STEACS pathway (three missed index type 
1 myocardial infarction and two missed 30 day events). The ESC pathway missed a 
similar proportion of men and women (10 men, 12 women). 
We performed a further sensitivity analysis excluding patients with evidence of 
myocardial ischaemia on the electrocardiogram or with a GRACE score >140 (n=224), 
of whom 71 patients had an index type 1 myocardial infarction. The diagnostic 
accuracy of both pathways improved. The ESC pathway still missed 13 index and one 
subsequent event (NPV 98.3% [95% CI, 97.3-99.0%]), whereas the High-STEACS 
pathway missed only one index and one subsequent event (NPV 99.7% [95% CI, 99.2-
99.9%] P<0.001).  
We evaluated the diagnostic performance of both pathways for a composite endpoint 
incorporating an index diagnosis of type 1 or type 2 myocardial infarction, or 
myocardial injury, or myocardial infarction or cardiac death at 30 days. The High-
STEACS pathway missed an additional five events, whilst the ESC pathway missed 
an additional nine events (High-STEACS NPV 99.0% [95% CI, 98.2-99.5%], nine 
false negatives; two index type 1 and five index type 2 myocardial infarction, two type 
1 myocardial infarction at 30 days, versus ESC NPV 96.9% [95% CI, 95.8-97.9%], 29 
false negatives; 18 index type 1 and nine index type 2 myocardial infarction, two type 




In patients with suspected acute coronary syndrome, we describe a clinical pathway 
utilising low cardiac troponin concentrations within the reference range to risk stratify 
patients. This approach identifies more patients as low risk at presentation, and has a 
better overall negative predictive value than guideline approved pathways based solely 
on the 99th centile. Implementation of this pathway has the potential to improve the 
efficiency and safety of early rule-out approaches for patients with suspected acute 
coronary syndrome. 
We make a number of important and clinically relevant observations. First, we 
demonstrate the High-STEACS pathway misses fewer patients with an index diagnosis 
of myocardial infarction, or myocardial infarction or cardiac death events at 30 days 
than the pathway approved by the European Society of Cardiology (4 missed events 
versus 20 missed events). Second, the negative predictive value of our pathway is 
99.5% and better than the existing ESC pathway across all pre-specified subgroups. In 
particular, the ESC pathway was less effective in men, those with a history of 
ischaemic heart disease, and those presenting early after the onset of symptoms. Third, 
in patients without an elevated troponin concentration at presentation, the High-
STEACS pathway identified half as low risk with a single measurement, compared to 
a third identified using the established pathway. This is despite being safer, and 
missing fewer patients with an index myocardial infarction.  
The European Society of Cardiology guideline recommends the use of high-sensitivity 
cardiac troponin assays, and their central algorithm advises the 99th centile be used as 
the threshold to rule in and rule out myocardial infarction at presentation and at three 
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hours (Roffi et al., 2016). However, the 99th centile may not be the optimal threshold 
to rule out myocardial infarction, and our observations suggest this threshold does not 
provide an acceptable NPV or sensitivity (97.9% [95%CI 96.9-98.7%] and 89.3% 
[95%CI 84.9-93.5%] respectively). The performance of the ESC pathway is improved 
by inclusion of a risk stratification threshold and recognition that changes in cardiac 
troponin concentration within the reference range are important. In a large external 
validation cohort, we report that more than two-thirds of patients with troponin 
concentrations above our risk stratification threshold at presentation can be safely 
ruled out at 3 hours if troponin concentrations are unchanged (<3 ng/L), with no missed 
diagnosis of type 1 myocardial infarction.  
Our findings are consistent with a recently published evaluation of the ESC pathway 
which reported a negative predictive value of 99.0% [95%CI 98.1-99.5%], and 
sensitivity of 93.2% [95%CI 87.5-96.8%] in a pooled analysis of five international 
cohorts (Pickering et al., 2016b). Importantly, this analysis included lower risk patients 
without ischaemia on the electrocardiogram. In practice, risk stratification and early 
rule-out pathways are only likely to be applied to patients without overt myocardial 
ischaemia on the electrocardiogram (Shah et al., 2016). However, interpretation of the 
electrocardiogram may be subjective and dependent on clinician experience, and 
therefore we included all patients in our evaluation to ensure our safety estimates were 
conservative.  Likewise, many clinicians use risk stratification tools to identify patients 
suitable for early discharge. Whilst the ESC guidelines do not advocate use of GRACE 
score for this purpose, it is widely used and is recommended to guide further 
investigation in patients whom myocardial infarction has been ruled out. When we 
restricted our analysis to patients with no significant ST-segment depression or T-wave 
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inversion on the electrocardiogram and GRACE scores of <140, we observed a modest 
improvement in the NPV of the ESC pathway (98.3% [95% CI, 97.3-99.0%]), 
although even in this lower risk group the ESC pathway was inferior to the High-
STEACS pathway (NPV 99.7% [95% CI, 99.2-99.9%]). Whilst the inclusion of all 
patients in the primary analysis ensures our safety estimates are conservative, it is 
important to highlight that in clinical practice, careful clinical assessment and risk 
assessment is mandatory for all diagnostic pathways. In implementing our pathway, 
we recommend that patients with overt myocardial ischemia on the electrocardiogram 
at presentation are admitted for further assessment (Appendix 2.5). 
Pickering and colleagues utilized a single diagnostic threshold for myocardial 
infarction (26 ng/L) in both men and women, although a sensitivity analysis showed 
the performance of the ESC pathway was similar using sex-specific thresholds 
(Pickering et al., 2016b). In our analysis, we observed a reduction in the performance 
of the ESC pathway in men evaluated using the same assay with sex-specific 
thresholds (34 ng/L in men, 16 ng/L in women; 15 missed events and 5 missed events, 
respectively). In our sensitivity analysis, use of a single diagnostic threshold of 26 ng/L 
in men and women did not improve the overall performance of the ESC pathway. In 
contrast, the safety of the High-STEACS pathway was robust across both sexes and 
all pre-specified subgroups of patients. Whilst the use of sex-specific thresholds in 
pathways that rely on the 99th centile remains contentious in clinical practice, risk 
stratification thresholds are not influenced by sex (Shah et al., 2015a), and therefore a 
single threshold can be applied equally to risk stratify men and women at presentation.  
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The efficacy of early rule-out pathways is also an important consideration. We 
demonstrate that the High-STEACS pathway ruled out a higher proportion of patients 
than the ESC pathway at presentation (40.7% versus 28.1%, P<0.001). Whilst our 
pathway rules out fewer patients at 3 hours (74.2% versus 78.9%), P<0.001), of the 
additional 57 patients ruled out by the ESC pathway, 1 in 5 (22.8%) were incorrectly 
ruled out and had an index diagnosis of type 1 myocardial infarction identified on 
subsequent testing. By identifying those patients with a change in cardiac troponin 
concentration (≥3 ng/L) from presentation to three hours and undertaking further 
testing, none of these events would be missed by the High-STEACS pathway. This 
highlights the value of high-sensitivity cardiac troponin assays, which permit the 
identification of small, but important changes in troponin concentration within the 
normal reference range, and allow refinement in the risk stratification of patients with 
suspected acute coronary syndrome. The only disadvantage of our pathway is that in 
prioritising safety, the specificity and PPV for a diagnosis of myocardial infarction is 
lower than the ESC pathway at 3 hours (4% and 7% respectively). Specificity is also 
important, but in our view it need not be prioritized in early rule out pathways. In 
patients we identify who require hospital admission, the diagnosis of myocardial 
infarction is best determined by demonstrating a rise and fall in cardiac troponin 
concentration over 6-12 hours.  
The latest ESC guidelines have introduced a one-hour pathway that incorporates a risk 
stratification step utilising high-sensitivity cardiac troponin concentrations within the 
reference range (Roffi et al., 2016). This approach shows promise, and has been 
validated using both high sensitivity troponin I and high sensitivity troponin T assays, 
with a NPV of 99.6% [95% CI, 98.4-100] and 99.1% [95% CI, 98.2-99.7%] 
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respectively (Rubini Gimenez et al., 2015, Mueller et al., 2016). However, to our 
knowledge no previous studies have directly compared pathways that utilise a risk 
stratification step with low cardiac troponin concentrations to those based exclusively 
on the 99th centile. Further studies are needed to compare the efficacy and safety of 
retesting at 1 and 3 hours in pathways that incorporate a risk stratification threshold.  
4.5.1 Limitations 
One of the limitations of these studies, including our own, is that they are observational 
in nature, and enrol selected patients rather than all consecutive patients. Indeed, as no 
patients were discharged on the basis of pathway decisions, the true efficacy and safety 
of this approach is unknown. The ESC pathway recommends repeat testing in patients 
who present within 6 hours of symptom onset. Whilst the inclusion of patients who 
present early is a strength of our study, fewer patients may be ruled out at presentation 
by the ESC pathway as a consequence. At present, clinicians do not have evidence 
from prospective randomised controlled trials to inform their practice (Jaffe, 2016). 
As such, we are conducting a multi-centred stepped-wedge cluster randomised trial to 
determine the efficacy and safety of our pathway (Appendix 2.5) in unselected 
consecutive patients across Scotland. The outcome of this trial will help to inform our 
practice, and provide an evidence base for future recommendations on the use of high-






The High-STEACS pathway, incorporating low cardiac troponin concentrations to risk 
stratify patients, rules out more patients on presentation and misses fewer index or 
recurrent myocardial infarction than guideline-approved pathways based exclusively 
on the 99th centile. Implementation of this pathway has the potential to improve the 
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Background: High-sensitivity cardiac troponin assays can help to identify patients 
who are at low risk of myocardial infarction in the Emergency Department. We aimed 
to determine if the addition of clinical risk scores would improve the safety of early 
rule out pathways for myocardial infarction. 
Methods and results: In 1,935 patients with suspected acute coronary syndrome, we 
evaluated the safety and efficacy of two rule out pathways, alone or in conjunction 
with low-risk TIMI (0 or 1), GRACE (≤108), EDACS (<16) or HEART (≤3) scores. 
The European Society of Cardiology (ESC) 3-hour pathway uses a single diagnostic 
threshold (99th centile), whereas the High-STEACS pathway applies different 
thresholds to rule out (<5 ng/L) and rule in (>99th centile) myocardial infarction. 
Myocardial infarction or cardiac death during the index presentation or at 30-days 
occurred in 14.3% of patients (276/1,935). The ESC pathway ruled out 70% with 27 
missed events giving a negative predictive value (NPV) of 97.9% (95% confidence 
interval [CI], 97.1 to 98.6%). Addition of a HEART score ≤3 reduced the proportion 
ruled out by the ESC pathway to 25%, but improved the NPV to 99.7% (95%CI 99.0 
to 100%, P<0.001). The High-STEACS pathway ruled out 65% with three missed 
events for a NPV of 99.7% (95%CI 99.4 to 99.9%). No risk score improved the NPV 
of the High-STEACS pathways, but all reduced the proportion ruled out (24-47%, 
P<0.001 for all).  
Conclusions: Clinical risk scores significantly improved the safety of the ESC 3-hour 
pathway, which relies on a single cardiac troponin threshold at the 99th centile to rule 
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in and rule out myocardial infarction. Where lower thresholds are used to rule out 
myocardial infarction, as applied in the High-STEACS pathway, risk scores halve the 






Chest pain is a common presenting symptom in the Emergency Department, and whilst 
many patients require investigation for acute coronary syndrome, the majority have 
alternative diagnoses (Zhelev et al., 2015, Goodacre et al., 2005, Skinner et al., 2010). 
Earlier identification of patients without myocardial infarction may improve patient 
experience and healthcare efficiency by reducing hospitalisation for unnecessary 
investigation, but such strategies can only be implemented if safety is not 
compromised.  
There are several pathways which permit the early rule out of myocardial infarction. 
The European Society of Cardiology (ESC) 3-hour pathway uses the 99th centile upper 
reference limit of a cardiac troponin assay to rule in and rule out myocardial infarction 
(Roffi et al., 2016). However, recent observations have questioned whether this 
pathway provides adequate diagnostic performance in the era of high-sensitivity 
cardiac troponin testing (Pickering et al., 2016b, Chapman et al., 2017b, Wildi et al., 
2016). The precision of high-sensitivity assays at very low concentrations has been 
exploited in the development of novel pathways that rule out myocardial infarction 
using thresholds well below the 99th centile. In an individual patient-level data meta-
analysis of 22,457 patients, a cardiac troponin I threshold of <5 ng/L and a non-
ischaemic electrocardiogram gave a NPV and sensitivity of 99.7% and 99.0% for 
myocardial infarction or cardiac death at 30-days, respectively (Chapman et al., 2017c). 
The same threshold has also been validated for the high-sensitivity cardiac troponin T 
assay in a recent pooled analysis (Pickering et al., 2017). When this rule out threshold 
was applied in a pathway that includes serial testing at 0 and 3 hours, five-fold fewer 
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patients were missed compared to a pathway that relies on the 99th centile to rule out 
myocardial infarction (Chapman et al., 2017b). 
Clinical risk scores provide an alternative approach to identify patients at low risk of 
myocardial infarction who might be suitable for early discharge, but a number of 
uncertainties remain (Katus et al., 2017). New risk scores were developed (Backus et 
al., 2013) or existing scores were incorporated into early rule out pathways primarily 
to overcome the limitations of contemporary troponin assays (Than et al., 2012). 
However, the role of clinical risk scores in pathways that incorporate high-sensitivity 
cardiac troponin testing is unclear, particularly in those pathways that apply different 
thresholds to rule out and rule in myocardial infarction. Here, we evaluate the safety 
and effectiveness of two established early rule out pathways, with and without the 






5.3.1 Study population 
Patients with suspected acute coronary syndrome were recruited from the Emergency 
Department of the Royal Infirmary of Edinburgh, a tertiary care hospital in Scotland, 
between 1st June 2013 and 31st March 2017 into a sub-study of the High-Sensitivity 
Troponin in the Evaluation of patients with Acute Coronary Syndrome (High-
STEACS) trial. All patients in whom the attending clinician requested cardiac troponin 
for suspected acute coronary syndrome were eligible for inclusion. We did not enrol 
patients with ST-segment elevation myocardial infarction, those who were unable to 
provide consent, or those from outside our region to ensure complete follow up. Blood 
samples were obtained at presentation and at 6-12 hours for high-sensitivity cardiac 
troponin testing as part of routine clinical care. Patients provided written informed 
consent for additional sampling at 3 hours with the results of testing at this time-point 
not used to guide patient care. This clinical trial was registered (NCT:01852123), 
approved by the national research ethics committee, and conducted in accordance with 
the Declaration of Helsinki.  
5.3.2 High-sensitivity cardiac troponin I assay 
The Abbott ARCHITECTSTAT high-sensitive cardiac troponin I assay (Abbott 
Laboratories, Abbott Park, IL) is a two-step chemo-luminescent assay with a limit of 
detection of 1.2 ng/L and coefficient of variation of less than 10% at 6 ng/L (Chin et 
al., 2014). This assay performance has been independently validated across multiple 
centres under routine laboratory working conditions, with a reported inter-laboratory 
coefficient of variation of 12.6% at 3.5 ng/L across 33 instruments (Shah et al., 2015a). 
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The upper reference limit 99th centiles were determined in 4,590 samples from healthy 
individuals as 16 ng/L for women and 34 ng/L in men (Shah et al., 2015b), and from 
10th December 2013 onwards these thresholds were used in clinical practice.  
5.3.3 Baseline characteristics 
Patient baseline characteristics, including chest pain characteristics, onset of 
symptoms, prior medical history, cardiovascular risk factors, medication, and clinical 
observations, in addition to investigations including serial 12-lead electrocardiography 
and cardiac imaging, were obtained from a dedicated case record form, patient 
questionnaire and the electronic patient record (TrakCare, InterSystems, Cambridge, 
MA). Hyperlipidaemia or hypertension were defined as a history of the condition, or 
by the use of lipid-lowering or anti-hypertensive therapies, respectively. Ischaemic 
heart disease was defined as a history of angina, prior myocardial infarction or prior 
coronary revascularisation. 
5.3.4 Diagnostic adjudication and clinical outcomes 
The final diagnosis was adjudicated for all patients by two independent cardiologists, 
with consensus from a third cardiologist where there was discrepancy following 
review of all clinical information, both non-invasive and invasive investigations and 
outcomes from presentation to 30 days. Patients were classified as having type 1 
myocardial infarction, type 2 myocardial infarction or myocardial injury in accordance 
with the third universal definition of myocardial infarction as reported previously 
(Roffi et al., 2016, Shah et al., 2015a). Any high-sensitivity cardiac troponin I 
concentration above the sex-specific 99th centile upper reference limit was considered 
evidence of myocardial necrosis. Type 1 myocardial infarction was defined as 
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myocardial necrosis in the context of a presentation with symptoms suggestive of acute 
coronary syndrome or evidence of myocardial ischemia. Patients with symptoms or 
signs of myocardial ischemia due to increased oxygen demand or decreased supply 
(e.g. tachyarrhythmia, hypotension or anaemia) secondary to an alternative pathology 
and myocardial necrosis were classified as type 2 myocardial infarction. Myocardial 
injury was defined as evidence of myocardial necrosis in the absence of any clinical 
features of myocardial ischaemia. Further details on the adjudication process are 
available in a supplementary appendix. Agreement for a diagnosis of type 1 
myocardial infarction was good (k=0.77; 95% CI 0.69-0.84).  
The primary outcome was a composite of index type 1 myocardial infarction, or type 
1 myocardial infarction or cardiac death at 30 days. We used regional and national 
registries in addition to individual patient follow up at 30 days to ensure follow up was 
complete for the entire study population. All subsequent events were adjudicated using 
the same approach as for the index presentation. TrakCare software application 
(InterSystems Corporation, Cambridge, MA, USA) is a regional electronic patient 
record system, which provides data on all hospital admissions to both tertiary or 
secondary care hospitals in the southeast of Scotland. All in-hospital and community 
deaths are recorded in a comprehensive national database, the General Register of 
Scotland. Cardiac death was defined as any death due to myocardial infarction, 




5.3.5 Clinical pathways 
We evaluated the safety and efficacy of the European Society of Cardiology 3-hour 
pathway and the High-STEACS pathway (Figure 5.1), with and without the addition 
of clinical risk scores, to rule out the composite outcome of index type 1 myocardial 
infarction, and type 1 myocardial infarction or cardiac death at 30 days. These 
pathways were selected as they represent examples of approaches using troponin as a 
continuous variable, or as a binary decision tool applying the 99th centile alone. To 
improve generalizability, where samples were available, we also evaluate the 



































The ESC 3-hour pathway rules out myocardial infarction in patients without ischaemia 
on the electrocardiogram where cardiac troponin concentrations are <99th centile at 
presentation in patients with symptoms for more than 6 hours. In patients with 
symptoms for less than 6 hours, a second troponin measurement is performed 3 hours 
from presentation, with myocardial infarction ruled out if cardiac troponin remains 
<99th centile or is >99th centile without a significant change in concentration (Roffi et 
al., 2016). Previously published guidance from the ESC Working Group on Acute 
Cardiac Care recommends use of a change in cardiac troponin concentration >50% of 
the 99th centile upper reference limit at 3 hours where the initial concentration is ≤99th 
centile, or >20% when the initial concentration was >99th centile (Thygesen et al., 
2012b). The ESC pathway recommends a GRACE score of <140 in those who are pain 
free as a final step prior to discharge. 
The derivation and validation of the High-STEACS pathway has been reported 
previously (Chapman et al., 2017b). This pathway was based on previous observations 
(Shah et al., 2015a, Chapman et al., 2017c), and utilises a risk stratification threshold 
of 5 ng/L at presentation. Patients without myocardial ischaemia on the 
electrocardiogram and cardiac troponin concentrations <5 ng/L at presentation are 
considered low risk, with myocardial infarction ruled out without further testing, 
unless they present early with symptom onset <2 hours from presentation where 
cardiac troponin is retested 3 hours after presentation. Patients with cardiac troponin 
concentrations ≥5 ng/L at presentation are retested at 3 hours. Myocardial infarction 
is ruled out at 3 hours if cardiac troponin concentrations are unchanged (delta <3 ng/L) 
and remain ≤99th centile.  
 
 155 
The ESC 1-hour pathway rules out myocardial infarction in patients without ischemia 
on the electrocardiogram where cardiac troponin concentrations are <2 ng/L at 
presentation and symptoms are present for more than 3 hours. In all other patients, 
myocardial infarction is ruled out if cardiac troponin concentrations are <5 ng/L at 
presentation with a change of <2 ng/L after one hour. 
 
5.3.6 Clinical risk scores 
We derived GRACE, TIMI, HEART and EDACS scores using prospectively collected 
clinical information documented in the case record form by the research nurse at the 
time of recruitment (Figure 5.2). We calculated the GRACE score for in hospital 
death; this algorithm is available online (Anderson and FitzGerald, 2010). In line with 
prior recommendations, a GRACE score of ≤108 (estimated in hospital mortality of 
<1%) (Hamm et al., 2011), a HEART score of ≤3 (Backus et al., 2013), a TIMI score 
of 0 or 1 (Antman et al., 2000) or an EDACS score of <16 were considered low risk 
(Than et al., 2014b). For comparison, we provide the diagnostic performance of the 





























Figure 5.2. Illustration of the components of the HEART, GRACE, EDACS and TIMI score.  
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5.3.7 Sensitivity analyses 
We evaluated the NPV of all approaches for a primary outcome encompassing type 1 
or type 2 myocardial infarction, or myocardial injury, or cardiac death at 30 days. As 
the High-STEACS pathway was derived in the first 1,218 participants included in our 
dataset, we repeated our analyses and excluded these subjects. In a further analysis, 
we tested both pathways excluding any patients who underwent invasive or non-
invasive cardiac testing within 30 days of index presentation. 
5.3.8 Statistical analyses 
Baseline characteristics are summarised as mean (standard deviation, SD) or median 
(inter-quartile range, IQR) as appropriate. Where there were missing data for 
continuous variables, we imputed the median value. The primary outcome was the 
negative predictive value (NPV) of each pathway, using the composite endpoint of 
index type 1 myocardial infarction, or subsequent type 1 myocardial infarction or 
cardiac death at 30 days (Shah et al., 2015a). As we estimated the NPV would approach 
100%, we used a Bayesian approach with a Jeffreys prior (beta distribution with both 
shape parameters equal to 0.5) as this is more robust when confidence intervals 
approach 0 or 1 (Brown et al., 2001). We determined absolute (hs-TnI3hr – hs-TnI0hr) 
and relative ([(hs-TnI3hr – hs-TnI0hr) / hs-TnI0hr] x 100) change in cardiac troponin 
concentration from presentation to 3 hours, and determined sensitivity, specificity and 
positive predictive value (PPV) with 95% confidence intervals (CI) using a Bayesian 
approach as per the NPV. We derived a weighted generalised score statistic to compare 
the NPV of each pathway with and without the addition of clinical risk scores 
(Leisenring et al., 2000). We evaluated pathway efficacy by determining the number 
of patients ruled out with the pathway alone, or with the combination of pathway and 
 
 158 
risk score as a proportion of the total study population, with comparison by 
McNemar’s test for paired proportions. A two-sided P<0.05 was considered 





We enrolled 1,951 patients with suspected acute coronary syndrome, of whom 1,935 
had a cardiac troponin I result available from presentation (Table 5.1, Table 5.2 and 
Appendix 3.1 respectively). The adjudicated diagnosis was type 1 myocardial 
infarction in 273 patients (14.1%), type 2 myocardial infarction in 77 patients (4%) 
and myocardial injury in 31 patients (1.6%), with 6 deaths from a cardiac cause at 30 









<5 ng/L at 
presentation 
(n=1,142) 
≤99th centile at 
presentation  
(n=1,639) 




Age  61.5 (14.2) 56.6 (12.6) 60.2 (14) 68.7 (13.6) 
Male (%) 1182 (61.1) 637 (55.8) 1012 (61.7) 170 (57.4) 
Chest pain (%)  1623 (84.1) 983 (86.4) 1387 (84.9) 236 (79.9) 
Symptom to arrival time (mins) 199 (118-464) 199 (114-462) 199 (115-445) 199 (138-528) 
Past medical history 
Diabetes mellitus (%) 286 (14.8) 124 (10.9) 229 (14.0) 57 (19.3) 
Hypertension (%) 769 (39.7) 358 (31.3) 630 (38.4) 139 (47.0) 
Hyperlipidaemia (%) 765 (39.5) 376 (32.9) 641 (39.1) 124 (41.9) 
Family History (%) 927 (47.9) 575 (50.4) 793 (48.4) 134 (45.3) 
Ischaemic Heart Disease (%) 582 (30.1) 252 (22.1) 484 (29.5) 98 (33.1) 
Previous MI (%) 460 (23.8) 172 (15.1) 374 (22.8) 86 (29.1) 
Previous PCI (%) 366 (18.9) 154 (13.5) 308 (18.8) 58 (19.6) 
Previous CABG (%) 117 (6.0) 31 (2.7) 96 (5.9) 21 (7.1) 
Previous Heart Failure (%) 66 (3.4) 10 (0.9) 45 (2.7) 21 (7.1) 
Previous Stroke (%) 119 (6.1) 45 (3.9) 97 (5.9) 22 (7.4) 
Smoker (%) 385 (19.9) 266 (23.3) 330 (20.1) 55 (18.6) 
Medication history 
Aspirin (%) 655 (33.9) 305 (26.7) 545 (33.3) 110 (37.2) 
Clopidogrel (%) 250 (12.9) 100 (8.8) 203 (12.4) 47 (15.9) 
Beta-blocker (%) 522 (27.0) 240 (21.0) 431 (26.3) 91 (30.7) 
ACE Inhibitor (%) 582 (30.1) 271 (23.7) 487 (29.7) 95 (32.1) 
Statin (%) 824 (42.6) 398 (34.9) 690 (42.1) 134 (45.3) 
Long Acting Nitrate (%) 369 (19.1) 156 (13.7) 296 (18.1) 73 (24.7) 
Calcium Channel Blocker (%) 242 (12.5) 109 (9.5) 199 (12.1) 43 (14.5) 
Warfarin (%) 105 (5.4) 34 (3.0) 83 (5.1) 22 (7.4) 
Electrocardiogram findings 
ST depression (%) 112 (5.8) 27 (2.4) 65 (4.0) 47 (15.9) 
ST elevation (%) 58 (3.0) 28 (2.5) 42 (2.6) 16 (5.4) 
T-wave inversion (%) 300 (15.5) 113 (9.9) 218 (13.3) 82 (27.7) 
Physiological parameters 
Systolic BP (mmHg)  137 (124-152) 137 (124-152) 137 (124-152) 137 (121-151) 
Diastolic BP (mmHg) 77 (68-88) 79 (70-89) 78 (69-88) 74 (66-85) 
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Heart rate (bpm)  75 (64-87) 75 (65-86) 75 (65-86) 76 (63-91) 
Temperature  36.5 (36.1-36.9) 36.5 (36.1-37) 36.5 (36.1-36.9) 36.5 (36-36.8) 
Respiratory rate 16 (16-18) 16 (16-18) 16 (16-18) 16 (16-18) 
Oxygen saturations 97 (96-98) 98 (96-99) 97 (96-99) 97 (96-98) 
Creatinine 74(67-84) 73 (66-78) 74 (67-82) 76 (69-94) 
Clinical risk scores 
HEART Score 5 (3-6) 4 (3-5) 4 (3-5) 7 (6-8) 
GRACE Score 100 (79-107) 91 (79-100) 100 (79-129) 129 (107-151) 
TIMI Score 1 (0-3) 1 (0-2) 1 (0-2) 3 (2-4) 
Adjudicated index diagnosis 
Type 1 myocardial infarction (%) 273 (14.1) 6 (0.5) 65 (4.0) 208 (70.3) 
Type 2 myocardial infarction (%) 77 (4.0) 5 (0.4) 24 (1.5) 53 (17.9) 
Myocardial injury (%) 31 (1.6) 0 (0.0) 1 (0.1) 30 (10.1) 
Outcomes at 30 days 
Type 1 myocardial infarction (%)a 8 (0.4) 0 (0.0) 3 (0.2) 5 (1.7) 
Cardiac death at 30 days (%) 6 (0.3) 0 (0.0) 2 (0.1) 4 (1.4) 
Type 1 myocardial infarction or 
cardiac death at 30 days (%) 
276 (14.3) 6 (0.5) 68 (4.1) 208 (70.3) 
Values are mean (SD),median (IQR) or n(%). MI – myocardial infarction. PCI – percutaneous coronary intervention. 





Table 5.2.  Investigation and management of patients stratified by troponin 




<5 ng/L at 
presentation 
(n=1,142) 
≤99th centile at 
presentation  
(n=1,639) 
>99th centile at 
presentation  
(n=296) 
In-hospital management  
Aspirin (%)  1055 (56.3) 564 (50.9) 839 (52.9) 216 (74.7) 
Clopidogrel (%) 217 (11.9) 27 (2.5) 54 (3.5) 163 (57.2) 
Ticagrelor (%)  6 (0.4) 1 (0.1) 2 (0.1) 4 (1.6) 
Heparin (%) * 157 (8.6) 11 (1.0) 25 (1.6) 132 (46.6) 
Cardiology referral (%) 888 (47.9) 378 (34.8) 627 (40.2) 261 (89.7) 
Investigation and management within 30 days of presentation 
Echocardiography (%) 183 (9.5) 36 (3.2) 90 (5.5) 93 (31.4) 
Coronary angiography (%) 220 (11.4) 24 (2.1) 72 (4.4) 148 (50.0) 
Percutaneous coronary 
intervention (%) 
138 (7.1) 9 (0.8) 36 (2.2) 102 (34.5) 
 
























































5.4.1 ESC 3-hour pathway 
A total of 1,886 patients (97.5%) were included, with 49 patients excluded due to 
missing 3-hour samples which were required for the ESC pathway (Figure 5.1). The 
ESC pathway identified 70% (1,328/1,886) of patients as low risk, with 27 missed 
events (25 index type 1 myocardial infarction, one type 1 myocardial infarction and 
one cardiac death at 30 days, Appendix 3.2) for a negative predictive value (NPV) of 
97.9% (95% confidence interval [CI] 97.1 to 98.6%) and sensitivity of 89.9% (95%CI 
86.3 to 93.4%; Table 5.3).  
5.4.2 ESC 3-hour pathway plus clinical risk scores  
When a HEART score of ≤3 was applied alongside the ESC pathway, the proportion 
identified as low risk fell from 70% to 24.8% (468/1,886, P<0.001). However, the 
NPV improved to 99.7% (95%CI 99.0 to 100%, P<0.001). A similar improvement in 
safety was observed when an EDACS score of <16 was applied, with a NPV of 99.2% 
(95%CI 98.5 to 99.7%, P<0.001), identifying 42.4% as low risk (800/1,886, P<0.001). 
A TIMI score of 0 or 1 gave a NPV of 99.2%, (95%CI 98.5 to 99.7%, P<0.001), and 
a GRACE score of ≤108 gave a NPV of 99.0% (95%CI 98.2 to 99.5%, P<0.001), with 
a reduction in the proportion identified as low risk to 43.5% (844/1,886, P<0.001) and 
49% (924/1,886, P<0.001) of patients, respectively. When a higher GRACE score of 
<140 was applied as recommended in the guideline, the NPV and sensitivity were 
lower at 98.1% (95%CI 97.3 to 98.8%) and 91.3% (95%CI 87.8 to 94.4%), 





Table 5.3. Diagnostic metrics for the European Society of Cardiology 3-hour pathway with and without clinical risk scores  
 
 
ESC – European Society of Cardiology, TIMI – Thrombolysis In Myocardial Infarction, GRACE – Global Registry of Acute Coronary Events, EDACS = Emergency Department Assessment of Chest pain 
























244 314 1301 27 97.9 (97.1-98.6) 89.9 (86.3-93.4) 43.7 (39.7-47.9) 80.5 (78.6-82.5) 70.4 
ESC 3-h + 
TIMI (0/1) 
265 777 838 6 99.2 (98.5-99.7) 97.6 (95.5-99.1) 25.5 (22.9-28.1) 51.9 (49.5-54.3) 44.8 
ESC 3-h + 
GRACE ≤108 
262 700 915 9 99.0 (98.2-99.5) 96.5 (94.0-98.3) 27.3 (24.5-30.1) 56.7 (54.2-59.1) 49.0 
ESC 3-h + 
EDACS <16 
265 821 794 6 99.2 (98.5-99.7) 97.6 (95.5-99.1) 24.4 (21.9-27.0) 49.2 (46.7-51.6) 42.4 
ESC 3-h + 
HEART ≤3 
270 1148 467 1 99.7 (99.0-100) 99.4 (98.3-100) 19.1 (17.1-21.1) 28.9 (26.7-31.2) 24.8 
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5.4.3 High-STEACS pathway 
A total of 1,917 patients (99.1%) were included, with 18 patients excluded due to 
missing 3-hour samples which were required for the High-STEACS pathway (Figure 
5.1). The High-STEACS pathway identified 64.9% (1,244/1,917) of patients as low 
risk, with three missed events (two index type 1 myocardial infarction and one type 1 
myocardial infarction at 30 days, Appendix 3.3) for a NPV of 99.7% (95%CI 99.4 to 
99.9%) and sensitivity of 98.7% (95%CI 97.4 to 99.8%; Table 5.4).  
5.4.4 High-STEACS pathway plus clinical risk scores 
When a HEART score ≤3 was applied alongside the High-STEACS pathway, the 
proportion identified as low risk fell to 24.3% (465/1,917, P<0.001). There was no 
improvement in the NPV (99.9%, 95%CI 99.6 to 100%, P=0.083). Similarly, no 
improvements in NPV were observed when the High-STEACS pathway was applied 
in conjunction with an EDACS score of <16 (NPV 99.7%, 95%CI 99.2 to 99.9%, 
P=0.912), a TIMI score of 0 or 1 (NPV 99.8%, 95%CI 99.4 to 100%, P=0.313), or a 
GRACE score of ≤108 (NPV 99.7%, 95%CI 99.3 to 100%, P=0.815). All risk scores 
reduced the proportion of patients identified as low risk (EDACS 41%, TIMI 44% and 









High-STEACS = High-Sensitivity Troponin in the Evaluation of patients with Acute Coronary Syndrome,  TIMI – Thrombolysis In Myocardial Infarction, EDACS – Emergency Department Assessment of 
























273 400 1241 3 99.7 (99.4-99.9) 98.7 (97.4-99.8) 40.6 (36.9-44.3) 75.6 (73.5-77.7) 64.9 
High-STEACS 
+ TIMI (0/1) 
275 808 833 1 99.8 (99.4-100) 99.5 (98.3-100) 25.4 (22.9-28) 50.8 (48.3-53.2) 43.5 
High-STEACS 
+ GRACE ≤108 
274 734 907 2 99.7 (99.3-100) 99.1 (97.7-99.8) 27.2 (24.5-30) 55.3 (52.9-57.7) 47.4 
High-STEACS 
+ EDACS <16 
274 851 790 2 99.7 (99.2-99.9) 99.1 (97.7-99.8) 24.4 (21.9-26.9) 48.1 (45.7-50.6) 41.3 
High-STEACS 
+ HEART ≤3 































5.4.5 Sensitivity analyses 
We repeated our analyses of the High-STEACS and ESC 3-hour pathways for a 
composite endpoint including type 1 or type 2 myocardial infarction, or myocardial 
injury, with similar performance observed (Appendix 3.4 and 3.5). As the High-
STEACS pathway was derived in the first 1,218 participants of this cohort study, we 
repeated our analyses and excluded these patients, with no differences observed in 
diagnostic performance (Appendix 3.6). In a further sensitivity analysis, we excluded 
any patients who underwent invasive or non-invasive cardiac testing, and observed no 
differences in safety or efficacy (Appendix 3.7). The diagnostic metrics for each risk 
score alone are provided in Appendix 3.8.  
5.4.6 ESC 1-hour rule out pathway 
Where samples were available at presentation and one hour (406/1,935), we evaluated 
the performance of the ESC 1-hour rule out pathway (Appendix 3.9). In this 
population, the prevalence of the primary outcome was 8.1% (33/406). The ESC 1-
hour pathway identified 37.7% (153/406) of patients as low risk at presentation, and a 
total of 71.4% (290/406) of patients as low risk at one hour, with no missed cases, for 
a NPV of 99.8% (95%CI 99.3 to 100%) and sensitivity of 98.5% (95%CI 94.4 to 
100%). As no cases were missed, no risk score improved safety, but all significantly 
reduced the proportion identified as low risk. When we applied the High-STEACS 
pathway in the subgroup of patients with one hour samples available, there were also 







5.5  Discussion 
In a prospective observational cohort study of patients with suspected acute coronary 
syndrome, we have evaluated the performance of high-sensitivity cardiac troponin 
testing in the European Society of Cardiology (ESC) 3-hour pathway, and the High-
STEACS pathway which applies a lower threshold to rule out myocardial infarction, 
with and without the addition of clinical risk scores. We make a number of clinically 
relevant observations.  
When used in isolation, the ESC pathway identifies a high proportion of patients as 
low risk, but the negative predictive value and sensitivity were poor, missing 27 index 
or 30-day events. The addition of a clinical risk score markedly improves safety, with 
the combination of ESC pathway and a HEART score ≤3 missing just one index event. 
However, this strategy identifies 3-fold fewer patients as low risk. Conversely, the 
High-STEACS pathway incorporates a lower threshold of 5 ng/L to rule out 
myocardial infarction, and has both a high negative predictive value and sensitivity, 
missing just three index or 30-day events and identifying two-thirds of patients as low 
risk. There was no improvement in diagnostic performance when the High-STEACS 
pathway was applied in conjunction with the TIMI, GRACE, EDACS or HEART 
scores, but there was a 2 to 3-fold reduction in the proportion of patients identified as 
low risk.  
The European Society of Cardiology 3-hour pathway was first introduced in the 2011 
Non-ST Elevation Acute Coronary Syndrome (NSTE-ACS) guideline, and has been a 
central component of our evaluation of patients with suspected acute coronary 
syndrome (Hamm et al., 2011, Roffi et al., 2016). This pathway was devised in an era 
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of contemporary cardiac troponin assays, where the upper reference limit was up to 
five-fold higher than that applied with current generation high-sensitivity assays (Mills 
et al., 2011). It is perhaps unsurprising that when evaluated with more sensitive assays, 
the diagnostic performance of this pathway is worse. Several recent studies have 
demonstrated a low negative predictive value, with diagnostic sensitivities <95%, well 
below the level deemed clinically acceptable (Pickering et al., 2016b, Chapman et al., 
2017b, Wildi et al., 2016). Although the ESC guideline includes a low risk GRACE 
score (≤140) as a final step prior to discharge, there is a lack of clarity as to the intended 
strategy for this approach in clinical practice. In the present analysis, we demonstrate 
a GRACE score ≤140 is not effective, but a more conservative GRACE score of ≤108 
does improve the NPV and sensitivity, although the latter remained at 96%. 
The GRACE and TIMI scores were derived in patients with confirmed myocardial 
infarction and were designed to guide prognostication and management. These scores 
have been extrapolated for use as risk stratification tools in patients with suspected 
acute coronary syndrome, and both improved the performance of the ESC pathway. In 
contrast, both the HEART and the EDACS scores were derived and validated in 
patients with suspected, not confirmed myocardial infarction. 
The HEART score has been shown to perform better than GRACE and TIMI in 
patients with suspected acute coronary syndrome (Backus et al., 2013). In this analysis, 
we demonstrate the greatest improvement in the safety of the ESC pathway when a 
HEART score of ≤3 was included. The ESC pathway and the HEART score appear 
synergistic, with the combination of strategies offering an improved safety profile than 
either in isolation. Our observation is consistent with a recent meta-analysis of 11,217 
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patients with suspected acute coronary syndrome, in whom a HEART score ≤3 gave a 
sensitivity of 96.7% (Van Den Berg and Body, 2017). The current HEART score uses 
troponin as categorical variable based on multiples of the upper reference limit. One 
option to improve the performance of the HEART score further would be to 
incorporate high-sensitivity cardiac troponin concentrations as a continuous marker of 
risk (Roffi et al., 2016), and to harness rather than omit this information to aid risk 
stratification. Similar improvements in the safety of the ESC pathway were observed 
when applied in conjunction with a low risk EDACS score. However, this approach 
identified almost twice as many patients as low risk. This observation may influence 
clinicians if considering which approach to implement in practice.  
The High-STEACS pathway applies a cardiac troponin threshold of <5 ng/L in 
conjunction with a non-ischemic ECG as an initial risk stratification step, with serial 
testing at 3 hours in all other patients. This pathway performs well in patients with 
suspected acute coronary syndrome, and we demonstrate no improvement in safety 
with the addition of clinical risk scores. When applied in isolation, the High-STEACS 
pathway ruled out 1,244 patients with 3 missed events (a miss rate of less than 1 in 
400 patients). The safety of pathways incorporating low concentrations of cardiac 
troponin for risk stratification is high and not improved by additional risk scores. One 
of the reasons this approach is so effective is that cardiac troponin concentrations are 
increased in patients with risk factors for acute coronary syndrome (such as 
hyperlipidemia, hypertension or renal impairment) or in those with subclinical 
coronary or structural heart disease that may not be evident at presentation to the 
Emergency Department (Chin et al., 2014, Shah et al., 2017, Miller-Hodges et al., 
2018, Twerenbold et al., 2018).  
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There are several alternatives to the two rule out pathways presented in this analysis 
(Cullen et al., 2017b). The European Society of Cardiology introduced a 0 and 1-hour 
rule out pathway in their 2015 guideline (Roffi et al., 2016). This pathway has 
excellent diagnostic performance and has been validated in a number of settings, 
including a subgroup analysis of the present study (Mueller et al., 2016, Neumann et 
al., 2016, Reichlin et al., 2015, Pickering et al., 2016a). However, the practicality of 
delivering presentation troponin results and obtaining serial testing at 1 hour may be 
challenging in many healthcare settings, and until point of care solutions that facilitate 
rapid turnaround times with similar test characteristics to laboratory troponin assays, 
safe alternative pathways with serial testing at 2 or 3 hours are required.  In such 
settings, we believe the ESC 3-hour pathway should be applied with a clinical risk 
score. Alternatively, the EDACS score alone provides excellent safety and efficacy 
when applied with a non-ischemic electrocardiogram and serial cardiac troponin 
testing at 0 and 2 hours, as recommended by the authors (Appendix 3.8) (Than et al., 
2014b)  
In settings where high-sensitivity cardiac troponin I testing is available, the High-
STEACS pathway is a more effective alternative approach, identifying more patients 
as low risk without compromising safety. The performance of this pathway is currently 
being evaluated in a stepped-wedge cluster randomized trial of ~30,000 patients in 





There are important limitations to the data presented. This is a single center 
observational cohort study. However, as a large tertiary cardiology center, we believe 
our findings are likely to be generalizable. The High-STEACS pathway was derived 
in the first 1,218 patients included in this population, and whilst the performance was 
identical in our sensitivity analysis excluding these patients, further external validation 
studies are required. As the majority of patients underwent serial sampling at 3 hours 
(Appendix 3.10), we were only able to evaluate the ESC 1-hour pathway in a minority 
of patients. As this strategy includes low concentrations of cardiac troponin to risk 
stratify patients, it is likely that the performance would be similar to the High-STEACS 
pathway in the full population. To date, no comparison studies of these approaches 
have been undertaken. We were not able to undertake evaluation of other validated 
rule out pathways such as ADAPT or T-MACS. Our analysis of the ESC 3-hour 
pathway focused on high-sensitivity cardiac troponin I. However, similar findings 
have been documented in studies of high-sensitivity cardiac troponin T (Pickering et 
al., 2016b). Finally, as with all observational cohort studies, no patients were 
discharged on the basis of the pathways evaluated, and differences in management 
may have influenced outcomes. Whilst we did not have information on rates of 
exercise tolerance testing or nuclear testing, patients with low troponin concentrations 
were less likely to undergo transthoracic echocardiography or invasive coronary 
angiography (Table 3.2) and when we repeated the primary analysis removing all 
patients who underwent these investigations (Appendix 3.7), we observed no reduction 
in safety. Nevertheless, the results of implementation studies are necessary to guide 






5.6  Conclusions 
Clinical risk scores significantly improve the safety of the European Society of 
Cardiology 3-hour pathway that relies on the 99th centile to rule out myocardial 
infarction. Where lower cardiac troponin I concentrations are used to rule out 
myocardial infarction, the risk scores evaluated half the proportion of patients ruled 
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Type 2 myocardial infarction and myocardial injury are common in clinical practice, 
but long-term consequences are uncertain. We aimed to define long-term outcomes 
and explore risk stratification in patients with type 2 myocardial infarction and 
myocardial injury.  
Methods 
We identified consecutive patients (n=2,122) with elevated cardiac troponin I 
concentrations (≥0.05 µg/L) at a tertiary cardiac centre. All diagnoses were 
adjudicated as per the Universal Definition of Myocardial Infarction. The primary 
outcome was all-cause death. Secondary outcomes included major adverse 
cardiovascular events (MACE; non-fatal myocardial infarction or cardiovascular 
death) and non-cardiovascular death. To explore competing risks, cause-specific 
hazard ratios were obtained using Cox regression models. 
Results 
The adjudicated index diagnosis was type 1 or type 2 myocardial infarction or 
myocardial injury in 1,171 (55.2%), 429 (20.2%) and 522 (24.6%) patients, 
respectively. At five years, all-cause death rates were higher in those with type 2 
myocardial infarction (62.5%) or myocardial injury (72.4%) compared with type 1 
myocardial infarction (36.7%). The majority of excess deaths in those with type 2 
myocardial infarction or myocardial injury were due to non-cardiovascular causes (HR 
2.32, 95%CI 1.92-2.81, versus type 1 myocardial infarction). Despite this, the 
observed crude MACE rates were similar between groups (30.6% versus 32.6%), with 
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differences apparent after adjustment for co-variates (HR 0.82, 95%CI 0.69-0.96). 
Coronary heart disease was an independent predictor of MACE in those with type 2 
myocardial infarction or myocardial injury (HR 1.71, 95%CI 1.31-2.24).   
Conclusions 
Despite an excess in non-cardiovascular death, patients with type 2 myocardial 
infarction or myocardial injury have a similar crude rate of major adverse 
cardiovascular events to those with type 1 myocardial infarction. Identifying 
underlying coronary heart disease in this vulnerable population may help target 






The diagnostic criteria for acute myocardial infarction were updated to accommodate 
the introduction of more sensitive cardiac troponin assays, and in recognition of the 
wide range of conditions that are associated with myocardial injury (White et al., 2014). 
The third universal definition of myocardial infarction recommends a classification 
based on etiology, where type 1 myocardial infarction is due to plaque rupture or 
erosion with atherothrombotic consequences, and type 2 myocardial infarction due to 
myocardial oxygen supply-demand imbalance in the absence of atherothrombosis. 
Patients with elevated cardiac troponin concentrations who do not have overt 
myocardial ischemia are classified as having myocardial injury (Thygesen et al., 
2012a). Whilst these diagnostic categories are considered distinct in guidelines, 
implementation in clinical practice has been challenging due to similarities between 
patients with type 2 myocardial infarction and myocardial injury, with the implications 
of these diagnoses uncertain. 
The Global Task Force is reviewing the classification of myocardial infarction, and 
recognizes the need to provide greater clarity for clinicians in practice (Alpert and 
Thygesen, 2016). Whilst patients with type 2 myocardial infarction and myocardial 
injury have higher crude rates of all-cause death compared with those with type 1 
myocardial infarction (Shah et al., 2015c, Javed et al., 2009, El-Haddad et al., 2012, 
Sarkisian et al., 2016, Saaby et al., 2014, Stein et al., 2014), differences do not always 
persist in adjusted analyses (Sandoval et al., 2017b, Neumann et al., 2017b) and few 
studies report cause of death or risk of future cardiovascular events (Gaggin et al., 
2017). If patients with type 2 myocardial infarction are at increased risk of 
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cardiovascular events attributable to atherosclerotic disease, then targeted 
investigation and preventative therapies have the potential to modify outcomes.  
In consecutive patients with elevated cardiac troponin concentrations measured using 
a sensitive assay, we previously observed that the diagnosis of type 2 myocardial 
infarction or myocardial injury was as common as type 1 myocardial infarction (Shah 
et al., 2015c). Here we report outcomes for these patients, and determine the clinical 
features associated with major adverse cardiovascular events, with the aim of 






6.3.1 Study population 
Consecutive hospital inpatients with elevated cardiac troponin I concentrations (≥0.05 
µg/L) were identified at a tertiary cardiac centre (Royal Infirmary of Edinburgh, 
Scotland, UK) during the validation (January 19th to July 31st 2008) and 
implementation (January 19th to July 31st 2009) phases of a contemporary sensitive 
cardiac troponin I assay (Shah et al., 2015c, Mills et al., 2011). We included all patients 
in whom cardiac troponin was requested by the attending clinician, regardless of 
suspected etiology or hospital department. All clinical details were obtained using an 
electronic patient record (TrakCare, InterSystems, Cambridge, MA). We excluded 
patients admitted for elective procedures, those with incomplete electronic hospital 
records, and patients who were not residents to ensure follow up was complete. 
6.3.2 Cardiac troponin assay 
Plasma cardiac troponin concentrations were measured using a contemporary sensitive 
cardiac troponin I assay (ARCHITECTSTAT, Abbott Laboratories, Abbott Park, IL). 
The study was divided into validation and implementation phases (Shah et al., 2015c, 
Mills et al., 2011). Only cardiac troponin concentrations above the diagnostic 
threshold of the previous generation assay (≥0.20 µg/L) were reported to clinicians 
during the validation phase, whereas concentrations above a revised diagnostic 
threshold (≥0.05 µg/L) were reported during the implementation phase. The 99th 
centile of this assay is 0.028 µg/L; however, a diagnostic threshold of ≥0.05 µg/L was 
implemented as this was the minimum concentration where the coefficient of variation 
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was <10% under local laboratory conditions. All troponin results were available to the 
research team irrespective of study phase. 
6.3.3 Diagnostic classification 
All diagnoses were classified as per the third universal definition of myocardial 
infarction (Thygesen et al., 2012a, Shah et al., 2015c). Patients were classified as 
having a type 1 myocardial infarction when myocardial necrosis occurred in the 
context of a presentation with suspected acute coronary syndrome with symptoms of 
myocardial ischemia, or evidence of myocardial ischemia on the electrocardiogram. 
Patients with symptoms or signs of myocardial ischemia that were thought to be due 
to increased oxygen demand (e.g. tachyarrhythmia or hypertrophy) or decreased 
supply (e.g. hypotension, hypoxia or anaemia) and myocardial necrosis in the context 
of an alternative clinical diagnosis were classified as having a type 2 myocardial 
infarction. Myocardial injury was defined as evidence of myocardial necrosis in the 
absence of any symptoms or signs of myocardial ischemia. For this analysis, we 
excluded patients classified as having type 3, type 4a or 4b, or type 5 myocardial 
infarction. Each case was reviewed and classified independently by two cardiologists, 
and any discrepancies were resolved by consensus through in-depth review of source 
data. Further information on the adjudication process is provided in Appendix 4.1. 
6.3.4 Clinical outcomes 
Clinical outcomes were identified using local and national population registries. We 
determined death using TrakCare (InterSystems, Cambridge, MA) and the National 
Register of Scotland (NRS), with future hospitalization for myocardial infarction or 
heart failure identified using an extract from the Scottish Morbidity Record (SMR01). 
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We defined death from a cardiovascular cause where one of the following ICD10 
codes were listed as primary cause of death: I20-25, I34-37, I42-43, I46, I48-51 and 
I60-69 (Appendix 4.2). The primary outcome was all cause death. Secondary 
outcomes included major adverse cardiovascular events (MACE; defined as 
cardiovascular death or subsequent myocardial infarction), non-fatal myocardial 
infarction, fatal myocardial infarction, hospitalization with heart failure, and non-
cardiovascular death. We obtained follow up for all patients until the primary outcome 
or date of censoring (16th November 2015). 
6.3.5 Ethical considerations 
The parent study protocol evaluated the implementation of a sensitive cardiac troponin 
assay, and was deemed to fall under the remit of audit and service evaluation by the 
NHS Lothian Regional Ethics Committee, therefore formal ethical approval was not 
required. For this study, we received approval from the Caldicott guardian to obtain 
long term follow up through local and national registries. 
6.3.6 Statistical analysis 
Baseline characteristics were summarized as mean (SD) or median (IQR) as 
appropriate, with patients grouped based on the classification of myocardial infarction. 
Crude incidence rates for primary and secondary outcomes were calculated, with risk 
ratios obtained using a generalized linear model with a log link, Poisson error 
distribution and robust variance estimates.(Yelland et al., 2011) We adjusted for 
clinically relevant covariates including age, sex, renal function (estimated glomerular 
filtration rate, eGFR), hemoglobin (g/L), diabetes mellitus, hypertension, coronary 
heart disease (defined as previous myocardial infarction, coronary revascularization or 
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known angina pectoris), stroke, peripheral vascular disease or cigarette smoking. The 
study period included a lowering of the upper reference limit for cardiac troponin from 
0.20 µg/L (validation phase) to 0.05 µg/L (implementation phase), and we therefore 
included study phase in all models. We repeated these analyses among only those 
patients who survived 30 days after presentation, defining the start of the follow-up 
period as 30 days post presentation. To explore competing risks, cause-specific hazard 
ratios were obtained using Cox regression models for type 1 myocardial infarction 
versus type 2 myocardial infarction or myocardial injury for MACE and non-
cardiovascular death. Penalised splines were used to accommodate departures from 
linearity. We examined for non-proportional hazards graphically and via the method 
proposed by Grambsch and Therneau (1994). In patients who survived to 30 days, we 
explored associations between covariates and future risk of MACE. Cumulative 
incidence plots were produced for secondary cardiovascular outcomes, which also 
illustrate the competing risk of non-cardiovascular death. We report 95% confidence 
intervals for all estimates, with all analyses performed using R (Version 3.2.2) using 
the survival and cmprsk packages (Team., 2015). The analysis code for this study has 





We identified 2,929 consecutive patients with elevated cardiac troponin concentrations 
(≥0.05 µg/L) of whom 807 met our exclusion criteria (Figure 6.1). In the study 
population (n=2,122), the adjudicated diagnosis was type 1 myocardial infarction in 
1,171 patients (55.2%), type 2 myocardial infarction in 429 patients (20.2%) and 












Figure 6.1 Consort diagram with identification of the study population. 
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6.4.1 Clinical characteristics 
Patients with type 2 myocardial infarction or myocardial injury were older, and there 
were a higher proportion of women than men compared to patients with type 1 
myocardial infarction. Anaemia or renal impairment was more common in patients 
with type 2 myocardial infarction or myocardial injury. A history of previous coronary 
revascularization was more frequent in those with type 1 myocardial infarction. At 
presentation, the prescription of anti-platelet, anti-hypertensive and lipid lowering 
therapies was similar across all patients (Table 6.1). The most common diagnoses in 
patients with type 2 myocardial infarction or myocardial injury were cardiac 
arrhythmia, decompensated left ventricular failure, pneumonia or long bone fracture, 




Table 6.1.  Baseline characteristics of the study population 
  












Age  68 (14) 75 (14) 76 (13) 
Male (%) 709 (60.5) 222 (51.7) 260 (49.8) 
Past Medical History 
Diabetes Mellitus (%) 185 (16.7) 93 (21.7) 96 (18.7) 
Hypertension (%) 533 (48.2) 254 (59.3) 303 (58.9) 
Hyperlipidaemia (%) 539 (48.6) 177 (41.5) 202 (39.5) 
Family History (%) 193 (18.1) 14 (3.3) 10 (2.0) 
Ischaemic Heart Disease 
(%) 
497 (44.7) 191 (44.6) 186 (36.3) 
Previous MI (%) 231 (23.9) 109 (26.0) 107 (20.9) 
Previous Stroke (%) 92 (8.3) 48 (11.2) 86 (16.8) 
Previous PVD (%) 85 (7.7) 29 (6.8) 39 (7.6) 
Previous PCI (%) 153 (14.7) 17 (4.0) 23 (4.5) 
Previous CABG (%) 62 (6.3) 30 (7.1) 32 (6.2) 
Smoker (%) 380 (34.0) 62 (14.5) 73 (14.0) 
Admission Medication 
Aspirin (%) 413 (49.7) 175 (44.1) 207 (45.9) 
Clopidogrel (%) 100 (12.2) 25 (6.3) 26 (5.8) 
Beta-blocker (%) 257 (31.2) 101 (25.7) 111 (24.6) 
ACE Inhibitor (%) 300 (36.4) 136 (34.4) 158 (35.1) 
Statin (%) 384 (46.5) 156 (39.5) 191 (42.4) 
Long Acting Nitrate (%) 124 (15.1) 48 (12.2) 43 (9.6) 
Calcium Channel Blocker 
(%) 
165 (20.1) 65 (16.5) 67 (14.9) 
GTN Spray (%) 250 (30.3) 76 (19.3) 63 (14.0) 
Diuretic (%) 230 (27.9) 170 (43.0) 196 (43.6) 
Warfarin (%) 35 (4.5) 38 (9.7) 52 (11.6) 
Baseline Investigations 
Haemoglobin (g/L)  133.9 (20.4) 121.4 (25) 120.2 (22.1) 
Urea (mmol/L)  8.2 (9.4) 10 (7.1) 12.02 (11.5) 
Creatinine (mmol/L)  106.8 (59.8) 132.5 (108.9) 155 (172.2) 
Corrected eGFR (ml/min)  69 (26) 58 (28) 54 (32) 
Cholesterol (mmol/L) 4.8 (1.3) 4.3 (1.2) 4.3 (1.4) 
Troponin I (µg/L)  2.42 (0.27-15.23) 0.14 (0.07-0.66) 0.13 (0.06-0.39) 
 
Values are mean (SD),median (IQR) or n(%). MI – myocardial infarction. PVD – peripheral vascular disease, PCI – 
percutaneous coronary intervention. CABG – coronary artery bypass grafting. ACE – angiotensin converting enzyme. 
GTN – glyceryl trinitrate, eGFR – estimated glomerular filtration rate,  Ischaemic Heart Disease – previous myocardial 
infarction or angina pectoris. 
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6.4.2 Clinical outcomes at five years in all patients 
During 8,809 person years follow up (median 4.9 years), death from any cause 
occurred in 1,231 patients (58%). In patients with type 2 myocardial infarction, at five 
years, the observed risk of death was higher compared to those with type 1 myocardial 
infarction (62.5% versus 36.7%, unadjusted relative risk (RR) 2.15, 95% confidence 
intervals (95%CI) 1.82-2.55. After incorporating age, sex, renal function, hemoglobin 
and other clinically relevant co-variates, the adjusted RR fell to 1.51, (95%CI 1.21-









Figure 6.2 Kaplan-Meier curves illustrating risk of death from any cause at five 
years stratified by index diagnosis, with table of number at risk. Pair-wise comparison 
of groups obtained using the log-rank test. 
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Table 6.2. Death and major cardiovascular events at 5 years stratified by diagnosis  
 
 Type 1 MI  
(n=1,171) 




Type 2 MI versus  
Type 1 MI 
 
Myocardial Injury  
versus Type 1 MI 
 








Death from any cause 430 (36.7%) 268 (62.5%) 378 (72.4%) 2.15 (1.82-2.55) 1.51 (1.21-1.87) 2.88 (2.43-3.40) 2.09 (1.72-2.55) 
MACE  382 (32.6%) 129 (30.1%) 162 (31.0%) 0.92 (0.77-1.09) 0.74 (0.62-0.88) 0.95 (0.81-1.11) 0.77 (0.66-0.89) 
   Non-fatal MI  209 (17.8%) 43 (10.0%) 35 (6.7%) 0.60 (0.45-0.79) 0.58 (0.44-0.77) 0.43 (0.31-0.58) 0.44 (0.32-0.60) 
   Cardiovascular death 253 (21.6%) 104 (24.2%) 145 (27.8%) 1.11 (0.92-1.34) 0.85 (0.70-1.03) 1.25 (1.07-1.46) 0.92 (0.79-1.07) 
Fatal MI 32 (2.7%) 9 (2.1%) 18 (3.4%) 0.81 (0.45-1.46) 0.64 (0.37-1.11) 1.17 (0.81-1.71) 0.93 (0.64-1.34) 
Heart failure 
hospitalization 
103 (8.8%) 25 (5.8%) 48 (9.2%) 0.71 (0.50-1.02) 0.77 (0.54-1.12) 1.03 (0.81-1.32) 1.08 (0.86-1.35) 
Non-cardiovascular 
death 
155 (13.2%) 153 (35.7%) 218 (41.8%) 2.33 (1.99-2.71) 1.66 (1.40-1.98) 2.54 (2.33-2.89) 1.84 (1.61-2.11) 
Event rates (number, %) for primary and secondary outcomes with adjusted relative risk (RR) and 95% confidence intervals (95% CI) at five years. MACE = major adverse 
cardiovascular events (non-fatal type 1 myocardial infarction or cardiovascular death), MI = myocardial infarction. For the composite of MACE, patients who experienced 




The five-year risk of non-fatal myocardial infarction or cardiovascular death (MACE) 
was similar in patients with type 2 compared to type 1 myocardial infarction (30.1% 
versus 32.6%, unadjusted RR 0.92, 95% CI 0.77-1.09, Figure 6.3), but lower after 
adjustment for age, sex and other co-variates (adjusted RR 0.74, 95% CI 0.62-0.88). 
Adjusting for the same co-variates, the cause-specific hazard ratio for MACE (with 
non-cardiovascular mortality as the competing outcome) was similar to the relative 
risk (HR 0.82 95% CI 0.69-0.96, Table 6.3, Appendix 5.5).  
 
Table 6.3. Cause-specific hazard ratio for MACE and non-cardiovascular death in 
patients with type 2 myocardial infarction or myocardial injury versus type 1 
myocardial infarction in unadjusted and fully adjusted Cox-regression models.    
 
 Major Adverse Cardiovascular Events 
 csHR (95% CI) P value 
Model 1 1.16 (1.00-1.34) 0.052 
Model 2 0.84 (0.72-0.98) 0.024 
Model 3 0.74 (0.63-0.87) <0.001 
Model 4 0.82 (0.69-0.96) 0.016 
 Non-Cardiovascular Death 
 csHR (95% CI) P value 
Model 1 3.73 (3.15-4.41) <0.001 
Model 2 2.63 (2.21-3.12) <0.001 
Model 3 2.27 (1.90-2.72) <0.001 
Model 4 2.32 (1.92-2.81) <0.001 
 
Model 1 – Unadjusted. Model 2 – Adjusted for Age and Sex. Model 3 – As per Model 2 with adjustment for estimated 
glomerular filtration rate.  Model 4: As per Model 3 with adjustment for haemoglobin, smoking, diabetes, 
hypertension, coronary artery disease, stroke, peripheral vascular disease and study phase. csHR- cause specific 




























Figure 6.3 Cumulative incidence curves illustrating risk of major adverse cardiovascular events (MACE; type 1 myocardial infarction or 
cardiovascular death) and competing risk of non-cardiovascular death at five years stratified by index diagnosis. 
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For the individual components of MACE, the risk of non-fatal myocardial infarction 
was lower in those with type 2 myocardial infarction compared to type 1 myocardial 
infarction (10.0% versus 17.8%, adjusted RR 0.58, 95% CI 0.44-0.77). Whilst the 
crude rates of cardiovascular death were higher for type 2 myocardial infarction 
compared to type 1 myocardial infarction (24.2% versus 21.6%) the adjusted relative 
risk was lower at 0.85 (95% CI 0.70-1.03). Risks of fatal-myocardial infarction and 
hospitalization with heart failure were comparable across groups (Table 6.2). Non-
cardiovascular death was higher in patients with type 2 myocardial infarction 
compared to type 1 myocardial infarction (35.7% versus 13.2%, adjusted RR 1.66, 
95% CI 1.40-1.98, Figure 6.3).  
We found similar relative risks for patients with myocardial injury compared to type 
1 myocardial infarction for most primary and secondary outcomes, but a lower risk of 
non-fatal myocardial infarction and higher risk of non-cardiovascular death were 
observed. Patients with myocardial injury had a higher risk of all-cause death and heart 




6.4.3 Clinical outcomes at five years in those who survive to 30 days 
In patients who survived from their initial presentation to 30 days, death from any 
cause occurred in 31% (333/1,074) of patients with type 1 myocardial infarction, 
56.1% (207/368) of patients with type 2 myocardial infarction and 67% (293/437) of 
patients with myocardial injury (Table 6.4). The adjusted relative risk of death for 
patients with type 2 myocardial infarction versus type 1 myocardial infarction was 
similar to that observed in the total population (adjusted RR 1.52, 95% CI 1.21-1.92). 
For all but one of the secondary outcomes, the relative risks were similar to those 
obtained in the main analysis.  However, the association between type of myocardial 
infarction and risk of MACE was weaker than was observed in the whole population, 
occurring in 27.4% (101/368) of patients with type 2 myocardial infarction and 27.7% 




Table 6.4. Death and major cardiovascular events at 5 years stratified by diagnosis in those who survived index hospitalization  
 
 Type 1 MI  
(n=1,074) 




Type 2 MI versus  
Type 1 MI 
 
Adjusted RR  
(95% CI) 
Myocardial Injury 
versus Type 1 MI 
 
Adjusted RR  
(95% CI) 
Death from any cause 333 (31.0%) 207 (56.1%) 293 (67.0%) 1.52 (1.21-1.92) 1.95 (1.60-2.39) 
MACE  298 (27.7%) 101 (27.4%) 135 (30.9%) 0.80 (0.65-0.98) 0.87 (0.73-1.02) 
   Non-fatal MI  198 (18.4%) 41 (11.1%) 34 (7.8%) 0.60 (0.45-0.81) 0.46 (0.34-0.64) 
   Cardiovascular death 172 (16.0%) 77 (20.9%) 118 (27.0%) 0.95 (0.76-1.18) 1.07 (0.90-1.27) 
Fatal MI 32 (3.0%) 9 (2.4%) 17 (3.9%) 0.65 (0.38-1.14) 0.90 (0.61-1.31) 
Heart failure hospitalization 92 (8.6%) 22 (6.0%) 39 (8.9%) 0.86 (0.58-1.26) 1.18 (0.91-1.52) 
Non-cardiovascular death 145 (13.5%) 121 (32.8%) 162 (37.1%) 1.55 (1.28-1.88) 1.61 (1.38-1.88) 
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In patients with type 2 myocardial infarction or myocardial injury, age, declining renal 
function, a history of diabetes mellitus, peripheral vascular disease and coronary artery 
disease were independent predictors of MACE at five years (Table 6.5). The presence 
of coronary artery disease was associated with an increase in the cause-specific hazard 
ratio for MACE at five years (HR 1.71, 95% CI 1.31-2.24), compared to those without 
coronary artery disease. When compared to patients with type 1 myocardial infarction, 
patients with type 2 myocardial infarction or myocardial injury with coronary artery 
disease had a higher risk of MACE (RR 1.56, 95% CI 1.29-1.88). The adjusted cause-
specific hazard ratio for MACE, which accounts for competing risk from non-




Table 6.5. Cause-specific hazard ratios for major adverse cardiovascular events in 
patients with type 2 myocardial infarction or myocardial injury alone who survive 





Major Adverse Cardiovascular Events 
(MACE) 
 
 Unadjusted HR (95% CI) 
Adjusted HR 
(95% CI) 
Age (per 10-year increase) 1.56 (1.39-1.75) 1.53 (1.34-1.75) 
Sex (male) 1.08 (0.84-1.38) 1.26 (0.97-1.64) 
Haemoglobin (per 10 g/L reduction) 1.10 (1.04-1.16) 1.04 (0.99-1.10) 
eGFR (per 10 ml/min reduction) 1.16 (1.10-1.21) 1.11 (1.05-1.17) 
Smoking 0.86 (0.60-1.23) 1.39 (0.94-2.05) 
Diabetes Mellitus 1.79 (1.36-2.35) 1.50 (1.12-2.01) 
Hypertension 1.61 (1.24-2.10) 1.02 (0.76-1.36) 
Stroke 1.54 (1.12-2.13) 1.12 (0.80-1.55) 
Peripheral Vascular Disease 2.43 (1.68-3.50) 1.82 (1.21-2.74) 
Validation phase 1.19 (0.92-1.53) 1.25 (0.96-1.63) 
Coronary Artery Disease  2.21 (1.73-2.83) 1.71 (1.31-2.24) 




























Figure 6.4. Cumulative incidence curves illustrating risk of major adverse cardiovascular events (MACE; type 1 myocardial infarction or 
cardiovascular death) and competing risk of non-cardiovascular death in those who survive to 30 days in patients with type 1 myocardial 
infarction, and in those with type 2 myocardial infarction or myocardial injury stratified by known coronary artery disease (CAD). 
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On discharge from hospital, patients with type 2 myocardial infarction or myocardial 
injury and a history of coronary artery disease were less likely than those with type 1 
myocardial infarction to be prescribed aspirin (66.2% versus 90.7%), a statin (69.2% 
versus 86.0%) or an ACE inhibitor (52.9% versus 71.3%, P<0.001 for all, Table 6.6). 
 
 
Table 6.6 Recommended therapies at discharge in patients with type 1 myocardial 
infarction, type 2 myocardial infarction and myocardial injury who survive to 30 days, 
stratified by the presence of coronary artery disease.  
 
 
P values obtained from group-wise comparison using Chi-square test. *P<0.001 in post hoc analysis 
comparing patients with type 2 myocardial infarction or myocardial injury with coronary artery disease 

















artery disease  
 
(n=325) 









     
Aspirin 896 (90.7%) 190 (66.2%) * 148 (37.7%) <0.001 
Clopidogrel 823 (80.7%) 52 (17.6%) * 31 (7.6%) <0.001 
Beta-blocker 651 (64.2%) 126 (42.6%) * 97 (23.7%) <0.001 
ACE Inhibitor 724 (71.3%) 156 (52.9%) * 124 (30.2%) <0.001 
Statin 872 (86.0%) 204 (69.2%) * 120 (29.3%) <0.001 
Long acting nitrates 143 (14.1%) 77 (26.1%) * 12 (2.9%) <0.001 
GTN Spray 671 (66.0%) 121 (41.0%) * 23 (5.6%) <0.001 
CC Blockers 165 (16.3%) 67 (22.7%) 43 (10.5%) <0.001 




In a cohort of consecutive hospitalized patients with elevated cardiac troponin 
concentrations, we classified the diagnosis of myocardial infarction according to the 
universal definition and report outcomes after five years follow up. We make several 
observations that have implications for clinical practice. First, over two-thirds of 
patients with type 2 myocardial infarction or myocardial injury are dead at five years. 
This mortality rate was twice that of patients with type 1 myocardial infarction, with 
differences primarily due to an excess in non-cardiovascular deaths. Second, major 
adverse cardiovascular events occurred in one-third of patients, and rates were similar 
irrespective of diagnostic classification. In those patients with type 2 myocardial 
infarction or myocardial injury, the presence of coronary heart disease was one of the 
strongest predictors of MACE. Those patients with type 2 myocardial infarction or 
myocardial injury with known coronary artery disease were less likely to receive 
secondary prevention therapies compared to those with type 1 myocardial infarction. 
Identifying patients with elevated cardiac troponin concentrations in the context of an 
acute illness who have underlying coronary heart disease may provide an opportunity 
for clinicians to improve the targeting of preventative therapies and reduce the risk of 
cardiovascular events.  
Several studies demonstrate that the diagnosis of type 2 myocardial infarction is 
common in clinical practice, responsible for between 2% and 37% of all elevations in 
cardiac troponin in unselected hospitalized patients and between 5% to 71% in 
unselected patients attending the Emergency Department (Melberg et al., 2010, Shah 
et al., 2015b, Smith et al., 2013, Sandoval et al., 2014b, Baron et al., 2016). Myocardial 
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injury has been reported in up to 70% of unselected patients (Javed et al., 2009, Saaby 
et al., 2013), but as the frequency of diagnosis is not reported by the majority of studies, 
failure to classify patients according to the criteria set out in the universal definition 
may inflate the incidence of type 2 myocardial infarction (Baron et al., 2015). Both 
type 2 myocardial infarction and myocardial injury increase the risk of all-cause death 
at up to three years (Javed et al., 2009, El-Haddad et al., 2012, Sarkisian et al., 2016, 
Saaby et al., 2014, Stein et al., 2014, Baron et al., 2016, Baron et al., 2015, Morrow et 
al., 2009, Bonaca et al., 2012). We now provide outcome data at five years 
demonstrating that two-thirds of patients with type 2 myocardial infarction or 
myocardial injury are dead with twice the event rate of patients with type 1 myocardial 
infarction. 
One of the key limitations of prior analyses is the majority have not reported the 
specific cause of death, and therefore estimates of the proportion of events which may 
be attributable to cardiovascular disease, are lacking (Sandoval and Thygesen, 2017, 
Sandoval, 2017). We found the excess in all-cause death in patients with type 2 
myocardial infarction or myocardial injury was largely attributable to a three-fold 
increase in non-cardiovascular death. As patients with type 2 myocardial infarction or 
myocardial injury are older, and have a higher prevalence of anaemia, renal 
impairment, and other co-morbidities, this is perhaps unsurprising. Nonetheless, it is 
notable that the crude risk of MACE in patients with type 2 myocardial infarction or 
myocardial injury was similar to that in patients with type 1 myocardial infarction. In 
models taking into account the differences in age, sex and other characteristics 
between patients with different index diagnoses, the risk of subsequent cardiovascular 
events was around 25% lower in patients with type 2 myocardial infarction or 
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myocardial injury than in patients with type 1 myocardial infarction. This may in part 
be attributable to competing risks, with the much higher rates of non-cardiovascular 
death reducing the pool of patients at risk of having a cardiovascular event. However, 
competing risks are not the only explanation for the lower rates of MACE in patients 
with type 2 myocardial infarction or myocardial injury, as in an adjusted analysis 
taking into account competing risks and other clinical variables, a difference in the 
cause-specific hazard ratio was still apparent between the groups.  
The diagnostic distinction between patients with type 2 myocardial infarction and 
myocardial injury is challenging, but worthwhile if the diagnosis conveys important 
prognostic information, or influences treatment decisions (Sarkisian et al., 2016, 
Collinson and Lindahl, 2015, Chapman and Mills, 2017, Chapman et al., 2017a). In 
our analysis, the recommended classification of type 2 myocardial infarction or 
myocardial injury did not differentially identify those patients at risk of MACE. This 
observation is consistent with previous studies and suggests alternate strategies for risk 
stratification may be required. In patients with type 2 myocardial infarction, the 
presence of obstructive coronary artery disease may influence prognosis. Outcomes 
from the SWEDEHEART registry of 41,817 patients with type 1 or 2 myocardial 
infarction demonstrated an increased risk of all-cause death in patients with type 2 
myocardial infarction with obstructive coronary artery disease compared to those 
without (Baron et al., 2016). Similarly, in a recent analysis of the APACE cohort, 
Nestelberger et al. (2017) found patients with type 2 myocardial infarction and 
coronary artery disease had a 90 day cardiovascular mortality of 3.6%, with no deaths 
observed in those without coronary artery disease. Our analysis supports these findings, 
with coronary artery disease one of the strongest predictors of MACE in patients with 
 
 206 
type 2 myocardial infarction or myocardial injury. The prevalence of coronary artery 
disease in patients with type 2 myocardial infarction or myocardial injury was 42% in 
our cohort, and varies between 36% to 78% in previous reports (Sarkisian et al., 2016, 
Neumann et al., 2017b, Baron et al., 2016, Saaby et al., 2013, Ambrose et al., 2012). 
However, estimates obtained from registry studies are hindered by selection bias as 
those who undergo angiography will have a higher pre-test probability of coronary 
artery disease, and the true prevalence of coronary artery disease in this group of 
patients remains uncertain (Januzzi and Sandoval, 2017).  
Importantly, patients with type 2 myocardial infarction or myocardial injury receive 
fewer prescriptions for preventative therapies compared to those with type 1 
myocardial infarction (Stein et al., 2014, Sandoval et al., 2017b, Sandoval et al., 2014b, 
Baron et al., 2016, Saaby et al., 2013, Baron et al., 2015). To date, there have been no 
randomized controlled trials evaluating secondary prevention in this population, and 
there are no formal recommendations for risk assessment or treatment. Given the 
current heterogeneity in application of the Universal Definition of Myocardial 
Infarction, the feasibility of delivering such a study with comparable observations 
across multiple healthcare settings is uncertain. Primary prevention guidelines 
recommend statin therapy where the predicted ten year risk of adverse cardiovascular 
events exceeds 10% (NICE., 2014a). In our study, patients who survive their initial 
presentation with type 2 myocardial infarction and are not already known to have 
coronary artery disease, the rate of MACE exceeds 10% at one year. Whilst this may 
be partially attributable to age and the presence of co-morbidities, a significant 
proportion may have unrecognized coronary artery disease and may benefit from 
further investigation or preventative therapies.  
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We believe clinicians should adopt a pragmatic approach, and risk stratify individual 
patients based on their likelihood of coronary artery disease. There are no risk 
assessment tools validated for use in this setting, therefore clinicians must review the 
presenting symptoms, medical history, cardiovascular risk factors, serial 12-lead 
electrocardiograms and any available imaging findings and apply clinical judgement. 
Where the probability of coronary disease is high, it may be reasonable to commence 
secondary prevention with aspirin and a statin in the absence of contraindications. If 
patients with type 2 myocardial infarction are found to have obstructive coronary 
artery disease, revascularization could plausibly reduce the risk of future cardiac 
events, but this strategy has not been evaluated. Where the probability of coronary 
disease is intermediate or low, further investigation (invasive or CT coronary 
angiography) should be considered to identify patients with underlying coronary artery 
disease, where the benefits of secondary prevention are well recognized. The optimal 
timing for investigation in this group of patients is also uncertain. Where the 
probability of type 1 myocardial infarction is high, invasive assessment should be 
considered on an urgent basis in line with standard practice. In those patients where 
myocardial injury or infarction is secondary to oxygen supply-demand imbalance, 
further assessment may need to be deferred until the patient has recovered from their 
primary illness. Furthermore, a recognition that these patients are at increased risk of 
non-cardiovascular events may lead to an improvement in outcomes, through better 





There are important limitations to the data presented. The study population was 
identified on the basis of an elevated troponin I concentration measured using a 
contemporary sensitive assay with a diagnostic threshold of 0.05 µg/L, and the true 
prevalence of myocardial injury and infarction could be higher using a lower threshold 
or a high-sensitivity cardiac troponin assay. Whilst two cardiologists adjudicated all 
index diagnoses using all available clinical information, with excellent intra-observer 
agreement, there remains potential for misclassification, particularly for type 2 
myocardial infarction and myocardial injury. There is likely to be variation in the in-
hospital treatments received which we could not adjust for, nor could we adjust for 
illness severity. As previously reported, a low proportion of patients with type 2 
myocardial infarction or myocardial injury underwent inpatient coronary angiography 
(Shah et al., 2015c). We therefore defined coronary artery disease based on a diagnosis 
of angina, previous myocardial infarction or previous coronary revascularization, 
which is likely to significantly underestimate the prevalence of coronary artery disease. 
Finally, subsequent hospitalizations and cardiovascular or non-cardiovascular death 
were determined using ICD-10 coding obtained from regional and national registry 
data, where there is the potential for both diagnostic and coding error. We were 









Over two-thirds of patients admitted to hospital with type 2 myocardial infarction or 
myocardial injury die within five years, with the majority of deaths due to non-
cardiovascular causes. Nonetheless, major adverse cardiovascular events occur in one-
third of patients with elevated cardiac troponin concentrations, irrespective of whether 
myocardial necrosis was spontaneous or secondary to another acute illness. Whilst 
patients with type 1 myocardial infarction were at highest risk, there was no separation 
of risk between those with a diagnosis of type 2 myocardial infarction or myocardial 
injury. In contrast, those patients with type 2 myocardial infarction or myocardial 
injury known to have coronary artery disease are at highest risk of cardiovascular 
events, and efforts to diagnose coronary artery disease may provide opportunities to 
























7.1 Summary of findings 
Chest pain is a common symptom in patients presenting to the Emergency Department, 
and often results in hospital admission for further testing despite as few as 20% of 
patients receiving a final diagnosis of acute coronary syndrome. Diagnostic delay 
introduces patient anxiety and is an inefficient use of healthcare resources. Cardiac 
troponin is a central component of the diagnostic criteria for myocardial infarction, 
and improvements in assay sensitivity offer both opportunities and challenges for 
clinical practice.  
The purpose of this thesis was to study the use of a clinically available high-sensitivity 
cardiac troponin I assay for the evaluation of patients with suspected acute coronary 
syndrome in practice. I hypothesised that a high-sensitivity cardiac troponin I risk 
stratification threshold of 5 ng/L would provide the optimal balance between safety 
and efficacy, and integration into a clinical pathway would offer improved 
performance over pathways based entirely on the 99th centile, with no improvement 
when contemporary clinical risk scores were applied. Furthermore, I investigated the 
long term outcomes of patients with myocardial infarction when classified by the 
universal definition, and hypothesised patients with type 2 myocardial infarction or 




7.1.1  Optimal risk stratification in suspected acute coronary syndrome  
Whilst there are a number of recommended risk stratification thresholds, there has 
been a lack of consensus as to the optimal approach for use in clinical practice. In a 
systematic review and meta-analysis, a high-sensitivity cardiac troponin I threshold of 
5 ng/L was shown to provide an excellent balance between safety and efficacy. When 
applied alongside a non-ischaemic electrocardiogram, this approach identifies nearly 
half of all patients as low risk, with a miss rate of less than one in two hundred patients. 
Although some statistical differences in negative predictive value were noted in pre-
specified subgroup analyses, this reflects the very high negative predictive value in 
low risk patient groups, and is of no clinical significance. The robust performance of 
this threshold across multiple healthcare settings with varying prevalence of 
myocardial infarction gives confidence that this approach is safe and generalisable in 
practice.   
 
7.1.2 Comparison of the efficacy and safety of novel rule out pathways 
Whilst there are several guideline approved pathways for the rule out of myocardial 
infarction in patients with suspected acute coronary syndrome, the most widely used 
approach recommended by the European Society of Cardiology was designed in the 
era of contemporary cardiac troponin assays and applies the upper reference limit (99th 
centile) as a threshold both to rule in and rule out myocardial infarction. In a 
prospective observational cohort study, I derived and validated a clinical pathway 
incorporating a risk stratification threshold of 5 ng/L at presentation and serial testing 
at 3 hours to identify patients with changing troponin concentrations, within the normal 
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reference range, who are at increased risk of myocardial infarction. This novel 
pathway identified more patients on presentation as suitable for rule out, and missed 
five-fold fewer myocardial infarction or cardiac death events at 30-days than the 
guideline approved pathway based exclusively on the 99th centile.  
 
7.1.3 Clinical risk scores in suspected acute coronary syndrome 
There are a number of additional approaches for the rule out of myocardial infarction. 
Clinical risk scores apply conventional risk factors for cardiovascular disease to 
estimate the probability of myocardial infarction. The most widely implemented scores, 
HEART, GRACE or TIMI, have been extensively validated when used alongside 
contemporary troponin assays, however, their impact on pathways applying high-
sensitivity cardiac troponin testing is less clear. The safety of the European Society of 
Cardiology 3-hour pathway, which applies the 99th centile alone, could be significantly 
improved by the addition of a clinical risk score. Conversely, no risk score improved 
the performance of a novel pathway incorporating a risk stratification threshold. The 
excellent performance of the novel pathway our understanding that patients with low 
troponin concentrations have fewer risk factors for coronary or structural heart disease, 
and are more likely to be admitted for serial testing.  Whilst not undertaken in this 
analysis, additional modelling such as determining the improvement in discrimination 
(C-statistic), calibration (Hosmer-Lemeshow Test), or calculating the net 
reclassification index could provide further insight to the additive benefit of such risk 
scores. All risk scores reduce efficacy, but this is justifiable for the ESC pathway where 
clear improvements in safety are apparent. 
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7.1.4 Long term outcomes of myocardial injury and infarction  
The universal definition of myocardial infarction suggests a classification based on 
aetiology, with type 1 myocardial infarction due to atherosclerotic plaque rupture, 
intraluminal thrombosis and distal microvascular occlusion, and type 2 myocardial 
infarction occurring due to myocardial oxygen supply or demand imbalance in the 
context of another illness. In a prospective observational cohort study, all consecutive 
patients with myocardial necrosis measured using a contemporary sensitive cardiac 
troponin assay were classified as per the universal definition. Patients with type 2 
myocardial infarction or myocardial injury were at significantly increased risk of all 
cause death, which persisted after adjustment for a number of clinically important co-
variates. Whilst not undertaken in this analysis, propensity score matching may have 
facilitated more accurate estimation of the effect size by adjusting for confounding by 
indication. Crude rates of cardiovascular events were comparable between groups, 
with patients with type 2 myocardial infarction or myocardial injury and known 
coronary artery disease at highest risk of adverse outcomes. Despite this, less than half 
of patients received optimal secondary prevention, suggesting a treatment gap exists, 
with the potential opportunity to improve clinical outcomes.      
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7.2 Future directions  
The results presented within this thesis have generated discussion, led to further 
research questions and have formed the basis of applications for research funding. 
Three key studies are described below, two of which have received funding and are in 
progress with the final proposal under review  
7.2.1 Prospective evaluation of the High-STEACS pathway 
We have demonstrated a clinical pathway incorporating a risk stratification threshold 
and serial testing offers improved performance over guideline approved pathways 
based on the 99th centile. However, as with the majority of studies conducted in this 
area, these findings are based on observational data, with no patients discharged on the 
basis of a cardiac troponin concentration. 
To address this key limitation and provide robust evidence of safety in clinical practice, 
we are conducting a prospective, multi-centre, stepped-wedge, cluster randomised 
controlled trial evaluating the safety and efficacy of the High-STEACS pathway in 
clinical practice (NCT:03005158). This trial is recruiting all consecutive patients in 
whom a high-sensitivity cardiac troponin concentration is requested in the Emergency 
Department for suspected acute coronary syndrome across six centres in Scotland. 
Patients are prospectively identified using electronic healthcare records. When the 
attending clinician requests a cardiac troponin, they provide a minimum data set for 
the order to be processed, including presenting complaint, time of symptom onset, and 
whether an acute coronary syndrome is suspected. There are three six-month phases 




Figure 7.1. Outline of study phases.  
 
 
During the validation phase, patients will be managed according to the established 
assessment protocol (standard care), which rules out myocardial infarction where 
cardiac troponin concentrations are <99th centile at presentation in patients with 
symptoms for more than 6 hours. In patients with symptoms for less 6 hours, a second 
troponin measurement is performed 12 hours from symptom onset, with myocardial 
infarction ruled out if cardiac troponin remains <99th centile. This will be followed by 
a 6-month randomisation phase where participating centres will be randomly stepped-
in to use the early rule-out pathway, with stratification by hospital size. A final 
calendar matched implementation phase will follow in which all sites will use the early 
rule-out pathway.  
The study design uses a co-primary endpoint with sequential hypothesis testing. The 
primary efficacy endpoint is the length of hospital stay, defined as the length from 
initial presentation to the Emergency Department until final discharge from hospital 
in minutes. The primary safety endpoint is the rate of type 1 or type 4b myocardial 
infarction or cardiac death after discharge and within 30 days of index presentation. 
For the primary efficacy endpoint, we hypothesise that implementation of the early 
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rule out pathway will reduce the overall length of stay compared to standard care. For 
the primary safety endpoint, we hypothesise the proportion of patients with type 1 or 
type 4b myocardial infarction or cardiac death after discharge and within 30 days of 
index presentation will not differ by more than 0.5%.  
The anticipated total study population is approximately 39,000. Based on simulation 
methods, a sample size of 38,994 patients will provide 99% power at the two-sided 
5% level of significance to detect a difference of at least 60 minutes in arithmetic mean 
length of stay (primary efficacy endpoint), and 90% power to demonstrate non-
inferiority assuming an event rate of 0.4% at 30-days (primary safety endpoint). All 
three phases of this trial are now complete, with blinded endpoint adjudication in 
progress and an aim to report in late 2018.  
7.2.2 Evaluating the mechanisms of type 2 myocardial infarction 
The definition of acute myocardial infarction has evolved to accommodate 
increasingly sensitive markers of myocardial necrosis and imaging methods that allow 
greater understanding of the pathogenic mechanisms of acute coronary syndrome. As 
such, the universal definition of myocardial infarction now proposes that we classify 
patients with myocardial infarction based on aetiology (Thygesen et al., 2012a). Whilst 
this classification has been used in clinical trials to refine clinical outcomes (Morrow 
et al., 2009, Bonaca et al., 2012, White et al., 2012), it has not been widely adopted in 
clinical practice, and the frequency and implications of subtypes of acute myocardial 
infarction are uncertain. I believe the diagnostic criteria for type 2 myocardial 
infarction require clarification and that this is necessary to encourage clinicians to 
adopt the proposed classification. This can only be achieved through prospective and 
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systematic evaluation of the clinical presentation, pathophysiological mechanisms and 
outcomes of unselected patients with acute myocardial injury in clinical practice.  
In a prospective observational cohort study (EVEREST-MI, ClinicalTrials.gov 
number: NCT:03338504), I am systematically evaluating the mechanisms of acute 
myocardial injury in unselected patients who present to hospital with an alternative 
primary illness likely to cause myocardial oxygen supply or demand imbalance 
(Appendix 5).  
All participants will undergo cardiac magnetic resonance imaging of the myocardium 
where there are no contraindications, in addition to evaluation of coronary anatomy by 
either invasive or non-invasive coronary angiography dependent on co-morbidities or 
the individual participant preference. For example, frail patients or those with severe 
peripheral vascular disease in whom intra-vascular access may be challenging would 
be more likely to undergo non-invasive imaging 
Cardiovascular magnetic resonance (CMR) will be performed using a 3T scanner 
(MAGNETOM Verio, Siemens AG, Healthcare Sector, Erlangen, Germany) at the 
Clinical Research Imaging Centre (CRIC), Edinburgh. The MRI scan will consist of 
localisers, axial and coronal HASTE images, standard breath-held and ECG-gated cine 
sequences in 2 chamber, 4 chamber and short axis views. Short-axis cine images will 
be obtained using a balanced steady-state free precession sequence from the mitral 
valve annulus to the apex (8 mm parallel slices with 2 mm spacing) for the assessment 
of left ventricle function and volumes. Left ventricle volumes, mass and ejection 
fraction will be assessed using dedicated software (Argus Ventricular Function, 
Siemens AG Healthcare Sector, Erlangen, Germany) and values indexed to body 
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surface area. Breath-held, ECG-gated T2 mapping sequences of the myocardium will 
be performed in the long-axis as a marker of myocardial inflammation. T1-weighted 
imaging of the coronary arteries will be performed to look for evidence of recent 
intraplaque thrombus or haemorrhage using the CATCH sequence. All patients will 
then receive 0.4mg (5ml) of peripheral Regadenoson (Rapiscan™) as a stress 
perfusion agent, and a bolus of 0.2 mmol/kg Gadolinium (Gadovist™), to quantify 
areas of myocardial ischaemia. Stress-perfusion imaging will not be undertaken in 
patients with severe asthma or chronic obstructive pulmonary disease, those on 
dipyridamole, theophylline or aminophylline, or those with atrioventricular block. 
Patients will be asked to withhold caffeine intake for 12 hours prior to imaging. This 
will be followed by standard late-gadolinium enhancement sequences. The late 
gadolinium enhancement and T2 mapping techniques will identify regions of new or 
old myocardial infarction as well as other patterns of injury such as the mid-wall 
pattern associated with myocarditis.  
Coronary angiography will be performed via the femoral or radial artery with 6F 
arterial catheters. In patients with one or more stenoses in a major epicardial vessel, a 
coronary pressure guidewire (PressureWire™ Aeris™, St. Jude Medical, St. Paul, 
Minnesota) will be used to determine distal coronary pressure and the fractional flow 
reserve (FFR) calculated at maximal adenosine-induced (intravenous 140 μg/kg/min) 
hyperaemia. As previously described, frequency domain optical coherence 
tomography (FD-OCT) will be performed in all three coronary vessels using a 
FastView® coronary imaging catheter (Terumo, Tokyo, Japan) with automated 
pullback at 20 mm/s to identify features consistent with vulnerable plaque or recent 
plaque rupture (Gudmundsdottir et al., 2015). If there is evidence of inducible 
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myocardial ischaemia due to coronary artery stenosis, revascularisation with 
percutaneous coronary intervention may be considered if in the patients best interests 
and on discussion with the patients attending clinician.   
Where invasive coronary angiography is contraindicated, CT coronary angiography 
will be performed according to previously published methodology (Newby, 2015). 
Imaging will be performed using a 128 multidetector row CT (Siemens Biograph, 
Siemens Healthcare, Erlangen, Germany). Patients with a heart rate exceeding 65 
beats/min will receive oral beta-blockade (50 or 100 mg metoprolol) 1 hour before 
computed tomography. Additional intravenous beta blockers will be given depending 
on heart rate at the time of imaging. All patients will receive sublingual glyceryl 
trinitrate (300 μg) immediately prior to dual cardiac and respiratory-gated computed 
tomography imaging of the coronary arteries. We will quantify total plaque burden 
using CT calcium scoring. A bolus of 80-100 mL of contrast (400 mg/mL; Iomeron, 
Bracco, Milan, Italy) will be injected intravenously at 5 mL/s. CT angiography will be 
evaluated jointly by a Radiologist and a Cardiologist with suitable training to 
determine the extent of coronary atherosclerosis. An assessment of the functional 
consequences of coronary artery stenosis will be made using the computed 
tomography fractional flow reserve (CT-FFR) technique, using the HeartFlowTM 
platform.(Min et al., 2012)  
Serial blood samples will be obtained on enrolment to the study, at 24 hours, and at 
last point of contact to the research team (on discharge from hospital or at outpatient 
visit for study imaging) in two 9 mL lithium-heparin tubes, two 9mL EDTA plasma 
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tubes and two 9mL serum tubes. Samples obtained will facilitate development of novel 
biomarkers using proteomic and genomic approaches.  
All patients will provide informed consent in line with routine clinical practice. We 
will report the results of all investigations to the patients attending clinician so therapy 
may be modified where this is felt to be of benefit. The target for completion of all 
diagnostic studies is 28 days from index presentation, with the aim to perform imaging 
as early as is feasible. 
I hypothesise that the majority of patients with myocardial injury secondary to oxygen 
supply or demand imbalance will have evidence of underlying obstructive coronary 
artery disease.  I aim to recruit 100 patients as this is a feasible sample size, and will 
complete recruitment over 12-18 months. As this is a pilot study, no formal power 
calculations have been performed.  
7.2.3 Novel biomarkers to distinguish type 1 and type 2 myocardial 
infarction 
Cardiac troponin is the only recommended biomarker for the detection of myocardial 
necrosis, and it is integral to the diagnostic criteria for myocardial infarction. However, 
as the cellular mechanisms of myocardial injury are thought to differ between subtypes 
of myocardial infarction, there may be opportunities to identify other candidate 
cardiovascular biomarkers which may distinguish subtypes of myocardial infarction, 
improving diagnostic accuracy.  
In patients with type 2 myocardial infarction, in the absence of plaque rupture, platelet 
aggregation, embolisation and microvascular obstruction, the profile of sarcomeric 
and inflammatory proteins released from the myocardium may differ compared to that 
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observed in patients with type 1 myocardial infarction. In patients recruited to the 
EVEREST-MI study in whom serial blood samples are obtained, I will undertake a 
systematic evaluation of the kinetics of cardiac troponin release, and will compare 
patients with type 2 myocardial infarction with an existing cohort of patients with 
confirmed type 1 myocardial infarction recruited at the time of primary PCI (Appendix 
6).  
EDTA plasma from 90 subjects (45 type 1 myocardial infarction, 45 type 2 myocardial 
infarction) will be transferred to Olink Proteomics (Upsalla Science Park, Upsalla, 
Sweden) for analysis. The Olink Proteomics Inflammation (96x96), Olink Proteomics 
Cardiovascular II (96x96) and Olink Proteomics Cardiovascular III (96x96)  biomarker 
panels are high-throughput, multiplex immunoassay systems capable of analysing 
multiple proteins associated with inflammatory or cardiovascular disease, 
simultaneously. A total 276 candidate proteins will be evaluated. This technology is 
facilitated by novel proximity extension assay (PEA) technology. Each panel contains 
92 oligonucleotide-labelled antibody pairs which bind to the target when present in the 
sample. Binding by antibody pairs triggers the formation of double-stranded DNA 
amplicons, which are quantified by real-time polymerase chain reaction (PCR). The 
resultant relative values are normalized and log transformed, where a high value 
correlates to a high protein content. PEA is a robust and reproducible technique, with 
intra-assay coefficient of variation (CV) ranging between 5% and 13%, and inter-assay 
CV between 9% and 39% dependent on assay type.  
We will explore the relationship between high-sensitivity cardiac troponin 
concentration and candidate biomarkers using pairwise correlation, illustrated in a 
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correlation matrix and ordered by hierarchical clustering. We anticipate a range of 
candidate biomarkers will be elevated in patients with type 1 and type 2 myocardial 
infarction, but some may distinguish between diagnoses. The association between 
biomarker value and diagnosis (type 1 or type 2 myocardial infarction) will be 
explored by fitting univariate generalised linear models with a binomial link. 
Candidate biomarkers which are predictive in univariate analysis will be evaluated in 
a multi-variate generalised linear model with adjustment for age, gender and renal 
function. A final model will be derived using backward elimination, including co-
variates with a P-value of <0.05. We will assess the discriminatory performance of the 
model by evaluating sensitivity, specificity, and area under the receiver operator curve 
(C statistic). For cardiac troponin, and candidate biomarkers which show significant 
associations with both diagnoses, we will evaluate the time course of biomarker release 
using a polynomial linear mixed effects model, with a random term for subject. Where 
candidate biomarkers show high discriminatory ability, we will perform validation 
studies using immunoassay and ELISA technology in stored samples.   
Understanding the mechanisms of acute myocardial injury in hospitalised patients and 
the contribution of coronary artery disease will lead to the development of a diagnostic 
algorithm and framework for clinicians to base their assessment, and will help to guide 






7.3 Clinical perspective 
The novel approaches to risk stratification described in this thesis demonstrate the 
potential of high-sensitivity cardiac troponin assays to improve diagnostic safety and 
efficiency in patients with suspected acute coronary syndrome, and complement prior 
research. By safely ruling out the diagnosis of myocardial infarction in nearly half of 
all patients presenting to the emergency department, we have the opportunity to 
improve patient experience and healthcare resource utilization at a time of increasing 
pressures on the National Health Service. Further work is ongoing to provide 
prospective, randomised controlled trial data in consecutive patients; the results of 
which have the potential to change our practice.  
Perhaps more relevant to the hospital physician is the diagnosis of type 2 myocardial 
infarction, which is twice as common as type 1 myocardial infarction in patients over 
the age of 75, and for which we have no evidence based recommendations for 
investigation or treatment. The task force for the universal definition of myocardial 
infarction recognise and acknowledge the lack of clear guidance for clinicians in 
practice. The EVEREST-MI study will provide insight into the underlying mechanism 
of myocardial injury in patients with type 2 myocardial infarction. This may guide 
recommendations for investigational strategy and facilitate prospective trials of 
secondary prevention therapies known to reduce future cardiovascular events in 
patients with type 1 myocardial infarction.  Such studies are necessary if we are to  
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APPENDIX 1  
THE OPTIMAL RISK STRATIFICATION 
THRESHOLD OF HIGH-SENSITIVITY CARDIAC 
TROPONIN I IN PATIENTS WITH SUSPECTED 




Appendix 1.1. Search Strategy  
 
I. Ovid MEDLINE(R) <1946 to Present> 
 
1. exp Chest Pain/ 
2. (chest adj2 pain*).ti,ab. 
3. chest discomfort.ti,ab. 
4. exp Acute Coronary Syndrome/ 
5. acute coronary syndrome*.ti,ab. 
6. ACS.ti,ab. 
7. exp Coronary Artery Disease/ 
8. coronary artery disease.ti,ab. 
9. exp Angina, Unstable/ 
10. unstable angina.ti,ab. 
11. Myocardial Infarction/di 
12. myocardial infarction.ti,ab. 
13. heart attack.ti,ab. 
14. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 
15. exp Troponin/du 
16. troponin*.ti,ab. 
17. hs-ctn*.ti,ab. 
18. 15 or 16 or 17 
19. exp Emergency Service, Hospital/ 
20. (emergency adj (room* or department*)).ti,ab. 
21. (ER or ED).ti,ab. 
22. (presenting or presented or presentation).ti,ab. 
23. (admission* or admitted).ti,ab. 
24. chest pain unit*.ti,ab. 
25. 19 or 20 or 21 or 22 or 23 or 24 
26. 14 and 18 and 25 
27. limit 26 to yr="2006 -Current" 
 
II. EMBASE <1974 to present> 
 
1. exp Chest Pain/ 
2. (chest adj2 pain*).ti,ab. 
3. chest discomfort.ti,ab. 
4. exp Acute Coronary Syndrome/ 
5. acute coronary syndrome*.ti,ab. 
6. ACS.ti,ab. 
7. exp Coronary Artery Disease/ 
8. coronary artery disease.ti,ab. 
9. exp Angina, Unstable/ 
10. unstable angina.ti,ab. 
11. Myocardial Infarction/di 
12. myocardial infarction.ti,ab. 
13. heart attack.ti,ab. 
14. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 
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15. exp Troponin/du 
16. troponin*.ti,ab. 
17. hs-ctn*.ti,ab. 
18. 15 or 16 or 17 
19. exp Emergency Service, Hospital/ 
20. (emergency adj (room* or department*)).ti,ab. 
21. (ER or ED).ti,ab. 
22. (presenting or presented or presentation).ti,ab. 
23. (admission* or admitted).ti,ab. 
24. chest pain unit*.ti,ab. 
25. 19 or 20 or 21 or 22 or 23 or 24 
26. 14 and 18 and 25 
27. limit 26 to yr="2006 -Current" 
 
 
III. Web of Science 
 
“chest pain” OR “acute coronary syndrome” OR “coronary artery disease” OR 
“unstable angina” OR “myocardial infarction” 
AND 
“troponin” 
[limit publication year from 2006 to present] 
 
 
IV.  The Cochrane Central Register of Controlled Trials 
 
#1 MeSH descriptor: [Myocardial Ischemia] explode all trees 
#2 MeSH descriptor: [Troponin] explode all trees 








Study Study type, country Inclusion criteria Exclusion criteria 
HighSTEACS-V 1 Multi-centre, UK Consecutive patients in whom the attending clinician 
requested cardiac troponin for suspected acute coronary 
syndrome  
Patients with ST-segment-elevation myocardial 
infarction (STEMI), already admitted during the 
study period, non-resident in Scotland.  
 
UTROPIA 2 Single-centre, USA Consecutive patients presenting to ED in whom cardiac 
troponin measurements were obtained on clinical 
indication. 
Patients <18 years old, with evidence of STEMI, 
pregnancy, trauma, declined to participate in 
research, without death date available, did not 
present through ED or were transferred from an 
outside hospital.  
 
HighSTEACS-P 3 Single-centre, UK Consecutive patients in whom the attending clinician 
suspected an acute coronary syndrome. 
Patients not resident in the south east of Scotland. 
 
 
HighSTEACS-S 4 Single-centre, UK Consecutive patients in whom the attending clinician 
requested cardiac troponin for suspected acute coronary 
syndrome. 
Patients with STEMI, those who were unable to 
provide consent or those from outside the region. 
EDACS 5 Single-centre,  
New Zealand  
Patients 18 years or over with at least five minutes of 
symptoms consistent with an acute coronary syndrome. 
Enrollment was consecutive during the hours of the 
available research nurse (normally 8AM to 11PM, 7 
days a week) 
Patients with STEMI, a clear cause other than acute 
coronary syndrome (ACS), inability to provide 
informed consent, staff considered recruitment to be 
inappropriate, transfer from another hospital, 
pregnancy, previous enrolment, or inability to be 
contacted after discharge. 
 
STENOCARDIA 6 Multi-centre, Germany Consecutive patients between 18 and 85 years of age 
presenting with acute angina pectoris or equivalent 
symptoms. 
Major surgery or trauma within the previous 4 
weeks, pregnancy, intravenous drug abuse, and 




Appendix 1.2 continued: Characteristics of the cohort studies included in the meta-analysis  
 
 
  Study Study type, country Inclusion criteria Exclusion criteria 
ADAPT-B 7 Multi-centre, Australia Consecutive patients 18 years or over, with at least five 
minutes of symptoms consistent with an acute coronary 
syndrome where the attending physician planned to 
perform serial cardiac troponin tests. 
Patients with STEMI, a clear cause other than ACS, 
inability to provide informed consent, staff 
considered recruitment to be inappropriate, transfer 
from another hospital, pregnancy, previous 




Single-centre, Australia Patients 18 years or over with at least five minutes of 
symptoms consistent with an acute coronary syndrome 
where the attending physician planned to perform serial 
cardiac troponin tests. 
 
Patients with STEMI, a clear cause other than ACS, 
inability to provide informed consent, staff 
considered recruitment to be inappropriate, transfer 
from another hospital, pregnancy, previous 
enrolment, or inability to be contacted after 
discharge. 
ROMI 9 Multi-centre, Canada Patients 18 years or over, presenting to the ED with 
symptoms of and investigated for ACS (cardiac 
troponin ordered by an Emergency Department 
physician) 
Patients with STEMI, death (all-cause) or serious 
ventricular cardiac dysrhythmia before troponin 
testing. Patients who had traumatic chest pain, 
including surgery or cardiac complications, 
NSTEMI, pulmonary embolus, known active 
malignancy, sepsis within the previous 30 days or 
previously enrolled or transferred from another 
primary care facility. 
HOPKINS 10 Single-centre, USA Patients with non-diagnostic initial ECGs, chief 
complaints of chest pain or shortness of breath and 
cardiac troponin ordered by treating clinician for 
possible acute myocardial infarction. Enrolment of 
patients occurred on weekdays from 9.00am to 9.00pm. 
Patients who left against medical advice or if initial 
blood samples were not obtained. 
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ADAPT-RCT 12 Single-centre,  
New Zealand 
Consecutive patients 18 years or older who present 
acutely to the Emergency Department with possible 
cardiac chest pain. Recruitment occurred between 
8AM and 10AM, 7 days a week. 
Patients with STEMI, an initial clear cause other 
than acute coronary syndrome, inability to provide 
informed consent, staff considered recruitment to be 
inappropriate, chest pain symptoms began more than 
12 hours before presentation, persisting chest pain, 
transfer from another hospital, pregnancy, previous 
inclusion in the study, or inability to be contacted 
after discharge. 
RING 13 Single-centre, Canada Patients ≥18 years old with onset of ACS symptoms in 
the past 6 hours, blood sample collection ordered by 
the ED physician for cardiac troponin measurement, 
informed consent obtained, and availability for 
telephone follow-up.  
Patients with STEMI, those referred directly to 
surgery, trauma patients, those with more than 6 
hours of symptoms and previously enrolled patients 
TI-AMO 14 Single-centre, The 
Netherlands 
Patients with symptoms suggestive of acute 
myocardial infarction for at least 3 hours in whom a 
high sensitivity troponin measurement was performed. 
Patients with STEMI who underwent primary 
intervention elsewhere, onset of symptoms >12 
hours prior to presentation or incomplete data 
collection. 
APACE 15 Multi-centre,  
New Zealand and Australia 
Consecutive patients presenting to the Emergency 
Department with symptoms suggestive of AMI within 
12 hours 
Patients with STEMI, terminal kidney failure on 
chronic dialysis, baseline troponin measurement 
were not available or where it was not possible to 
accurately adjudicate the final diagnosis. 
APACE 15 Multi-centre,  
New Zealand and Australia 
Consecutive patients presenting to the Emergency 
Department with symptoms suggestive of AMI within 
12 hours 
Patients with STEMI, terminal kidney failure on 
chronic dialysis, baseline troponin measurement 
were not available or where it was not possible to 
accurately adjudicate the final diagnosis. 
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Study Study type, country Inclusion criteria Exclusion criteria 
BACC 16 Single-centre, Germany Patients >18 years of age with suspected acute 
myocardial infarction, with the ability to provide 
written informed consent. 
STEMI. 
TRUST 17 Single-centre, UK Consecutive patients attending the Emergency 
Department at least 18 years old and at least five min 
of chest pain suggestive of acute coronary syndrome, 
and for whom the attending physician determined 
inpatient evaluation was required. 
Patients with STEMI, new left bundle branch block, 
ECG changes diagnostic of ischemia, arrhythmias, 
hs-TnT sample not suitable for analysis, age ≥80 
years, atypical symptoms in the absence of chest 
discomfort, a clear non-ACS cause for chest pain at 
presentation, another medical condition requiring 
hospital admission, refusal and inability to give 
informed consent, non-English speaking, pregnancy, 
renal failure requiring dialysis or inability to be 
contacted after discharge. 
STOCKPORT 18 Single-centre, UK Adult patients presenting to the Emergency 
Department with suspected cardiac chest pain. 
Patients with STEMI, new left bundle branch block, 
new-onset ECG changes diagnostic of ischemia 
(ST-segment depression ≥1mm or T-wave inversion 
consistent with ischemia), significant arrhythmias, 
age <18 years, a clear cause of the symptoms other 
than acute coronary syndromes, pregnancy, declined 
to take part, did not have capacity to provide 
informed consent, did not speak English, prisoner, 
already included and those deemed inappropriate for 
researcher to approach patient (eg, terminal illness), 
follow-up considered impossible. 
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Appendix 1.2 continued: Characteristics of the cohort studies included in the meta-analysis  
 
 
Study title acronyms: 
HighSTEACS-V: High-sensitivity cardiac troponin in the evaluation of patients with Suspected Acute Coronary Syndrome - Validation 
HighSTEACS-S: High-sensitivity cardiac troponin in the evaluation of patients with Suspected Acute Coronary Syndrome - Sub-study 
UTROPIA: Use of Abbott high sensitivity cardiac troponin I assay in acute coronary syndromes 
HighSTEACS-P: High-sensitivity cardiac troponin in the evaluation of patients with Suspected Acute Coronary Syndrome - Pilot 
EDACS: Emergency department assessment of chest pain score 
IMPACT: Improved assessment of chest pain trial 
ADAPT: 2-hour accelerated diagnostic protocol to assess patients with chest pain symptoms using contemporary troponins as the only biomarker 
ROMI: Rule out of myocardial infarction 
RING: Reducing the time interval for identifying new guideline  
BACC: Biomarkers in acute cardiovascular care 
APACE: Advantageous predictors of acute coronary syndromes evaluation 
TRUST: Triage rule-out using high-sensitivity troponi  
Study Study type, country Inclusion criteria Exclusion criteria 
    
MANCHESTER 19 Single-centre, UK Consecutive adult patients presenting to the 
Emergency Department with suspected cardiac chest 
pain occurring in the previous 24 hours. 
Patients with STEMI, new left bundle branch block, 
new-onset ECG changes diagnostic of ischemia 
(ST-segment depression ≥1mm or T-wave inversion 
consistent with ischemia), pregnancy, significant 
arrhythmias, age <18 years, pregnancy, patients with 
another medical condition necessitating hospital 
admission, did not have capacity to provide 
informed consent, those with renal failure requiring 
dialysis, patients with chest trauma and suspected 
myocardial contusion, those who did not speak 
English, prisoners, patients for whom all means of 
follow-up would be impossible and those deemed 









Study  Reference assay Reference assay cutoff (ng/L) Study protocol intended time 
of troponin sampling 
(hours from presentation) 
HighSTEACS-V 1 Abbott hs-TnI 16 in women and 34 in men 0, 6-12 
UTROPIA 2 Abbott hs-TnI 16 in women and 34 in men 0, 3-24 
HighSTEACS-P 3 Abbott hs-TnI 16 in women and 34 in men 0, 6-12 
HighSTEACS-S 4 Abbott hs-TnI 16 in women and 34 in men 0, 6-12 
EDACS 5 Abbott hs-TnI 16 in women and 26 in men 0, 2 
STENOCARDIA 6 Abbott c-TnI 32 0, 3, 6 
ADAPT-B 7 Beckman Coulter Accu c-TnI 40 + ≥20% change 0, 2, 6-12 
IMPACT 8 Beckman Coulter Accu c-TnI 40 + ≥20% change 0, 2, 6-12 
ROMI 9 Abbott c-TnI 30 + ≥30 change if <100, or ≥20% 0, 3-6 
HOPKINS 10 Abbott c-TnI 60 + ≥30% change 0, 3-9 
ADAPT-C 11 Abbott c-TnI (New Zealand) 30 + ≥20% change 0, 2, 6-12 
ADAPT-RCT 12 Abbott c-TnI 32 0, 2, 6-12 
RING 13 Roche Elecsys c-TnT 40 + ≥3SD change if <100, or 20% 0, 1.5, 3 
TI-AMO 14 Roche hs-TnT 14 + ≥7 change 0, 2.5-4.5 
APACE 15 Roche hs-TnT 14 + ≥10 change 0, 1, 2, 3, 6 
BACC 16 Roche hs-TnT 14 0, 3 
TRUST 17 Roche hs-TnT 14 0, 6 
STOCKPORT 18 Roche hs-TnT 14 0, 12 
MANCHESTER 19 Roche hs-TnT 14 0, 12 
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Appendix 1.4: Assessment of bias based on the QUADAS-2 Framework. 
 
Patient Selection: Consecutive or random patient sample recruited without significant exclusions = low risk 
Index test: Pre-specified threshold using index text under study = low risk 
Reference standard: Interpretation of independent reference standard without knowledge of index test result = low risk 
Flow and timing: Appropriate interval between index and reference test without exclusions = low risk 
Patient selection: Included patients and setting match the review standard = low risk 
Index test: Index test, conduct and interpretation consistent with the review question = low risk 
Reference standard: Target condition matches the reference standard = low risk 
There was no evidence of publication bias (Rank correlation test for funnel plot asymmetry P=0.54) 
Study 
 








timing Patient selection Index test 
Reference 
standard 
HighSTEACS-V 1 Low Low Low Low Low Low Low 
UTROPIA 2 Low Low Low Low Low Low Low 
HighSTEACS-P 3 Low Low Low Low Low Low Low 
HighSTEACS-S 4 Low Low Low Low Low Low Low 
EDACS 5 Low Low Low Low Low Low Low 
STENOCARDIA 6 Low Low High Low Low Low Low 
ADAPT-B 7 Low Low High Low Low Low Low 
IMPACT 8 Low Low High Low Low Low Low 
ROMI 9 Low Low High Low Low Low Low 
HOPKINS 10 Low Low High Low Low Low Low 
ADAPT-C 11 Low Low High Low Low Low Low 
ADAPT-RCT 12 Low Low High Low Low Low Low 
RING 13 Low Low High Low Low Low Low 
TI-AMO 14 Low Low Unclear Low Low Low Low 
APACE 15 Low Low Unclear Low Low Low Low 
BACC 16 Low Low Unclear Low Low Low Low 
TRUST 17 High Low Unclear Low Low Low Low 
STOCKPORT 18 High Low Unclear Low Low Low Low 
MANCHESTER 19 High Low Unclear Low Low Low Low 
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Appendix 1.5: Analysis code 
 
All analysis was performed using R (version 3.2.2) using the metafor package. For 







Appendix 1.6. Missed outcomes in patients with high-sensitivity cardiac troponin I concentration <5 ng/L by assay used for adjudication 
 

























death at 1 
year 
High-sensitivity cardiac troponin I cohorts 
High-STEACS Validation 1         Reference assay (URL): Abbott hsTnI  >16ng/L (F) >34ng/L (M) 
64 M Chest pain 85 Yes Hypertension 
Previous MI 
Previous PCI 
1 850 1 850 Type 1 MI PCI to RCA 
and LAD 
No No 
70 F Chest pain 799 Yes Previous MI 3 70 3 70 Type 1 MI PCI to LAD No No 




4 6,480 4 6,480 Type 1 MI PCI to RCA No No 
80 M Chest pain 75 No Hypertension 
Angina 
3 534 3 534 Type 1 MI Medical No No 




4 78 4 78 Type 1 MI PCI to RCA No No 
69 F Chest pain 164 No Hypertension 
Previous MI 
Previous PCI 
4 852 4 852 Type 1 MI Medical No No 
69 F Chest pain 237 No Previous MI 
Previous PCI 
1 17 1 17 Type 1 MI Medical No No 
44 M Chest pain 63 Yes Smoker 
Hyperlipidaemia 
2 14,008 2 14,008 Type 1 MI Medical No No 





The reference assay results relate to the assay used for diagnostic adjudication. In high-sensitivity cardiac troponin I cohorts, this assay was also used in clinical practice. 







Appendix 1.6. continued. Missed outcomes in patients with high-sensitivity cardiac troponin I concentration <5 ng/L by assay 
 























death at 1 
year 
UTROPIA 2           Reference assay (URL): Abbott hsTnI >16ng/L (F)  >34ng/L (M) 
60 F Chest pain - Yes Smoker 
Hypertension 
2 1,190 2 1,190 Type 1 MI PCI No No 
80 M Chest pain 968 Yes Diabetes mellitus 
Hypertension 
Angina 
4 267 4 267 Type 1 MI CABG No No 




1 37 1 37 Type 1 MI PCI No No 
High-STEACS Pilot study 3              Reference assay (URL): Abbott hsTnI >16ng/L (F)  >34ng/L (M) 




3 1,094 3 1,094 Type 1 MI Medical No No 
High-STEACS Sub-study 4         Reference assay (URL): Abbott hsTnI >16ng/L (F)  >34ng/L (M) 
60 M Chest pain 113 Yes Smoker 
Angina 
Previous PCI 
2 2,932 2 2,932 Type 1 MI PCI to RCA 
and D1 
No No 




4 6,594 4 6,594 Type 1 MI PCI to LCx No No 
EDACS 5           Reference assay (URL): Abbott hsTnI  >16ng/L (F)  >26ng/L (M) 




3 6 3 6 Type 1 MI 
at 4 days 
Medical No - 
The reference assay results relate to the assay used for diagnostic adjudication. In high-sensitivity cardiac troponin I cohorts, this assay was also used in clinical practice. 
Abbreviations: (-) data not available. MI – myocardial infarction, PCI – percutaneous coronary intervention, CABG – coronary artery bypass graft, RCA – right coronary artery, D1 – diagonal artery, LCx – 




Appendix 1.6. continued. Missed outcomes in patients with high-sensitivity cardiac troponin I concentration <5 ng/L by assay 
 























death at 1 
year 
EDACS continued 5          Reference assay (URL): Abbott hsTnI  >16ng/L (F)  >26ng/L (M) 




2 215 2 215 Type 1 MI Angiography 
No PCI 
No - 
44 M Chest pain 
Dyspnoea 




Contemporary cardiac troponin I and T cohorts 
ADAPT Brisbane 7          Reference assay (URL): Beckmann Coulter AccuTnI  >40 ng/L 
65 F Chest pain 570 No Hypertension 
Hyperlipidaemia 
4 4 10 200 NSTEMI Medical No - 
IMPACT 8           Reference assay (URL): Beckmann Coulter AccuTnI  >40 ng/L 
44 M Chest pain 
Dyspnoea 
100 No Diabetes Mellitus 
Hypertension 
Hyperlipidaemia 
3 2 20 2,000 NSTEMI PCI No No 
63 M Chest pain 
Dyspnoea 
120 No None 2 5 90 100 NSTEMI PCI No - 
57 M Chest pain 
Dypsnoea 
45 No None 2 8 10 120 NSTEMI CABG No No 
44 M Chest pain 
Presyncope 
1,370 No Smoker 3 5 10 160 NSTEMI PCI No No 





M Back pain 
Diaphoresis 
- - Hypertension 
Hyperlipidaemia 
Angina 
3 3 10 600 Type 1 MI Medical - - 
The reference assay results relate to the assay used for diagnostic adjudication. In high-sensitivity cardiac troponin I cohorts, this assay was also used in clinical practice. 




Appendix 1.6. continued. Missed outcomes in patients with high-sensitivity cardiac troponin I concentration <5 ng/L by assay 
 






on ECG  
















death at 1 
year 
ROMI continued 9                Reference assay (URL): Abbott cTnI >30 ng/L 
40 M Chest pain - - Smoker 
Hypertension 
Hyperlipidaemia 
4 4 10 5,200 Type 1 MI PCI - - 
50 F Chest pain - - Smoker 
Hypertension 
1 434 10 920 Type 1 MI PCI - - 
55 F Chest pain - - Smoker 4 84 10 100 Type 1 MI Angiogram 
Medical 
- - 
HOPKINS 10           Reference assay (URL): Abbott cTnI >60 ng/L 
63 F Chest pain 91 - Smoker 
Hypertension 
Hyperlipidaemia 
4 16,007 <LOD 9,530 Type 1 MI PCI - - 
ADAPT Christchurch 11         Reference assay (URL): Abbott cTnI >30 ng/L 




2 423 310  330 Type 1 MI PCI to RCA No - 
40 M Chest pain 645 No Hyperlipidaemia 
Angina 
Previous MI 
4 5 50  60 Type 1 MI PCI to LAD No - 
60 M Chest pain 120 Yes Hypertension 
Hyperlipidaemia 
2 2 40  220 Type 1 MI PCI to LCx 
and LAD 
No - 
71 M Chest pain 230 No Angina 
Previous PCI 
4 4 150 180 Type 1 MI Angiogram 
No PCI 
No - 
ADAPT RCT 12           Reference assay (URL): Abbott cTnI  >32 ng/L 
68 F Chest pain 130 No Hypertension 
Hyperlipidaemia 
Previous MI 




Abbreviations: (-) data not available. MI - myocardial infarction, PCI – percutaneous coronary intervention, LAD – left anterior descending artery, RCA – right coronary artery, LCx – circumflex artery, MPS 




Appendix 1.6. continued. Missed outcomes in patients with high-sensitivity cardiac troponin I concentration <5 ng/L by assay 
 























death at 1 
year 
High-sensitivity cardiac troponin T cohorts 
APACE 14           Reference assay (URL): Roche hs-TnT >14 ng/L 
73 M Chest pain 240 No Hypertension 
Hyperlipidaemia 
Previous MI 
3 4 33 33 Type 2 MI Medical No No 




4 5 20 20 Type 2 MI Medical No No 
74 F Chest pain 60 No Smoker 
Hypertension 
Hyperlipidaemia 
3 11 10 17 Type 1 MI PCI No No 
44 M Chest pain 120 No Smoker 
Hypertension 
Hyperlipidaemia 
4 257 5 74 Type 1 MI PCI No No 
75 M Chest pain 60 No Hypertension 
Hyperlipidaemia 
Angina 
3 9 6 15 Type 1 MI Medical No No 
93 F Chest pain 540 No Hypertension 
Hyperlipidaemia 
Angina 
4 4 41 41 Type 1 MI None No No 





4 14 9 93 Type 1 MI PCI No No 










None No No 




Appendix 1.6. continued. Missed outcomes in patients with high-sensitivity cardiac troponin I concentration <5 ng/L by assay 























death at 1 
year 
TRUST  15           Reference assay (URL): Roche hs-TnT   >14 ng/L 
73 F Chest pain 199 No Hypertension 
Hyperlipidaemia 
Angina 
4 - 15 26 Type 1 MI Medical 
 
No No 
68 M Chest pain 2915 No Diabetes Mellitus 
Hypertension 
Previous MI 
1 - 24 18 Type 1 MI Medical No No 




1 - 7 16 Type 1 MI Medical No No 




3 - 28 20 Type 1 MI Medical No No 




3 - 11 15 Type 1 MI Medical No No 
61 M Chest pain 111 No Diabetes Mellitus 
Hyperlipidaemia 
1 - 29 53 Type 1 MI PCI No No 




3 - 6 18 Type 1 MI Medical No No 
56 F Chest pain 70 No Hyperlipidaemia 
Previous MI 
1 - 6 437 Type 1 MI PCI No No 
75 F Chest pain 4540 No Diabetes Mellitus 
Hypertension 
Hyperlipidaemia 
1 - 20 25 Type 1 MI PCI No No 
48 M Chest pain 472 No Smoker 
Hypertension 
Hyperlipidaemia 
1 - 21 16 Type 1 MI 
 
 
Medical No No 
Abbreviations: (-) data not available. MI – myocardial infarction, PCI – percutaneous coronary intervention 
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Appendix 1.6. continued. Missed outcomes in patients with high-sensitivity cardiac troponin I concentration <5 ng/L by assay  
 






















death at 1 
year 
TRUST  continued 15          Reference assay (URL): Roche hs-TnT   >14 ng/L 




4 - 19 15 Type 1 MI Medical No No 
TIAMO 16           Reference assay (URL): Roche hs-TnT  >14 ng/L 
52 M Chest pain - Yes - 4 - 
 
3 - Type 1 MI PCI - - 
BACC 17           Reference assay (URL): Roche hs-TnT   >14 ng/L 
56 F Chest pain - Yes Hypertension 
Hyperlipidaemia 
Previous MI 
4 7,782 3 1,797 Type 1 MI PCI to LAD No - 
59 M Chest pain - Yes Smoker 4 110 7 50 Type 1 MI Angiogram 
No PCI 
No No 




3 9 25 25 Type 1 MI PCI to RCA 
CABG 
No No 
52 M Chest pain - No  4 41 8 32 Type 1 MI PCI to RCA No - 
47 M Chest pain - Yes Smoker 3 3,932 10 949 Type 1 MI PCI to LAD No No 




2 93 9 50 Type 1 MI PCI to LAD No No 
MANCHESTER 19          Reference assay (URL): Roche hs-TnT >14 ng/L 
80 M Chest pain 517 Yes Hypertension 2 - - 136 NSTEMI Angiogram 
Medical 
- - 





APPENDIX 2  
COMPARISON OF THE EFFICACY AND SAFETY 
OF EARLY RULE OUT PATHWAYS FOR ACUTE 




Appendix 2.1  Baseline characteristics for the APACE external validation cohort 
 
APACE Study*  
(n=2,533) 
Age  61 (16.0) 
Male (%) 1,722 (68.0) 
Primary Symptom  
   Chest Pain 2,214 (87.4) 
Symptom onset   
   Minutes since onset  300 (120-720) 
   Less than three hours (%) 717 (28.5) 
   Less than six hours (%) 1,338 (53.2) 
   Over six hours (%) 1,054 (41.9) 
Cardiovascular Risk Factors  
   Smoker (%) 635 (25.1) 
   Diabetes mellitus (%) 451 (17.8) 
   Hypertension (%) 1,591 (62.8) 
   Hyperlipidaemia (%) 1,293 (51.0) 
   Family history (%) 987 (40.9) 
   Known angina (%) 883 (34.9) 
   Previous MI (%) 621 (24.5) 
   Previous PCI (%) 646 (25.5) 
   Previous CABG (%) 228 (9.0) 
   Stroke (%) 149 (5.9) 
   Peripheral vascular disease (%) 146 (5.8) 
Troponin concentration at presentation  
   <5 ng/L (%) 1,348 (53.2) 
   ≥5 ng/L and ≤ 99th centile (%) 735 (29.0) 
   >99th centile (%) 450 (17.8) 




*The APACE study is a prospective cohort study of patients with suspected acute 
coronary syndrome presenting to the Emergency Department of Basel and six other 
centers in Europe between April 2006 and August 2015.  Blood samples were obtained 
on presentation and at 3, and 6h for high-sensitivity cardiac troponin I testing. All 
diagnoses were adjudicated by two independent cardiologists; the diagnosis of type 1 
myocardial infarction required at least one high-sensitivity cardiac troponin I 
concentration above the sex-specific 99th centile upper reference limit (16 ng/L 





   Type 1 myocardial infarction (%) 289 (11.4) 
   All myocardial infarction (%) 378 (14.9) 
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Appendix 2.2. Patients ruled out by the ESC pathway at 0 and 3 hours meeting the primary outcome  














Index Diagnosis Risk Factors Initial ECG Management 
81 Male 444 31 (0) 
33 (3) 
39 (12) 
6.5 2 Chest Pain Type 1 MI Hypertension 
Hyperlipidaemia 




T wave Inversion 
PCI to LCx 
57 Male 440 33 (0) 
80 (3) 
144 (5)  
142.4 47 Chest Pain Type 1 MI Previous Smoker 
Family History of CHD 
Sinus Rhythm  PCI to OM1 
70 Male 375 17 (0) 
160 (3) 
2583 (6) 








84 Male 4900 25 (0) 
44 (3) 





Atrial Fibrillation PCI to SVG-D1 
82 Female 86 11 (0) 
15 (3) 
26 (10)  
36.4 4 Chest Pain Type 1 MI Hypertension Sinus Rhythm Medical 
62 Male 70 27 (0) 
32 (3) 
50 (11) 






Sinus Rhythm Medical 
87 Male 139 5 (0) 
16 (3) 
691 (10) 
220.0 11 Chest Pain Type 1 MI Previous Smoker 
Hypertension 
Ischaemic Heart Disease 
Previous CABG 
Atrial Fibrillation 




73 Male 180 26 (0) 
29 (3) 
41 (9) 
11.5 3 Chest Pain Type 1 MI Previous Smoker 
Hypertension 
Hyperlipidaemia 






58 Male 122 26 (0) 
33 (3) 
46 (11) 
26.9 7 Dyspnoea Type 1 MI Previous Smoker 
Diabetes 
Family history of CHD 





T wave inversion 
Medical 
63 Female 151 10 (0) 
16 (3) 
167 (10) 
60.0 6 Chest Pain Type 1 MI Current Smoker 
Family history of CHD 
Sinus Rhythm 
ST Depression  
PCI to LAD 
66 Male 89 12 (0) 
31 (3) 
202 (10) 
158.3 19 Chest Pain Type 1 MI Hypertension 
Previous MI 
Previous PCI 
Sinus Rhythm Medical 
60 Male 81 2 (0) 
6 (3) 
2932 (11) 
200.0 4 Chest Pain Type 1 MI Current Smoker 
Family History of CHD 
Ischaemic Heart Disease 
Previous PCI 
Sinus Rhythm 
T wave inversion 
(old) 
PCI to RCA/D1 
56 Male 262 8 (0) 
14 (3) 
307 (10) 
75.0 6 Chest Pain Type 1 MI Previous Smoker 
Hypertension 
Hyperlipidaemia 
Family history of CHD 
Ischaemic Heart Disease 
Previous MI 
Previous PCI 
Sinus Rhythm Medical 
77 Male 272 21 (0) 
26 (3) 
56 (10) 























PCI to LCx 
Instent Restenosis 
60 Male 295 14 (0) 
14 (3) 
170 (8) 
0 0 Chest Pain Type 1 MI Current Smoker 
Hypertension 
Hyperlipidaemia 
Family history of CHD 





70% stenosis OM1 
Medical  
88 Female 222 15 (0) 
19 (3) 
26.7 4 Chest Pain Type 1 MI Ischaemic heart disease 
Previous MI 
Previous PCI 
Family history of CHD 
Sinus Rhythm Medical 
89 Female 165 16 (0) 
18 (3) 
24 (10) 
12.5 2 Chest Pain Type 1 MI Hypertension 
Family history of CHD 
Ischaemic Heart Disease 
Sinus Rhythm Medical 














Family history of CHD 




First Degree HB 




ongoing chest pain 
two days post 
index presentation 
 
Missed Type 1 MI 
  
73 Female 425 9 (0) 
11 (3) 
  
22.2 2 Chest Pain Paroxysmal AF Previous Smoker 
Hypertension 
Hyperlipidaemia 





T wave inversion 
Re-presented with 
inferior STEMI 14 
days post index 
presentation 
 
PCI to RCA 
 
Type 1 MI 
Demarcations for missed index events with ≥6 hours symptoms (n=4), <6 hours symptoms (n=14) and 30 day events (n=2) 
AF = atrial fibrillation, CABG = coronary artery bypass graft, CHD = coronary heart disease, LBBB = left bundle branch block, RBBB = right bundle branch block, MI = myocardial infarction, PCI = percutaneous 
coronary intervention, STEMI = ST-segment elevation myocardial infarction.  
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Appendix 2.3. Patients ruled out by the High-STEACS pathway at 0 and 3 hours meeting the primary outcome 













Index Diagnosis Risk Factors Initial ECG Management 
81 Male 444 31 (0) 
33 (3) 
39 (12) 
6.45 2 Chest Pain Type 1 MI Hypertension 
Hyperlipidaemia 




T wave Inversion 
PCI to LCx 
60 Male 295 14 (0) 
14 (3) 
170 (8) 
0 0 Chest Pain Type 1 MI Current Smoker 
Hypertension 
Hyperlipidaemia 
Family history of CHD 





70% stenosis OM1 
Medical 














Family history of CHD 









ongoing chest pain 
two days post 
index presentation 
 
Missed Type 1 MI  
73 Female 425 9 (0) 
11 (3) 
   
22.2 2 Chest Pain Paroxysmal AF Previous Smoker 
Hypertension 
Hyperlipidaemia 





T wave inversion 
Re-presented with  
inferior STEMI 
14 days post index 
presentation 
 
PCI to RCA 
 
Type 1 MI  
Demarcation for missed index events (n=2) and 30 day events (n=2) 
AF = atrial fibrillation, CABG = coronary artery bypass graft, CHD = coronary heart disease, LBBB = left bundle branch block, RBBB = right bundle branch block, MI = myocardial infarction, PCI = percutaneous 
coronary intervention. STEMI = ST-segment elevation myocardial infarctio
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Appendix 2.4 2x2 table with diagnostic performance of the High-STEACS 
pathway at 6 hours 
 
 
 Type 1 MI No Type 1 MI 
 




Pathway rules out 4 939 
 
 
Patients with cardiac troponin concentrations <5 ng/L who present over two hours 
from time of symptom onset are ruled out on presentation. Those ≥5 ng/L and <99th 
centile on presentation, and those who present within two hours of symptom onset are 
re-tested at three hours. Those with a change in cardiac troponin of <3 ng/L are ruled 









Diagnostic algorithm of the High-STEACS pathway, currently being evaluated as part 
of a multi-centre stepped-wedge cluster randomised trial in unselected consecutive 
patients across Scotland. *In the High-STEACS pathway, patients with cardiac 
troponin concentrations <5 ng/L who present within two hours of symptom onset are 












































 Presentation 3 hours from 
presentation  
















100 (1,218)  95.6 (1,164) 58.2 (709) 













HIGH-SENSITIVITY CARDIAC TROPONIN AND 
CLINICAL RISK SCORES IN PATIENTS WITH 




















Patients without initial sample (n=16)
Outcomes
Type 1 myocardial infarction (n=273)




Type 1 myocardial infarction (n=268)
Type 2 myocardial infarction (n=75)
Myocardial injury (n=30)
Cardiac death (n=6)
a 18 patients excluded as missing required serial sample for HighSTEACS pathway
b 49 patients excluded as missing required serial sample for ESC pathway
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Appendix 3.2. Summary of missed index or 30-day events using the ESC 3 hour pathway. 
 

















Peak   
Presenting 
Symptom 






82 F 86 11 15 26 Chest pain Index Type 1 MI 2 169 17 5 
62 M 70 27 32 43 Chest pain Index Type 1 MI 3 107 24 5 
73 F 150 35 34 37 Chest pain Index Type 1 MI 2 129 14 6 
64 M 199 42 45 48 Chest pain Index Type 1 MI 4 129 16 6 
89 M 317 68 74 934 Chest pain Index Type 1 MI 4 214 27 7 
85 M 150 16 12 - Chest pain Cardiac death (30d) 3 107 23 6 
80 F 191 17 17 15 Chest pain Index Type 1 MI 3 129 19 7 
79 M 107 37 35 28 Chest pain Index Type 1 MI 3 173 22 7 
73 M 180 26 29 41 Chest pain Index Type 1 MI 4 107 24 5 
82 M 126 19 20 22 Chest pain Type 1 MI (30d) 4 169 24 6 
66 M 89 12 31 202 Chest pain Index Type 1 MI 3 107 18 5 
56 M 202 8 14 307 Chest pain Index Type 1 MI 3 65 10 5 
65 F 57 47 44 - Chest pain Index Type 1 MI 2 79 10 6 
88 F 82 18 15 12 Chest pain Index Type 1 MI 4 141 24 6 
66 M 305 22 36 50 Palpitations Index Type 1 MI 3 79 22 5 
60 M 295 14 14 170 Chest pain Index Type 1 MI 3 65 14 4 
88 F 222 15 19 - Chest pain Index Type 1 MI 3 129 20 5 
89 F 165 16 18 24 Chest pain Index Type 1 MI 1 129 20 6 
80 F 144 21 21 - Jaw pain Index Type 1 MI 2 129 16 6 
 
 274 
58 M 112 20 33 35 Chest pain Index Type 1 MI 0 95 14 4 
54 M 96 22 32 36 Chest pain Index Type 1 MI 1 85 16 3 
58 F 135 20 21 19 Chest pain Index Type 1 MI 2 107 16 6 
72 M 199 56 58 - Chest pain Index Type 1 MI 2 129 25 5 
57 M 458 33 80 144 Chest pain Index Type 1 MI 0 65 14 4 
70 M 375 17 160 2583 Chest pain Index Type 1 MI 4 84 18 6 
85 F 1616 7 12 19 Chest pain Index Type 1 MI 1 129 18 5 




Appendix 3.3. Summary of missed index or 30-day events using the High-STEACS pathway. 
 

















Peak   
Presenting 
Symptom 






82 M 126 19 20 22 Chest pain Type 1 MI (30d) 4 169 24 6 
60 M 295 14 14 170 Chest pain Index Type 1 MI 3 65 14 4 




Appendix 3.4. Diagnostic metrics for the European Society of Cardiology 0h / 3h pathway with and without clinical risk scores for a composite 























low risk (%) 
ESC Pathway  327 231 1279 49 96.3 (95.2-97.2) 86.9 (83.4-90.2) 58.6 (54.5-62.6) 84.7 (82.9-86.5) 70.4 
ESC Pathway + 
TIMI (0/1) 
368 674 836 8 99.0 (98.2-99.6) 97.7 (96.0-99.0) 35.3 (32.5-38.3) 55.4 (52.8-57.9) 44.8 
ESC Pathway + 
GRACE ≤108 
362 600 910 14 98.4 (97.5-99.1) 96.2 (94.0-97.9) 37.6 (34.6-40.7) 60.3 (57.8-62.7) 49.0 
ESC Pathway + 
EDACS <16 
363 723 787 13 98.3 (97.3-99.1) 96.4 (94.3-98.0) 33.4 (30.7-36.3) 52.1 (49.6-54.6) 42.4 
ESC Pathway + 
HEART ≤3 
374 1044 466 2 99.5 (98.6-99.9) 99.3 (98.3-99.9) 26.4 (24.1-28.7) 30.9 (28.6-33.2) 24.8 
 
ESC – European Society of Cardiology, TIMI – Thrombolysis In Myocardial Infarction, GRACE – Global Registry of Acute Coronary Events, EDACS – Emergency Department Assessment of 
Chest pain Score, CI – confidence interval
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Appendix 3.5. Diagnostic metrics for the HighSTEACS pathway with and without clinical risk scores for a composite outcome of type 1 or type 























low risk (%) 
High-STEACS 
Pathway  
378 295 1238 6 99.5 (99.0-99.8) 98.3 (97.0-99.5) 56.2 (52.4-59.9) 80.7 (78.8-82.7) 64.9 
High-STEACS 
+ TIMI (0/1) 
382 701 832 2 99.7 (99.2-100) 99.4 (98.3-99.9) 35.3 (32.5-38.2) 54.3 (51.8-56.8) 43.5 
High-STEACS 
+ GRACE ≤108 
381 627 906 3 99.6 (99.1-99.9) 99.1 (97.9-99.8) 37.8 (34.8-40.8) 59.1 (56.6-61.5) 47.4 
High-STEACS 
+ EDACS <16 
382 743 790 2 99.7 (99.2-99.9) 99.4 (98.3-99.9) 34.0 (31.3-36.8) 51.5 (49.0-54.0) 41.3 
High-STEACS 
+ HEART ≤3 
384 1068 465 0 99.9 (99.6-100) 99.9 (99.5-100) 26.5 (24.2-28.8) 30.3 (28.1-32.7) 24.3 
 
High-STEACS = High-Sensitivity Troponin in the Evaluation of patients with Acute Coronary Syndrome,  TIMI – Thrombolysis In Myocardial Infarction,  
GRACE – Global Registry of Acute Coronary Events, EDACS – Emergency Department Assessment of Chest pain Score, CI – confidence interval 
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low risk (%) 
High-STEACS 
Pathway 




























low risk (%) 
High-STEACS 
Pathway 
74 326 1176 1 99.9 (99.6-100) 98.0 (94.9-100) 18.6 (14.9-22.5) 78.3 (76.2-80.3) 74.6 
ESC Pathway 64 252 1225 11 99.1 (98.5-99.5) 84.9 (76.8-92.5) 20.3 (16.1-24.9) 82.9 (81.0-84.8) 79.6 



























low risk (%) 
TIMI 0/1 213 674 967 63 93.8 (92.3-95.2) 77.1 (72.0-81.8) 24.0 (21.3-26.9) 58.9 (56.5-61.3) 53.7 
GRACE  ≤108 201 566 1075 75 93.4 (91.9-94.8) 72.7 (67.4-77.8) 26.2 (23.2-29.4) 65.5 (63.2-67.8) 60.0 
EDACS <16 * 273 834 767 3 99.5 (99.0-99.9) 98.7 (97.1-99.7) 24.7 (22.2-27.3) 47.9 (45.5-50.4) 41.0 
HEART ≤3  268 1136 505 8 98.3 (97.1-99.3) 96.9 (94.6-98.6) 19.1 (17.1-21.2) 30.8 (28.6-33.0) 26.8 
 
*  When EDACS is applied in isolation, the following low risk criteria are recommended: 1) EDACS Score <16, 2) No myocardial ischaemia on the ECG and 3) troponin concentrations are 
≤99th centile at 0 and 2 hours. Than M et al. Emerg Med Australas. 2014;26:34-44.  
 






























33 83 290 0 99.8 (99.3-100) 98.5 (94.4-100) 28.6 (20.8-37.1) 77.7 (73.4-81.8) 71.4 
ESC 1-hour + 
TIMI (0/1) 
33 149 224 0 99.8 (99.1-100) 98.5 (94.4-100) 18.3 (13.1-24.2) 60.0 (55.0-64.9) 55.2 
ESC 1-hour + 
GRACE ≤108 
33 134 239 0 99.8 (99.2-100) 98.5 (94.4-100) 19.9 (14.3-26.3) 64.0 (59.1-68.8) 58.9 
ESC 1-hour +  
EDACS <16 
33 151 222 0 99.8 (97.2-100) 98.5 (94.4-100) 18.1 (12.9-24.0) 59.5 (54.5-64.4) 54.7 
ESC 1-hour + 
HEART ≤3 
33 239 134 0 99.6 (98.6-100) 98.5 (94.4-100) 12.3 (8.7-16.4) 36.0 (31.2-40.9) 33.0 
  












 Presentation 3 hours from 
presentation  
6 – 12 hours 
from 
presentation 
1 hour from 














100 (1,935)  94.9 (1,837) 51.2 (990) 21 (406) 






Included if ≥ 30 
and ≤90 
minutes from 









Appendix 3.11. Additional information on diagnostic adjudication  
 
Criteria for adjudication of patients with myocardial necrosis 
 
 
Type 1 myocardial infarction 
 
Myocardial necrosis (any cardiac troponin I [cTnI] 
concentration above the upper reference limit) with rise 
and or fall in cTnI concentration where serial testing 




Type 2 myocardial infarction 
 
Myocardial necrosis (any cTnI concentration above the 
upper reference limit) with rise and or fall in cTnI 
concentration where serial testing was available AND 
symptoms OR signs of myocardial ischaemia AND 
evidence of increased oxygen demand (e.g. 
tachyarrhythmia, hypertrophy) or reduced supply (e.g. 
hypotension, hypoxia or anaemia) in context of 





Myocardial necrosis (any cTnI concentration above the 
upper reference limit) without symptoms OR signs of 




The process of adjudication was conducted by two cardiologists independently. Both had access to the 
electronic patient record. The adjudicated diagnosis was reached by evaluating the attending clinicians 
documentation of the presenting complaint, past medical history, cardiovascular risk factors and clinical 
examination findings including routine observations (pulse, blood pressure, pulse oximetry, temperature 
and conscious level). All investigation results undertaken by the attending clinician were available for 
review, including biochemistry and haematology results, the 12 lead electrocardiogram, echocardiogram, 
chest X-ray and invasive coronary angiography findings when performed. Both adjudicating cardiologists 








LONG TERM OUTCOMES IN PATIENTS WITH 








Appendix 4.1 Additional information on diagnostic adjudication 
 
Criteria for adjudication of patients with myocardial necrosis 
 
 
Type 1 myocardial 
infarction 
 
Myocardial necrosis (any cardiac troponin I [cTnI] 
concentration above the upper reference limit) with 
rise and or fall in cTnI concentration where serial 
testing was available AND symptoms OR signs of 
myocardial ischaemia  
 
 
Type 2 myocardial 
infarction 
 
Myocardial necrosis (any cTnI concentration above 
the upper reference limit) with rise and or fall in 
cTnI concentration where serial testing was 
available AND symptoms OR signs of myocardial 
ischaemia AND evidence of increased oxygen 
demand (e.g. tachyarrhythmia, hypertrophy) or 
reduced supply (e.g. hypotension, hypoxia or 





Myocardial necrosis (any cTnI concentration above 
the upper reference limit) without symptoms OR 
signs of myocardial ischaemia in context of 
alternative clinical diagnosis  
 
The process of adjudication was conducted by two cardiologists independently. Both had access 
to the electronic patient record. The adjudicated diagnosis was reached by evaluating the 
attending clinicians documentation of the presenting complaint, past medical history, 
cardiovascular risk factors and clinical examination findings including routine observations 
(pulse, blood pressure, pulse oximetry, temperature and conscious level). All investigation results 
undertaken by the attending clinician were available for review, including biochemistry and 
haematology results, the 12 lead electrocardiogram, echocardiogram, chest X-ray and invasive 
coronary angiography findings when performed. Both adjudicating cardiologists had access to the 
final discharge letter documenting the attending clinicians’ final diagnosis. We did not apply 
specific criteria to define supply or demand imbalance,(Saaby et al., 2014) but adjudicated 
myocardial supply or demand imbalance on an individual patient basis, in line with most studies 







Appendix 4.2  Additional information on classification of cardiovascular death 
ICD Code Definition 
Ischaemic heart diseases 
I20 Angina pectoris 
I21 Acute myocardial infarction 
I22 Subsequent myocardial infarction 
I23 Certain current complications from acute myocardial infarction 
I24 Other acute ischaemic heart diseases 
I25 Chronic ischaemic heart disease 
Other forms of heart disease 
I34 Non-rheumatic mitral valve disorders 
I35 Non-rheumatic aortic valve disorders 
I36 Non-rheumatic tricuspid valve disorders 
I37 Pulmonary valve disorders 
I42 Cardiomyopathy 
I43 Cardiomyopathy in diseases classified elsewhere 
I46 Cardiac arrest 
I48 Atrial fibrillation and flutter 
I49 Other cardiac arrhythmias 
I50 Heart failure 
I51 Complications and ill-defined descriptions of heart disease 
Cerebrovascular diseases 
I60 Subarachnoid haemorrhage 
I61 Intracerebral haemorrhage 
I62 Other nontraumatic intracerebral haemorrhage 






I64 Stroke, not specified as haemorrhage or infarction 
I65 Occlusion and stenosis of precerebral arteries, not resulting in infarction 
I66 Occlusion and stenosis of cerebral arteries, not resulting in infarction 
I67 Other cerebrovascular diseases 
I68 Cerebrovascular disorders in diseases classified elsewhere 






Appendix 4.3  Analysis code 
 
All analysis was performed using R (version 3.2.2) using the survival and cmprsk 
packages. For transparency, the analysis code is available open source via GitHub. 
 





Appendix 4.4. Most common primary discharge diagnoses in patients with an 
adjudicated diagnosis of type 2 myocardial infarction or myocardial injury.  
 
 
Type 2 Myocardial Infarction Myocardial Injury 
Arrhythmia (19.1%, 82/429) Heart Failure (12.8%, 67/522) 
Pneumonia (13.5%, 58/429) Arrhythmia (10.9%, 57/522) 
Heart Failure (12.4%, 53/429) Pneumonia (9.6%, 50/522) 






Appendix 4.5. Cause-specific hazard ratios for major adverse cardiovascular events 




Penalised smoothing splines used for age and eGFR (estimated glomerular filtration rate) in 




Major Adverse Cardiovascular Events 
(MACE) 
 
 Unadjusted HR (95% CI) 
Adjusted HR 
(95% CI) 
Age (per 10-year increase) 1.60 (1.50-1.70) - 
Sex (male) 0.85 (0.73-0.98) 1.09 (0.93-1.28) 
Haemoglobin (per 10 g/L reduction) 1.18 (1.14-1.21) 1.07 (1.03-1.11) 
eGFR (per 10 ml/min reduction) 1.20 (1.17-1.24) - 
Smoking 0.66 (0.55-0.79) 1.26 (1.02-1.56) 
Diabetes Mellitus 1.77 (1.49-2.10) 1.36 (1.14-1.64) 
Hypertension 1.66 (1.42-1.93) 1.05 (0.89-1.24) 
Coronary Artery Disease 2.52 (2.16-2.94) 1.80 (1.52-2.14) 
Stroke 1.88 (1.53-2.31) 1.10 (0.89-1.38) 
Peripheral Vascular Disease 2.07 (1.65-2.59) 1.45 (1.14-1.86) 
Validation phase 1.21 (1.04-1.40) 1.16 (0.99-1.35) 
Type 1 Myocardial Infarction 1.00 1.00 
Type 2 Myocardial Infarction / 






Appendix 4.6. Adjusted relative risks of primary and secondary outcomes for patients 




 Myocardial Injury versus  
Type 2 MI 
 
Adjusted RR  
(95% CI) 
Death from any cause 1.27 (1.08-1.48) 
MACE  0.99 (0.87-1.13) 
   Non-fatal MI  0.80 (0.61-1.03) 
   Cardiovascular death 1.07 (0.94-1.22) 
Fatal MI 1.18 (0.87-1.58) 
Heart failure hospitalization 1.23 (1.03-1.46) 
Non-cardiovascular death 1.12 (0.99-1.26) 
 
Models adjusted for age, gender, renal function, haemoglobin and history of hypertension, 
stroke, peripheral vascular disease, diabetes mellitus, smoking, coronary artery disease and 
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1. Protocol Approval 
 





Dr Andrew Chapman    
Chief Investigator Signature  Date 
 
Prof Nicholas Mills 
   







































2. Investigator Statement 
 
Evaluating the role of coronary artery disease to resolve the diagnosis of Type 2 
Myocardial Infarction 
 
I agree to conduct the study according to this protocol, the principles of 
International Conference on Harmonisation Tripartite Guidelines for Good 
Clinical Practice (ICH GCP) and the applicable regulatory requirements.  Any 
changes in procedure will only be made if necessary to protect the safety, rights 
or welfare of the patients. 
 
I agree to take responsibility for the conduct of the study and ensure that all other 
staff involved are adequately informed about the protocol and amendments and 








   
Signature of Investigator  Date 
   
   
   

























Myocardial injury is common in patients without acute coronary syndrome, and 
therefore international guidelines propose a classification of patients with myocardial 
infarction by aetiology. This differentiates between myocardial infarction due to 
plaque rupture (type 1) and myocardial oxygen supply-demand imbalance (type 2) in 
other acute illnesses. However, these guidelines have not been widely adopted as the 
diagnostic criteria for type 2 myocardial infarction are not clearly defined. Patients 
with type 2 myocardial infarction have poor long term outcomes, with at least twice 
the mortality at five years compared to those with an index type 1 myocardial 
infarction. Despite the majority of deaths being attributable to non-cardiovascular 
events, the rate of future type 1 myocardial infarction or cardiovascular death is similar 
regardless of index classification. If this future risk is related to the presence of 
underlying coronary artery disease, then there may be the potential to improve 
outcomes through targeted investigation and secondary prevention. We will undertake 
a systematic evaluation of the mechanism of myocardial injury and the role of coronary 
artery disease in 100 patients with elevated cardiac troponin concentrations where the 
diagnosis is likely to be type 2 myocardial infarction. These studies will help improve 
the assessment of patients with myocardial injury, refine the diagnostic criteria for type 




































The definition of acute myocardial infarction has evolved to accommodate 
increasingly sensitive markers of myocardial necrosis and imaging methods that allow 
greater understanding of the pathogenic mechanisms of acute coronary syndrome. As 
such, the universal definition of myocardial infarction now proposes that we classify 
patients with myocardial infarction based on aetiology.(1)   Whilst this classification 
has been used in clinical trials to refine clinical outcomes(2-4), it has not been widely 
adopted in clinical practice, and the frequency and implications of subtypes of acute 
myocardial infarction are uncertain. We believe the diagnostic criteria for type 2 
myocardial infarction require clarification and that this is necessary to encourage 
clinicians to adopt the proposed classification. This can only be achieved through 
prospective and systematic evaluation of the clinical presentation, pathophysiological 
mechanisms and outcomes of unselected patients with acute myocardial injury in 
clinical practice.  
 
Classification of myocardial infarction 
The Universal Definition of Myocardial Infarction differentiates between type 1 
myocardial infarction due to thrombosis of an atherosclerotic plaque, and type 2 
myocardial infarction due to an imbalance in myocardial oxygen supply and demand 
in another acute illness.(1) The classification describes evidence of myocardial necrosis 
in the absence of myocardial ischemia as myocardial injury. Myocardial infarction 
presenting as sudden death (type 3), or after percutaneous coronary intervention (type 
4) and coronary artery bypass grafting (type 5) are also defined. This classification is 
contentious and was based on expert consensus rather than evidence from prospective 
clinical trials. The most controversial diagnosis is that of type 2 myocardial infarction 
as these patients are heterogeneous, and have myocardial ischemia secondary to a wide 
range of primary acute medical or surgical conditions. It is here where the diagnosis 
of type 2 myocardial infarction has the greatest potential for benefit and for harm. For 
instance, a patient with type 2 myocardial infarction secondary to a tachyarrhythmia 
may be identified as having three vessel coronary artery disease and undergo surgical 
revascularisation. In contrast, the inappropriate use of anti-platelet agents and anti-
coagulants in a patient with myocardial ischemia due to hypotension and occult 
gastrointestinal bleeding is likely to accelerate bleeding and may be fatal.  
The global task force are reviewing the Universal Definition of Myocardial Infarction 
and recognise the need to provide clearer diagnostic criteria and guidance.(5) Based on 
the current guideline the differentiation between patients with type 2 myocardial 
infarction and myocardial injury is subjective and therefore inconsistent in clinical 
practice.(6,7) Likewise, in the absence of an accepted definition it is difficult to conduct 
randomised trials to determine the effectiveness of secondary prevention, such as 










Incidence of type 2 myocardial infarction and myocardial injury in clinical 
practice 
 
Following improvements in assay performance, we introduced a more sensitive 
troponin assay at our institution.(8,9) The validation and subsequent implementation of 
this assay provided an opportunity to assess the impact of lowering the diagnostic 
threshold on the incidence, management and clinical outcome of patients with type 2 
myocardial infarction and myocardial injury.(10) We systematically evaluated all 
patients with elevated plasma troponin concentrations irrespective of their presenting 
complaint who were admitted to the Royal Infirmary of Edinburgh during the 
validation and implementation of a sensitive cardiac troponin I assay (n=2,122) and 
made a number of novel observations. First, type 2 myocardial infarction and 
myocardial injury are as common as type 1 myocardial infarction in clinical practice. 
The incidence of type 2 myocardial infarction or myocardial injury increases with age 
and is more common than type 1 myocardial infarction in patients ≥75 years of age. 
Lowering the diagnostic threshold preferentially increased the number of patients 
identified with type 2 myocardial infarction or myocardial injury. Indeed, for every 
additional patient reclassified as type 1 myocardial infarction, we identified three 
patients with type 2 myocardial infarction or myocardial injury (257 versus 672 
patients, P<0.001).(10) This is important as the advent of newer highly sensitive cardiac 
troponin assays with lower thresholds may identify an even higher proportion of 
patients with previously undetectable myocardial injury.  
 
Long term outcomes in patients with type 2 myocardial infarction and myocardial 
injury 
Patients with type 2 myocardial infarction have poor outcomes,(11-15) worse than those 
with type 1 myocardial infarction, with 62.5% (268/429) versus 36.7% (430/1,171) 
dead at five years (adjusted hazard ratio [HR] 1.36, 95%CI 1.16-1.59). Survival in 
patients with myocardial injury is worse, even compared to those with type 2 
myocardial infarction with 72.4% (378/522) dead at five years (HR 1.25, 95%CI 1.07-












1171 1032 1006 985 964 945
429 333 313 294 284 272
















































































Despite the excess in five-year mortality being largely attributable to non-
cardiovascular death, the risk of future major adverse cardiovascular events (MACE; 
future type 1 myocardial infarction or cardiovascular death) is similar, regardless of 
index diagnosis. We found patients with type 2 myocardial infarction or myocardial 
injury and known coronary artery disease were at significantly increased risk of 
MACE, yet the majority of patients did not receive invasive coronary investigation nor 















Indeed, given patients with type 2 myocardial infarction are older and have a higher 
prevalence of co-morbidities, it is likely that there is an unrecognised burden of 
previously clinically quiescent coronary artery disease. It is here where there may be 
the opportunity to improve patient outcomes through identification and targeted 





































































































5. Study Objectives 
 
We propose to systematically evaluate the mechanisms of acute myocardial injury in 
unselected patients who present to hospital with an alternative primary illness likely 
to cause myocardial oxygen supply or demand imbalance. All patients will be assessed 
by a member of the study team during their index admission and will undergo a 
detailed assessment of their coronary anatomy with either computed tomography 
coronary angiography (CTCA), CT calcium scoring and non-invasive fractional flow 
reserve assessment (CT-FFR) or invasive coronary angiography with optical 
coherence tomography (OCT) and invasive fractional flow reserve (FFR). The pattern 
of myocardial injury and its functional consequence will be evaluated by cardiac 
magnetic resonance (CMR) imaging. We will determine the kinetics of cardiac 
troponin release using serial testing at multiple time points throughout admission, and 
quantify other proteins and the expression of long non-coding RNA and associated 
mRNA to identify differences related to the presence of coronary artery disease, which 
may help to identify new biomarkers. 
 
Understanding the mechanisms of acute myocardial injury in hospitalised patients and 
the contribution of coronary artery disease will lead to the development of a diagnostic 
algorithm and framework for clinicians to base their assessment, and will help to guide 
future therapeutic trials.   
 
 
5.1 Original Hypothesis 
The majority of patients with myocardial injury secondary to oxygen supply or 







6. Trial Design 
 
Design: Prospective cohort study  
Setting: Royal Infirmary of Edinburgh, a tertiary cardiac centre 
Study population:  
We will identify consecutive patients with acute myocardial injury (defined as a rise 
and or fall in cardiac troponin concentration on serial testing, with at least one value 
>99th centile) where the likely mechanism of injury is thought to be myocardial oxygen 
supply and demand imbalance (e.g secondary to hypoxia, hypotension, tachycardia or 
anaemia). Patients will be identified through screening of cardiac troponin 
measurements using the electronic patient record and laboratory databases at the 
recruiting site. The chief investigator is a clinical research fellow and honorary 
cardiology registrar in NHS Lothian, and has access to electronic patient records as 
part of routine clinical care. All patients screened will be recorded in a screening log. 
In patients that meet our inclusion criteria, but have one or more exclusion criteria and 
therefore are not eligible for enrolment, we will record demographic and clinical 
information from the electronic patient record with approval from the local Caldicott 
Guardian (including age, gender, previous medical history such as hypertension, 
diabetes, stroke, angina, myocardial infarction, previous angioplasty or bypass 
surgery, medication history, presenting complaint and ECG findings). Patients who 
meet both the inclusion and exclusion criteria, will be approached and those who 
provide consent will comprise the study population and be allocated a unique study 
number.  
 
Number of participants: 
We will recruit one hundred patients from the Royal Infirmary of Edinburgh, Scotland. 
 
Inclusion criteria: 
- Unscheduled hospital admission with acute myocardial injury (defined as a rise 
and or fall in high-sensitivity cardiac troponin I concentrations on blood 
testing) 
- A suspected aetiology of myocardial oxygen supply and demand imbalance 
 
Exclusion criteria: 
- Unable or unwilling to give informed consent 
- Women who are pregnant, breastfeeding or of child-bearing potential (women 
who have experienced menarche, are pre-menopausal and have not been 
sterilised) will not be enrolled into the trial. 
- Probable type 1 myocardial infarction  
- Renal impairment (estimated glomerular filtration rate ≤30ml/min/1.73m2) 
- Severe hepatic impairment 








- To determine the prevalence and severity of coronary artery disease (defined 
as stenosis >50% in a major epicardial vessel) in patients with myocardial 





- To determine the functional significance of coronary artery stenosis using the 
invasive or CT fractional flow reserve technique.  
- To determine the prevalence of intraluminal plaque rupture using optical 
coherence tomography 
- To evaluate the pattern of myocardial injury or infarction using the late 
gadolinium enhancement technique 
- To determine the presence of myocardial ischaemia quantified using stress-
perfusion magnetic resonance imaging. 
- To validate a prediction model derived in patients with an adjudicated 
diagnosis of type 2 myocardial infarction identified in the High-STEACS 
clinical trial. 
- To identify novel biomarkers that differentiate between type 1 and type 2 
myocardial infarction 
- To evaluate the relationship between coronary artery disease and 
cardiovascular outcomes  
 
Consent 
The chief investigator will screen all measurements of cardiac troponin I to identify 
patients with evidence of myocardial injury within the previous 24 hours, and after 
review of the electronic patient record will liaise other members of the clinical team 
to identify patients who may be suitable for recruitment. The clinical team will 
approach the patient to obtain verbal consent for the researcher to discuss the study. 
All patients will receive a patient information sheet at the time of screening and will 
be provided with an opportunity to ask questions. Eligible patients will be given a 
minimum of one hour to consider the written material and the investigator or another 
suitably qualified member of the research team will then re-attend to provide an 
opportunity for further questions. As patients may be recruited from the emergency 
department or the acute medical unit where there is potential for early discharge, a 
short time interval is necessary to permit recruitment prior to hospital discharge. Audit 
data shows it takes 124 minutes from arrival to troponin result at the Royal Infirmary 
of Edinburgh. Assuming a patient is identified as suitable within 30 minutes of sample 
result, this leaves only 90 minutes for screening and recruitment prior to possible 
discharge at four hours, in line with government standards. An independent study 
observer will be available to discuss any aspect of the study. Written informed consent 







Withdrawal from study 
Participation in this study is voluntary and subjects will be free to withdraw from study 
at any point should they wish to do so. Patients retain the right to ask for blood samples 
to be destroyed at any time.   
 
7. Study Procedures 
 
All participants will undergo cardiac magnetic resonance imaging of the myocardium 
where there are no contraindications, in addition to evaluation of coronary anatomy by 
either invasive or non-invasive coronary angiography dependent on their co-
morbidities or patient preference (Appendix 1 – Flow Diagram). For example, frail 
patients or those with severe peripheral vascular disease in whom intra-vascular access 
may be challenging would be more likely to undergo non-invasive imaging. This 
clinical decision will be made in discussion with the consultant responsible for the 
patient’s ongoing care by the investigators who are all cardiologists with experience 
of both invasive and non-invasive diagnostic imaging. Such investigations are often 
considered by the attending clinician as part of routine clinical care, but decisions are 
challenging given the lack of evidence to date. All patients will provide informed 
consent in line with routine clinical practice. We will report the results of all 
investigations to the patients attending clinician so therapy may be modified where 
this is felt to be of benefit. The target for completion of all diagnostic studies is 28 
days from index presentation, with the aim to perform imaging as early as is feasible. 
 
Cardiac Magnetic Resonance Imaging 
Cardiovascular magnetic resonance (CMR) will be performed using a 3T scanner 
(MAGNETOM Verio, Siemens AG, Healthcare Sector, Erlangen, Germany) at the 
Clinical Research Imaging Centre (CRIC), Edinburgh, where there is established 
experience in research MRI. The MRI scan will consist of localisers, axial and coronal 
HASTE images, standard breath-held and ECG-gated cine sequences in 2 chamber, 4 
chamber and short axis views. Short-axis cine images will be obtained using a 
balanced steady-state free precession sequence from the mitral valve annulus to the 
apex (8 mm parallel slices with 2 mm spacing) for the assessment of left ventricle 
function and volumes. Left ventricle volumes, mass and ejection fraction will be 
assessed using dedicated software (Argus Ventricular Function, Siemens AG 
Healthcare Sector, Erlangen, Germany) and values indexed to body surface area. 
Breath-held, ECG-gated T2 mapping sequences of the myocardium will be performed 
in the long-axis as a marker of myocardial inflammation. T1-weighted imaging of the 
coronary arteries will be performed to look for evidence of recent intraplaque 
thrombus or haemorrhage using the CATCH sequence. All patients will then receive 
0.4mg (5ml) of peripheral Regadenoson (Rapiscan™) as a stress perfusion agent, and 
a bolus of 0.2 mmol/kg Gadolinium (Gadovist™), to quantify areas of myocardial 
ischaemia. Stress-perfusion imaging will not be undertaken in patients with severe 
asthma or chronic obstructive pulmonary disease, those on dipyridamole, theophylline 
or aminophylline, or those with atrioventricular block. Patients will be asked to 
withhold caffeine intake for 12 hours prior to imaging. This will be followed by 
standard late-gadolinium enhancement sequences. The late gadolinium enhancement 






as well as other patterns of injury such as the mid-wall pattern associated with 
myocarditis.  
 
Invasive coronary angiography and optical coherence tomography 
Coronary angiography will be performed via the femoral or radial artery with 6F 
arterial catheters. In patients with one or more stenoses in a major epicardial vessel, a 
coronary pressure guidewire (PressureWire™ Aeris™, St. Jude Medical, St. Paul, 
Minnesota) will be used to determine distal coronary pressure and the fractional flow 
reserve (FFR) calculated at maximal adenosine-induced (intravenous 140 μg/kg/min) 
hyperaemia. As previously described, frequency domain optical coherence 
tomography (FD-OCT) will be performed in all three coronary vessels using a 
FastView® coronary imaging catheter (Terumo, Tokyo, Japan) with pullback at 20 
mm/s to identify features consistent with vulnerable plaque or recent plaque rupture.(16) 
If there is evidence of inducible myocardial ischaemia due to coronary artery stenosis, 
revascularisation with percutaneous coronary intervention may be considered if in the 
patients best interests.   
CT coronary angiography  
CT coronary angiography will be performed in the Clinical Research Imaging Centre, 
according to previously published methodology.(17) Imaging will be performed using 
a 128 multidetector row CT (Siemens Biograph, Siemens Healthcare, Erlangen, 
Germany). Patients with a heart rate exceeding 65 beats/min will receive oral beta-
blockade (50 or 100 mg metoprolol) 1 hour before computed tomography. Additional 
intravenous beta blockers will be given depending on heart rate at the time of imaging. 
All patients will receive sublingual glyceryl trinitrate (300 μg) immediately prior to 
dual cardiac and respiratory-gated computed tomography imaging of the coronary 
arteries. We will quantify total plaque burden using CT calcium scoring. A bolus of 
80-100 mL of contrast (400 mg/mL; Iomeron, Bracco, Milan, Italy) will be injected 
intravenously at 5 mL/s. CT angiography will be evaluated jointly by a Radiologist 
and a Cardiologist with suitable training to determine the extent of coronary 
atherosclerosis. An assessment of the functional consequences of coronary artery 
stenosis will be made using the computed tomography fractional flow reserve (CT-
FFR) technique, using the HeartFlowTM platform.(18)  
High-sensitivity cardiac troponin I assay 
Serial blood samples will be obtained on enrolment to the study, at 24 hours, and at 
last point of contact to the research team (on discharge from hospital or at outpatient 
visit for study imaging) in two 9 mL lithium-heparin tubes, two 9mL EDTA plasma 
tubes and two 9mL serum tubes. Samples obtained will facilitate development of novel 
biomarkers using proteomic and genomic approaches. The maximum sample volume 
obtained will be 180 ml. We will obtain wastage serum (surplus) from routinely 
obtained clinical samples. All blood samples will be stored at -80 degrees Celsius for 
future development, evaluation and audit of novel and existing cardiovascular 
biomarkers. High-sensitivity cardiac troponin I concentrations will be measured in 
batch processing using the ARCHITECTSTAT high-sensitive troponin I assay (Abbott 
Laboratories, Abbott Park, IL). This assay has a limit of detection of 1.2 ng/L and the 
inter-assay CV<10% at 4.7 ng/L. The upper reference limit (99th centile) is 26 ng/L, 
and is two-fold higher in men (34 ng/L) than in women (16 ng/L).(19,20) All samples 







We will extract total RNA from blood samples, and perform qPCR to quantify the 
expression of long non-coding RNA and associated mRNA. We aim to determine 
relative expression of candidate transcripts across the multiple patient phenotypes of 
coronary artery disease. 
Data collection and record linkage: 
CHI is a population register containing details of all Scottish residents registered with 
a General Practitioner and will be used to link all data sources. The Scottish Morbidity 
Record (SMR) will be used to identify the rate of myocardial infarction or 
cardiovascular death at 1 year. As in our previous studies, additional clinical 
information will be obtained through the TrakCare software application (InterSystems 
Corporation, Cambridge, MA, USA); with further information collected through a 
standardised pro forma.(8,9) This will include details of their presenting complaint, risk 
factors and past medical history including the following: time of onset of symptoms, 
time of hospitalisation, patient demographics (e.g. age and sex, cardiovascular risk 
factors, medical therapy on admission), GRACE score, heart rate, blood pressure, 
management in the Emergency Department, referral to cardiology, and discharge 
location. Any change to medical therapy will be extracted from the patients’ 
standardised electronic discharge summary. Reports from diagnostic coronary 
angiography, percutaneous and surgical coronary revascularisation will be extracted 
from the TOMCAT database (Cardiovascular Information Management System, 
Philips Healthcare). This information is stored locally on NHS Lothian servers. The 
trial results will be reported in accordance with the CONSORT guidelines and, where 
possible, the clinical profile of non-recruited and ineligible patients will be recorded 
with Caldicott approval.   
  
8. Statistical Analysis  
 
Power calculations: 
This exploratory analysis will determine the prevalence of coronary artery disease in 
patients with myocardial injury secondary to oxygen supply and demand imbalance. 
During our pilot study,(19) 1,126 consecutive patients were recruited over eight weeks. 
An adjudicated diagnosis of type 2 myocardial infarction or myocardial injury was 
made in 74 patients, and we therefore anticipate that 9 patients per week will meet the 
inclusion and exclusion criteria. We aim to recruit 100 patients as this is a feasible 
sample size, and will complete recruitment over 12-18 months. As this is exploratory 
analysis, no formal power calculations have been performed. 
 
Statistical analysis:  
We will report the prevalence of coronary artery stenosis in those with type 2 
myocardial infarction. We will derive linear mixed-effects models to compare the 
release kinetics of cardiac troponin in patients with type 2 myocardial infarction, with 
a control cohort of individuals with type 1 myocardial infarction. We will determine 
whether differences in release kinetics may aid identification of such patients in 
clinical practice. We will validate a prediction model of coronary disease in patients 
with type 2 myocardial infarction, derived in the HighSTEACS clinical trial, with 






9. Expected Results 
 
To date, no study has prospectively evaluated patients with myocardial injury 
secondary to myocardial oxygen supply or demand imbalance for the presence of 
obstructive coronary artery disease. From our previous studies, we know patients with 
these diagnoses are older, and have a higher prevalence of co-morbid conditions such 
as hypertension and hyperlipidaemia. We anticipate that the majority of patients will 
have evidence of obstructive coronary artery disease on diagnostic testing. At present, 
this patient population are understudied and have extremely poor outcomes. By 
determining the role of coronary artery disease in the pathogenesis of type 2 
myocardial infarction and myocardial injury, we can better inform clinicians on the 
importance of risk stratification for coronary disease in this population. Ultimately, 
this study will guide the rationale and design of future therapeutic trials of secondary 






10. Safety Reporting and Study Monitoring 
 
10.1 Trial Management Group 
 
The trial management group will meet regularly and consists of the grant applicants, 
the trial manager, and research team. 
 
10.2 Safety Reporting 
An adverse event (AE) is any untoward medical occurrence in a study participant, 
which does not necessarily have a causal relationship with the study intervention.  
An adverse reaction (AR) is any untoward and unintended response that has 
occurred due to the intervention.  
A serious adverse event (SAE) or serious adverse reaction (SAR). Any AE or AR 
that: 
• results in death of the study participant; 
• is life threatening*; 
• requires in-patient hospitalisation^ or prolongation of existing hospitalisation; 
• results in persistent or significant disability or incapacity; 
• consists of a congenital anomaly or birth defect; 
• results in any other significant medical event not meeting the criteria above. 
 
*Life-threatening in the definition of an SAE or SAR refers to an event where the 
participant was at risk of death at the time of the event. It does not refer to an event 
which hypothetically might have caused death if it were more severe. 
 
^Any hospitalisation that was planned prior to enrolment will not meet SAE criteria. 
Any hospitalisation that is planned post enrolment will meet the SAE criteria. 
10.3 identifying AEs and SAEs 
The risk of AEs/SAEs relates to the investigations to be undertaken as part of the study, 
namely invasive coronary angiography, CT coronary angiography or cardiac magnetic 
resonance imaging. Any likely AE or SAE will be identified at or immediately after 
the time of the investigation taking place. Patients will be given the opportunity to 
contact the research team should they develop new symptoms. If there is any doubt as 
to whether a clinical observation is an AE, the event will be recorded.  
10.4 Recording AEs and SAEs 
When an AE/SAE occurs, the Investigator, or another suitably qualified physician in 
the research team will review all documentation (e.g. hospital notes, laboratory and 
diagnostic reports) related to the event.  The Investigator will then record all relevant 
information in the Case Record Form and or AE log and on the SAE form (if the AE 
meets the criteria of serious). The information to be recorded will include the type of 
event, onset date, assessment of severity and causality, date of resolution and treatment 






existed prior to informed consent) will be recorded as medical history and only 
recorded as adverse events if medically judged to have worsened during the study. All 
AE or SAE will be recorded from the time of first intervention. AEs and SAEs will be 
followed up until outcome of recovered, recovered with sequelae or death of study 
participant.  
We will not record, notify or report the development of a simple radial or femoral 
haematoma related to invasive coronary angiography where this is managed 
conservatively with pressure and where hospital admission was not required.  
Worsening of the Underlying Condition during the Trial 
Medical occurrences or symptoms of deterioration that are expected due to the 
participant’s underlying condition will be recorded in the patient’s medical notes and 
will only be recorded as AEs on the AE log if medically judged to have unexpectedly 
worsened during the study. Events that are consistent with the expected progression of 
the underlying disease will not be recorded as AEs.  
10.5 Assessment of AEs and SAEs 
Each AE will be assessed for seriousness, causality, severity and ARs will be assessed 
for expectedness by the Principal Investigator or another suitably qualified physician 
in the research team who has been delegated this role.  
Assessment of Seriousness 
The Investigator will make an assessment of seriousness as defined above. 
Assessment of Causality 
The Investigator will make an assessment of whether the AE/SAE is likely to be 
related to the study intervention according to the definitions below.   
 
• Unrelated: where an event is not considered to have occurred as a result of the 
study intervention. 
 
• Possibly Related: The nature of the event, the underlying medical condition, 
concomitant medication or temporal relationship make it possible that the AE 
has a causal relationship to the study intervention. 
 
If two assessments of causality are made (for example between the Primary and the 
Chief Investigator), the ‘worst case’ assessment will be used for reporting purposes.  
Assessment of Expectedness 
If the AE is judged to be related to the study intervention, the Investigator will make 
an assessment of expectedness:  
Expected: the type of event is expected in line with the study intervention 
Unexpected: the type of event was not listed in the protocol or related 
documents/literature as an expected occurrence. 






The Investigator will make an assessment of severity for each AE and record this on 
the CRF/AE log or SAE form according to one of the following categories: 
Mild: an event that is easily tolerated by the participant, causing minimal discomfort 
and not interfering with every day activities. 
Moderate: an event that is sufficiently discomforting to interfere with normal 
everyday activities. 
Severe: an event that prevents normal everyday activities. 
10.6 Reporting of SAEs 
Once the Investigator becomes aware that an SAE has occurred in a study participant, 
the information will be reported to the ACCORD Research Governance within 
24 hours. If the Investigator does not have all information regarding an SAE, they 
should not wait for this additional information before notifying ACCORD.  The SAE 
report form can be updated when the additional information is received. 
The SAE report will provide an assessment of causality and expectedness at the time 
of the initial report to ACCORD according to Sections 10.5 Assessment of Causality 
and 10.5, Assessment of Expectedness. 
The SAE form will be transmitted via email to safety@accord.scot 
10.7 Follow up procedures 
After initially recording an AE or recording and reporting an SAE, the Investigator 
will make every effort to follow each event until a final outcome can be recorded or 
reported as necessary. Follow up information on an SAE will be reported to the 
ACCORD office. If, after follow up, resolution of an event cannot be established, an 
explanation will be recorded on the CRF or AE log or additional information section 
of SAE form. 
 
11. Oversight Arrangements 
Inspection of Records 
Investigators and institutions involved in the study will permit trial related monitoring 
and audits on behalf of the sponsor, REC review, and regulatory inspection(s).  In the 
event of audit or monitoring, the Investigator agrees to allow the representatives of the 
sponsor direct access to all study records and source documentation. In the event of 
regulatory inspection, the Investigator agrees to allow inspectors direct access to all 
study records and source documentation. 
Risk Assessment 
A study specific risk assessment will be performed by representatives of the co-
sponsors, ACCORD monitors and the QA group, in accordance with ACCORD 
governance and sponsorship SOPs. Input will be sought from the Chief Investigator or 
designee. The outcomes of the risk assessment will form the basis of the monitoring 
plans and audit plans. The risk assessment outcomes will also indicate which risk 







Study Monitoring And Audit 
The ACCORD Sponsor Representative will assess the study to determine if an 
independent risk assessment is required.  If required, the independent risk assessment 
will be carried out by the ACCORD Quality Assurance Group to determine if an 
audit should be performed before/during/after the study and, if so, at what frequency. 
Risk assessment, if required, will determine if audit by the ACCORD QA group is 
required. Should audit be required, details will be captured in an audit plan. Audit of 
Investigator sites, study management activities and study collaborative units, facilities 
and 3rd parties may be performed. 
 
12.  Good Clinical Practice 
Ethical Conduct 
The study will be conducted in accordance with the principles of the International 
Conference on Harmonisation Tripartite Guideline for Good Clinical Practice (ICH 
GCP). 
Before the study can commence, all required approvals will be obtained and any 
conditions of approvals will be met. 
Investigator Responsibilities 
The Investigator is responsible for the overall conduct of the study at the site and 
compliance with the protocol and any protocol amendments.  In accordance with the 
principles of ICH GCP, the following areas listed in this section are also the 
responsibility of the Investigator.  Responsibilities may be delegated to an appropriate 
member of study site staff.   
Informed Consent 
The Investigator is responsible for ensuring informed consent is obtained before any 
protocol specific procedures are carried out. The decision of a participant to participate 
in clinical research is voluntary and should be based on a clear understanding of what 
is involved. 
Participants must receive adequate oral and written information – appropriate 
Participant Information and Informed Consent Forms will be provided. The oral 
explanation to the participant will be performed by the Investigator or qualified 
delegated person, and must cover all the elements specified in the Participant 
Information Sheet and Consent Form. 
The participant must be given every opportunity to clarify any points they do not 
understand and, if necessary, ask for more information. The participant must be given 
sufficient time to consider the information provided.  It should be emphasised that the 
participant may withdraw their consent to participate at any time without loss of 
benefits to which they otherwise would be entitled. 
The participant will be informed and agree to their medical records being inspected by 






The Investigator or delegated member of the trial team and the participant will sign 
and date the Informed Consent Form(s) to confirm that consent has been obtained. The 
participant will receive a copy of this document and a copy filed in the Investigator 
Site File (ISF) and participant’s medical notes (if applicable). 
 
Study Site Staff 
The Investigator must be familiar with the protocol and the study requirements.  It is 
the Investigator’s responsibility to ensure that all staff assisting with the study are 
adequately informed about the protocol and their trial related duties. 
Data Recording 
The Principal Investigator is responsible for the quality of the data recorded in the CRF 
at each Investigator Site.  
Investigator Documentation 
The Principal Investigator will ensure that the required documentation is available in 
local Investigator Site files ISFs.  
GCP Training 
For non-CTIMP (i.e. non-drug) studies all researchers are encouraged to undertake 
GCP training in order to understand the principles of GCP. However, this is not a 
mandatory requirement unless deemed so by the sponsor.  GCP training status for all 
investigators should be indicated in their respective CVs.  
Confidentiality 
All laboratory specimens, evaluation forms, reports, and other records must be 
identified in a manner designed to maintain participant confidentiality.  All records 
must be kept in a secure storage area with limited access.  Clinical information will 
not be released without the written permission of the participant.  The Investigator and 
study site staff involved with this study may not disclose or use for any purpose other 
than performance of the study, any data, record, or other unpublished, confidential 
information disclosed to those individuals for the purpose of the study.  Prior written 
agreement from the sponsor or its designee must be obtained for the disclosure of any 
said confidential information to other parties. 
Data Protection 
All Investigators and study site staff involved with this study must comply with the 
requirements of the Data Protection Act 1998 with regard to the collection, storage, 
processing and disclosure of personal information and will uphold the Act’s core 
principles. Access to collated participant data will be restricted to individuals from the 
research team treating the participants, representatives of the sponsor(s) and 
representatives of regulatory authorities. 
Computers used to collate the data will have limited access measures via user names 
and passwords. Published results will not contain any personal data that could allow 







13.  Study Conduct Responsibilities 
Protocol Amendments 
Any changes in research activity, except those necessary to remove an apparent, 
immediate hazard to the participant in the case of an urgent safety measure, must be 
reviewed and approved by the Chief Investigator.   
Amendments will be submitted to a sponsor representative for review and 
authorisation before being submitted in writing to the appropriate REC, and local R&D 
for approval prior To Participants Being Enrolled Into An Amended Protocol. 
Management of Protocol Non Compliance 
Prospective protocol deviations, i.e. protocol waivers, will not be approved by the 
sponsors and therefore will not be implemented, except where necessary to eliminate 
an immediate hazard to study participants. If this necessitates a subsequent protocol 
amendment, this should be submitted to the REC, and local R&D for review and 
approval if appropriate. 
Protocol deviations will be recorded in a protocol deviation log and logs will be 
submitted to the sponsors every 3 months. Each protocol violation will be reported to 
the sponsor within 3 days of becoming aware of the violation.  All protocol deviation 
logs and violation forms should be emailed to QA@accord.scot 
Deviations and violations are non-compliance events discovered after the event has 
occurred.  Deviation logs will be maintained for each site in multi-centre studies.  An 
alternative frequency of deviation log submission to the sponsors may be agreed in 
writing with the sponsors. 
Serious Breach Requirements 
A serious breach is a breach which is likely to effect to a significant degree: 
(a) the safety or physical or mental integrity of the participants of the trial; or 
(b) the scientific value of the trial. 
If a potential serious breach is identified by the Chief investigator, Principal 
Investigator or delegates, the co-sponsors (seriousbreach@accord.scot) must be 
notified within 24 hours.  It is the responsibility of the co-sponsors to assess the impact 
of the breach on the scientific value of the trial, to determine whether the incident 
constitutes a serious breach and report to research ethics committees as necessary.  
Study Record Retention 
All study documentation will be kept for a minimum of 3 years from the protocol 
defined end of study point. When the minimum retention period has elapsed, study 
documentation will not be destroyed without permission from the sponsor. 
End of Study 






The Investigators or the co-sponsor(s) have the right at any time to terminate the study 
for clinical or administrative reasons.  
The end of the study will be reported to the REC, and R+D Office(s) and co-sponsors 
within 90 days, or 15 days if the study is terminated prematurely. The Investigators 
will inform participants of the premature study closure and ensure that the appropriate 
follow up is arranged for all participants involved. End of study notification will be 
reported to the co-sponsors via email to resgov@accord.scot.  
A summary report of the study will be provided to the REC within 1 year of the end 
of the study. 
Continuation of treatment following the end of study 
Detail if intervention will be continued to be provided following the end of the study.  
If not provide justification 
Insurance and Indemnity 
The co-sponsors are responsible for ensuring proper provision has been made for 
insurance or indemnity to cover their liability and the liability of the Chief Investigator 
and staff. 
The following arrangements are in place to fulfil the co-sponsors' responsibilities: 
• The Protocol has been designed by the Chief Investigator and researchers 
employed by the University and collaborators.  The University has insurance 
in place (which includes no-fault compensation) for negligent harm caused 
by poor protocol design by the Chief Investigator and researchers employed 
by the University. 
• Sites participating in the study will be liable for clinical negligence and other 
negligent harm to individuals taking part in the study and covered by the duty 
of care owed to them by the sites concerned.  The co-sponsors require 
individual sites participating in the study to arrange for their own insurance 
or indemnity in respect of these liabilities. 
• Sites which are part of the United Kingdom's National Health Service will 
have the benefit of NHS Indemnity. 
• Sites out with the United Kingdom will be responsible for arranging their own 
indemnity or insurance for their participation in the study, as well as for 
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Measurement of high 
sensitivity cardiac Troponin I 
(hs-TnI) 
Adjudication and Classification
Step 1: Two cardiologists independently review all clinical information including
- Baseline characteristics
- Cardiac investigations including imaging results
- Outcomes up to 30 days
Step 2: Classification according to the Universal Definition of Myocardial Infarction











































Rise or fall in hs-TnI
(peak sample)
Study Population identified 
(n=100)
Serial hs-TnI measurement 
(first 72 hours)
Exclusions
CT Coronary AngiographyInvasive Coronary Angiography
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Summary of research project 
Type 2 myocardial infarction is common, and occurs due to myocardial oxygen supply 
or demand imbalance, during an episode of tachyarrhythmia, hypotension or hypoxia 
secondary to another medical condition. Unlike type 1 myocardial infarction, due to 
atherosclerotic plaque rupture and intraluminal thrombosis, type 2 myocardial 
infarction is poorly understood, yet it is responsible for almost half of all detectable 
myocardial injury in hospitalised patients. At present, distinguishing patients with type 
1 and type 2 myocardial infarction is challenging in clinical practice as there are no 
objective criteria for diagnosis, investigation or management, and clinical outcomes 
are extremely poor, with as few as 1 in 3 patients alive at five years. 
 
In a prospective cohort study of patients with type 2 myocardial infarction, we aim to 
screen candidate cardiovascular biomarkers and identify those which could distinguish 
patients with type 1 and type 2 myocardial infarction. Identification of objective 
biomarkers has the potential to allow more accurate diagnosis in clinical practice, and 
would facilitate the identification of patients for therapeutic trials of secondary 







The definition of acute myocardial infarction has evolved to accommodate 
increasingly sensitive markers of myocardial necrosis and imaging methods that allow 
greater understanding of the pathogenic mechanisms of acute coronary syndrome. 1 
The third universal definition of myocardial infarction recommends a classification 
based on aetiology (Figure 1), where type 1 myocardial infarction is due to plaque 
rupture or erosion with intracoronary luminal thrombosis, and type 2 myocardial 
infarction due to myocardial oxygen supply-demand imbalance in the context of an 
alternate medical condition such as tachyarrhythmia, hypotension or hypoxia. Patients 
with elevated cardiac troponin concentrations who do not have overt myocardial 
ischemia are classified as having myocardial injury.2 
 
The universal definition makes a distinction between type 1 and type 2 myocardial 
infarction based on likely aetiology, but in clinical practice there remains considerable 
overlap and to date there have been no prospective mechanistic studies to evaluate the 
range of underlying pathophysiology in these patients. Acute myocardial injury may 
occur in a variety of cardiac and non-cardiac illnesses (Table 1) as a consequence of 
myocardial oxygen supply-demand mismatch (hypotension, tachycardia or 
hypoxemia), due to direct injury in sepsis or viral myocarditis, or as part of the 
pathophysiological process in acute left ventricular failure. However, in some cases 
the presenting illness may be associated with a pro-inflammatory and pro-thrombotic 
state with myocardial injury due to embolisation of platelet aggregates and thrombus 
from an otherwise silent vulnerable plaque. Furthermore, myocardial injury can occur 






important, but unrecognised stable coronary artery disease. Chronic myocardial injury 
may occur in structural heart disease (hypertensive heart disease, ischaemic or dilated 
cardiomyopathy) or secondary to other non-cardiac illness such as chronic renal failure. 
As an example, the detection of chronic myocardial injury may be clinically useful in 
valvular heart disease, with serum cardiac troponin I concentrations associated with 
cardiac mass, replacement fibrosis and prognosis in patients with aortic stenosis.3  
The Global Task Force is reviewing the classification of myocardial infarction, and 
recognize the need to provide greater clarity for clinicians in practice.4 Patients with 
type 2 myocardial infarction and myocardial injury have higher crude rates of all-cause 
death compared with those with type 1 myocardial infarction, 5-10  with two-thirds of 
patients dead at five years and an equivalent crude rate of major adverse cardiovascular 
events (myocardial infarction or cardiac death).11At present, we have no objective 
criteria to guide the diagnosis, investigation and management of patients with type 2 
myocardial infarction, and differentiating patients is subjective.12 Prior studies have 
suggested significant heterogeneity in the prevalence of type 2 myocardial infarction 
between centres, reflecting the difficulties in consistent application of the guideline 
recommendations. If objective criteria could be developed to identify patients with 
type 2 myocardial infarction, this would allow clinicians to improve the accuracy of 
diagnosis, and facilitate the development of therapeutic trials of proven secondary 










Detection of myocardial injury  
Cardiac troponin is an integral component of the contractile apparatus of the 
cardiomyocyte, expressed exclusively within the myocardium. It is a complex of three 
subunits, C, I and T, which regulates calcium mediated excitation-contraction coupling. 
The majority of cardiac troponin is intracellular, with >90% of troponin isoforms 
located within the sarcomere, and the remainder unbound within the cytoplasmic 
pool.13 The mechanisms of cardiac troponin release into the circulation are thought to 
include myocyte necrosis, apoptosis, formation and release of membranous blebs, 
increased membrane permeability and release of proteolytic troponin degradation 
products.13 However, the underlying cause of troponin release will often differ. 
Cardiac troponin may be released when  cardiomyocytes undergo mechanical stretch 
in response to pressure or volume overload, through activation of intra-cellular 
proteases associated with intra-cellular degradation of troponin.14 Tachycardia may 
stimulate stress-responsive integrins within the cardiomyocyte, triggering release of 
intact cardiac troponin I from viable cardiomyocytes in the absence of necrosis.15 
Furthermore, troponin release has also been demonstrated in vivo in patients who 
develop reversible ischaemia during nuclear perfusion imaging with stress testing.16 
Cardiac troponin is the only recommended biomarker for the detection of myocardial 
necrosis, and it is integral to the diagnostic criteria for myocardial infarction.1 
However, as the cellular mechanisms of myocardial injury are thought to differ 
between subtypes of myocardial infarction, there may be opportunities to identify 
other candidate cardiovascular biomarkers which may distinguish subtypes of 
myocardial infarction, improving diagnostic accuracy. We hypothesise that in the 






obstruction in type 2 myocardial infarction, the profile of sarcomeric and inflammatory 
proteins released from the myocardium will differ compared to that observed in 
patients with type 1 myocardial infarction.   
 
Aims and objectives 
• To identify candidate biomarkers that differentiate between type 1 myocardial 
infarction due to plaque rupture or erosion with thrombosis, and type 2 




Design: Prospective observational case-control study  
Setting: Royal Infirmary of Edinburgh, a tertiary cardiac centre 
Study population: Patients presenting to the Emergency Department of the Royal 
Infirmary of Edinburgh, a tertiary cardiac centre, with symptoms or signs of 
myocardial ischaemia and evidence of myocardial necrosis (defined as a rise and or 
fall in cardiac troponin concentration on serial testing, with at least one value >99th 
centile).   
 
Type 1 myocardial infarction 
We will identify patients presenting to hospital with an adjudicated diagnosis of type 
1 myocardial infarction. Patients will be classified as having a type 1 myocardial 
infarction when myocardial necrosis occurs in the context of an isolated presentation 
with symptoms suggestive of myocardial ischemia, or evidence of myocardial 






independently by two cardiologists, and any discrepancies resolved by consensus 
through in-depth review of all clinical investigations. Ethical approval has been 
obtained as part of South East Scotland BioResource scheme (SR546, 15/ES/0094). 
 
Type 2 myocardial infarction 
We will identify patients with an adjudicated diagnosis of type 2 myocardial infarction 
enrolled into a trial entitled ‘Evaluating the role of coronary artery disease to Resolve 
the diagnosis of Type 2 myocardial infarction’ (EVEREST-MI). Patients with 
symptoms or signs of myocardial ischemia that were thought to be due to increased 
oxygen demand (e.g. tachyarrhythmia or hypertrophy) or decreased supply (e.g. 
hypotension, hypoxia or anaemia) and myocardial necrosis in the context of an 
alternative clinical diagnosis are classified as having a type 2 myocardial infarction. 
Each case is reviewed and classified independently by two cardiologists, and any 
discrepancies resolved by consensus through in-depth review of all clinical 
investigations. This clinical trial is using imaging (CT or invasive coronary 
angiography and cardiac MRI) to better understand the mechanism of myocardial 
injury. This clinical trial is recruiting, registered at clinicaltrials.gov (NCT:03338504), 
approved by the national research ethics committee and is being conducted in 
accordance with the Declaration of Helsinki.   
 
Subjects  
We will evaluate 45 patients with type 1 myocardial infarction and 45 patients with 
type 2 myocardial infarction. As this is a pilot study to identify and validate candidate 








In all patients venous blood samples will be obtained at the time of recruitment and at 
24 hours and serum, lithium-heparin and EDTA plasma prepared for storage. All 
samples will be anonymised and linked by a unique non-identifiable ID. High-
sensitivity cardiac troponin I concentrations will be measured in batch processing 
using the ARCHITECTSTAT high-sensitive troponin I assay (Abbott Laboratories, 
Abbott Park, IL). This assay has a limit of detection of 1.2 ng/L and the inter-assay 
CV<10% at 4.7 ng/L.3 The upper reference limit (99th centile) is 26 ng/L, and is two-
fold higher in men (34 ng/L) than in women (16 ng/L).17,18 
 
Proteomic analysis: 
EDTA plasma from 90 subjects (45 type 1 myocardial infarction, 45 type 2 myocardial 
infarction) will be transferred to Olink Proteomics (Upsalla Science Park, Upsalla, 
Sweden) for analysis. The Olink Proteomics Inflammation (96x96), Olink Proteomics 
Cardiovascular II (96x96) and Olink Proteomics Cardiovascular III (96x96)  biomarker 
panels are high-throughput, multiplex immunoassay systems capable of analysing 
multiple proteins associated with inflammatory or cardiovascular disease, 
simultaneously. A total 276 candidate proteins will be evaluated. This technology is 
facilitated by novel proximity extension assay (PEA) technology. Each panel contains 
92 oligonucleotide-labelled antibody pairs which bind to the target when present in the 
sample. Binding by antibody pairs triggers the formation of double-stranded DNA 
amplicons, which are quantified by real-time polymerase chain reaction (PCR). The 






correlates to a high protein content. PEA is a robust and reproducible technique, with 
intra-assay coefficient of variation (CV) ranging between 5% and 13%, and inter-assay 
CV between 9% and 39% dependent on assay type. Whilst a novel technique, Olink 
Proteomics have informed the outcomes of several recent cardiovascular studies.19,20 




Baseline characteristics will be summarised as mean (standard deviation, SD) or 
median (inter-quartile range, IQR) as appropriate. Patient characteristics in those with 
type 1 myocardial infarction will be compared to those with type 2 myocardial 
infarction using a chi-square test or Wilcoxon rank sum test as appropriate. We will 
explore the relationship between high-sensitivity cardiac troponin concentration and 
candidate biomarkers using pairwise correlation, illustrated in a correlation matrix and 
ordered by hierarchical clustering.20 We anticipate a range of candidate biomarkers 
will be elevated in patients with type 1 and type 2 myocardial infarction, but some may 
distinguish between diagnoses. The association between biomarker value and 
diagnosis (type 1 or type 2 myocardial infarction) will be explored by fitting univariate 
generalised linear models with a binomial link. Candidate biomarkers which are 
predictive in univariate analysis will be evaluated in a multi-variate generalised linear 
model with adjustment for age, gender and renal function. A final model will be 
derived using backward elimination, including co-variates with a P-value of <0.05. 
We will assess the discriminatory performance of the model by evaluating sensitivity, 






troponin, and candidate biomarkers which show significant associations with both 
diagnoses, we will evaluate the time course of biomarker release using a polynomial 
linear mixed effects model, with a random term for subject. Comparisons will be 
adjusted for multiple testing using the Bonferroni method. All statistical analyses will 
be performed using the statistical package R (Version 3.2.2). 
 
Potential of research for patient care 
Patients with type 2 myocardial infarction are understudied, commonly excluded from 
trials of cardiovascular therapies which focus on patients with type 1 myocardial 
infarction where the mechanisms of disease are better understood. This is despite type 
2 myocardial infarction being a common condition, affecting twice as many patients 
over the age of 75 years than type 1 myocardial infarction, and outcomes for these 
patients are extremely poor, with as few as one-third alive at five years after index 
diagnosis.  
 
The international collaboration responsible for the universal definition of myocardial 
infarction acknowledge the limitations in the current classification.4 Lack of accurate 
diagnostic tools limits our ability to do further research into the underlying 
pathophysiology of this condition. The identification of candidate biomarkers in the 
proposed study would provide avenues for further research. We will select candidate 
biomarkers with high discriminatory ability for type 1 or type 2 myocardial infarction, 
and perform validation studies using immunoassay and ELISA technology in our 
stored samples. This will facilitate quantification of total protein concentration and 






study will form the basis of a project of work to provide a more robust, objective means 
of diagnosis in patients with type 2 myocardial infarction, to allow planning and 
delivery of prospective clinical trials of cardiovascular therapy with the aim of 












TYPE 1 MYOCARDIAL INFARCTION
TYPE 2 MYOCARDIAL INFARCTION
TYPE 3 MYOCARDIAL INFARCTION
TYPE 4 MYOCARDIAL INFARCTION
TYPE 5 MYOCARDIAL INFARCTION
Spontaneous myocardial infarction related to ischaemia due to a primary
coronary event such as plaque erosion and/or rupture, fissuring, or dissection
Myocardial infarction secondary to ischaemia due to either increased oxygen
demand or decreased supply
Sudden unexpected cardiac death often with symptoms suggestive of
myocardial ischaemia
Myocardial infarction associated with percutaneous coronary intervention (4a)
or stent thrombosis (4b)
Myocardial infarction associated with cardiac surgery
MYOCARDIAL INJURY
Multifactorial aetiology; acute or chronic based on change in cardiac troponin
































Adapted from the Third Universal Definition of Myocardial Infarction 2  
Primary myocardial 
ischaemia 
Supply or demand 
imbalance causing 
myocardial ischaemia 









Coronary Artery Dissection  
Anaemia 
Aortic dissection  
Aortic valve disease 
Tachy- or Brady- Arrhythmias 
Coronary embolism or 
vasculitis 
Coronary endothelial 
dysfunction   
Coronary vasospasm 
Hypertension  






















Pulmonary embolism  
Pulmonary hypertension 
Acute Kidney Injury 
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